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Migraine is a common and disabling episodic neurovascular disease1 that affects ~15% 
of the world population; it is three times more common among women of reproductive 
age than men.2, 3 Recurrent migraine attacks are characterized by severe headache 
accompanied to various degrees by nausea, vomiting, and increased sensitivity to 
light, sound, and smell, lasting anywhere between an hour to days (migraine without 
aura).4 Attack frequency differs widely among patients, from one per year to several 
per week. every day, millions of people are plagued by blistering migraines, which 
ranks among the most disabling medical conditions worldwide.2, 5
Migraine aura. One-third of migraine patients also experience transient focal 
neurological symptoms termed aura that usually precede or sometimes accompany 
the headache (migraine with aura).4,6 Aura symptoms can be visual, sensory or motor, 
or involve language or brain stem function. Aura often shows a characteristic spread, 
such as a scintillating scotoma gradually expanding from a point of origin in one 
hemi visual field (Figure 1), or paresthesias marching up from the fingers and hand 
to sequentially involve the arm and then lower face. This form of spread pattern 
suggests an intracortical event propagating in a retinotopic or somatotopic fashion. 
It is widely accepted7,8 that the symptomatology of migraine aura is caused by the 
electrophysiological event called spreading depression (SD), an intense neuronal 
and glial spreading depolarization wave slowly propagating (~3 mm/min) in cerebral 
cortical or subcortical grey matter.9-11 Mechanisms of migraine headache are still 
debated, although there is general agreement that activation and sensitization 
of the trigeminovascular nociceptive pathways is a critical step.12,13 A large body 
of experimental evidence strongly suggests that SD is capable of activating the 
trigeminovascular system, and thus directly relevant for headache mechanisms.11 The 
figure 1. Scintillating scotoma of visual migraine aura. Fovea is indicated by x, and the time between 
each successive drawing by the numbers in minutes. The zig-zag pattern at the propagating wavefront 
represents scintillations (i.e., positive symptom at the wavefront) while the gray shaded area represents 
visual loss (i.e., scotoma, negative symptom).15 Visual aura is caused by SD in occipital cortex.
1. MIGRAINE 
 
Migraine is a common and disabling episodic neurovascular disease1 that affects ~15% of 
the world population; it is three times more common among women of reproductive age than 
men.2, 3 Recurrent migraine attacks are characterized by severe headache accompanied to 
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conditions worldwide.2, 5 
 
Migraine aura. One-third of migraine patients also experience transient focal neurological 
symptoms termed aura that usually precede or sometimes accompany the headache 
(migraine with aura).4,6 Aura symptoms can be visual, sensory or motor, or involve language 
or brain stem function. Aura often shows a characteristic spread, such as a scintillating 
scotoma gradually expanding from a point of origin in one hemi visual field (Figure 1), or 
paresthesias marching up from the fingers and hand to sequentially involve the arm and then 
lower face. This form of spread pattern suggests an intracortical event propagating in a 
retinotopic or somatotopic fashion. It is widely accepted7,8 that the symptomatology of 
migrain  aura is caused by the electrophysiological ev nt called spreading depression (SD), 
an intense neuronal and glial spreading depolarization wave slowly propagating (~3 
mm/min) in cerebral cortical or subcortical grey matter.9-11 Mechanisms of migraine 
headache are still debated, although there is general agreement that activation and 
sensitization of the trigeminovascular nociceptive pathways is a critical step.12,13 A large 
body experimental evidence strongly suggest th t SD is capable of activating the 
trigeminovascular system, and thus directly relevant for headache mechanisms.11 The 
trigeminovascular system consists of nociceptive trigeminal afferents surrounding the 
intracranial vessels. These perivascular trigeminal afferents project through the trigeminal 
ganglion to neurons in the trigeminocervical complex, and then relayed to the thalamus 




2. SPREADING DEPRESSION  
 
Definition. Spreading depression (SD) is an intense neuronal and glial depolarization wave 
that slowly propagates in brain tissue (~3 mm/min) by way of gray matter contiguity 
irrespective of functional divisions or vascular territories.16 The near-complete loss of 
membrane potential is a result of massive transmembrane ionic and water shifts, including 
K+ and glutamate efflux, and Na+, Ca2+ and water influx, which last up to a minute and does 
not lead to injury in otherwise normal brain tissue. All these ionic and water shifts create a 
signature extracellular negative slow potential shift (aka DC shift) accompanied by 
Figure 1. Scintillating scotoma of visual migraine aura. Fovea is indicated by x, and the time 
between each successive drawing by the numbers in minutes.  The zig-zag pattern at the propagating 
wavefront represents scintillations (i.e., positive symptom at the wavefront) while the gray shaded area 




trigeminovascular system consists of nociceptive trigeminal afferents surrounding 
the intracranial vessels. These perivascular trigeminal afferents project through the 
trigeminal ganglion to neurons in the trigeminocervical complex, and then relayed to 
the thalamus where all nociceptive inputs are integrated.14
2.  SPREADING DEPRESSION 
Definition. Spreading depression (SD) is an intense neuronal and glial depolarization 
wave that slowly propagates in brain tissue (~3 mm/min) by way of gray matter contiguity 
irrespective of functional divisions or vascular territories.16 The near-complete loss 
of membrane potential is a result of massive transmembrane ionic and water shifts, 
including K+ and glutamate efflux, and Na+, Ca2+ and water influx, which last up to a 
minute and does not lead to injury in otherwise normal brain tissue. All these ionic and 
water shifts create a signature extracellular negative slow potential shift (aka DC shift) 
accompanied by suppression of action potentials and synaptic activity (Figure 2). As a 
result, electrocorticogram (eCoG) is depressed, hence the historical term ‘‘spreading 
depression’’ originally coined by Leao.17 Similar spreading depolarization events also 
occur in ischemic brain, and are termed peri-infarct depolarizations (PIDs) or injury 
depolarizations (see below). Therefore, SD is a form of spreading depolarization event 
that occurs in otherwise normal brain.
Basic electrophysiology. SD is triggered when a sufficiently strong stimulus (e.g., topical 
application of concentrated KCl solution, direct cathodal electrical stimulation, seizure 
activity or tissue ischemia) simultaneously depolarizes a minimum critical volume of 
brain tissue estimated to be ~1 mm3 in rodent cortex, in vivo.18 The depolarizing stimulus 
overloads the extracellular K+ ([K+]
e
) clearance mechanisms causing [K+]
e
 to exceed a critical 
threshold concentration of ~12 mM.18-24 These thresholds can vary in different species 
and brain regions depending on neuronal and excitatory synaptic density among other 
factors.25,26 The inciting event causes a sudden drop in membrane resistance via opening 
of non-selective large conductance cation channels, the presence and identity of which 
are yet incompletely understood.27 As a result, both intracellular and extracellular ions 
move along their transmembrane concentration gradients. Massive K+ efflux raises [K+]
e
 
from ~3 mM at resting state28-30 to about ~30-50 mM, and sometimes as high as 80 mM, 
in an all-or-none fashion, in most species, tissues and model systems.19,22,29,31-34 This large 
K+ efflux is reciprocated by Na+ and Cl- influx that pulls water, causing cell swelling.22,35-40 
extracellular space shrinks by as much as 50%.41, 42 Depolarization also triggers Ca2+ 
influx and a more than 10-fold drop in [Ca2+]
e
,22,43,44 which, along with Na+ and water 
influx, leads to release of many if not all neurotransmitters and neuromodulators within 
the depolarized tissue. extracellular glutamate, aspartate, glycine, GABA and taurine 
concentrations increase during SD,32,45,46 and similar increases have been shown for 
catecholamine and ascorbate levels.47-49 
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Propagation of SD. It is believed that the rise in [K+]
e
 and glutamate act as chemical 
signals diffusing to and depolarizing adjacent cells, and in this way the depolarization 
slowly spreads. The massive rise in [K+]
e
 to levels sufficient to depolarize neighboring 
cells is the critical factor mediating the contiguous spread of the wave.20,22,50 elevated 
extracellular levels of the strongly depolarizing excitatory amino acids (glutamate 
and aspartate) further fuel SD and facilitate its propagation by activating NMDA 
receptors.51,52 For the released K+ and glutamate to reach the critical depolarization 
threshold of adjacent cells, high neuronal and synaptic density and low extracellular 
space volume are required; therefore, white matter is characteristically resistant to SD. 
However, SD can be triggered in subcortical grey matter structures such as striatum, 
thalamus and hippocampus, with the exception of brain stem, which is resistant to SD 
unless tested in immature animals or after pharmacological preconditioning (e.g., K+-
channel blockade).53-57 Lastly, cortical SD can propagate into subcortical structures 
that have direct gray matter contiguity with the cortex.58  
Recovery of SD. The massive redistribution of ions, water and neurotransmitters 
is self-limited. A number of mechanisms, including the Na+/K+-ATPase, intracellular 
buffering of [Ca++]
i
, reuptake and metabolism or spatial buffering by the astrocytic 
network, and quite likely vascular clearance, all help restore the homeostasis usually 
suppression of action potentials and synaptic activity (Figure 2). As a result, 
electrocorticogram (ECoG) is depressed, hence the historical term ‘‘spreading depression’’ 
originally coined by Leao.17 Similar spreading depolarization events also occur in ischemic 
brain, and are termed peri-infarct depolarizations (PIDs) or injury depolarizations (see 
below). Therefore, SD is a form of spreading depolarization event that occurs in otherwise 
normal brain. 
 
Basic electrophysiology. SD is triggered when a sufficiently strong stimulus (e.g., topical 
application of concentrated KCl solution, direct cathodal electrical stimulation, seizure activity 
or tissue ischemia) simultaneously depolarizes a minimum critical volume of brain tissue 
estimated to be ~1 mm3 in rodent cortex, in vivo.18 The depolarizing stimulus overloads the 
extracellular K+ ([K+]e) clearance mechanisms causing [K+]e to exceed a critical threshold 
concentration of ~12 mM.18-24 These thresholds can vary in different species and brain 
regions depending on neuronal and excitatory synaptic density among other factors.25,26 The 
inciting event causes a sudden drop in membrane resistance via opening of non-selective 
large conductance cation channels, the presence and identity of which are yet incompletely 
understood.27 As a result, both intracellular and extracellular ions move along their 
transmembrane concentration gradients. Massive K+ efflux raises [K+]e from ~3 mM at 
resting state28-30 to over ~30-50 mM, and sometimes as high as 80 mM, in an all-or-none 
fashion, in most species, tissues and model systems.19,22,29,31-34 This large K+ efflux is 
reciprocated by Na+ and Cl- influx that pulls water, causing cell swelling.22,35-40 Extracellular 
space shrinks by as much as 50%41, 42. Depolarization also triggers Ca2+ influx and a more 
than 10-fold drop in [Ca2+]e,22,43,44 which, along with Na+ and water influx, leads to release of 
many if not all neurotransmitters and neuromodulators within the depolarized tissue. 
Extracellular glutamate, aspartate, glycine, GABA and taurine concentrations increase 
during SD,32,45,46 and similar increases have been shown for catecholamine and ascorbate 
levels.47-49  
 
Figure 2. Representative tracings of electrocorticogram (ECoG) and extracellular DC potential during a cortical 
SD wave in rat brain, triggered by 1M KCl briefly applied on to the occipital cortex, and recorded by two 
intracortical glass microelectrodes placed in series with the KCl application site. SD is characterized by transient 
depression of cortical electrical activity and a slow DC shift 20-30 mV in amplitude lasting less than 1 min. When 
triggered by an intense stimulus that simultaneously depolarizes a minimum critical volume of brain tissue, SD 
spreads centrifugally to be detected first at the proximal (E1), and after a latency, at the distal (E2) 
microelectrode. In otherwise normal tissue, ECoG activity starts to recover a few minutes after the onset of SD, 
but may take up to 10 min to return to normal. The speed of propagation is calculated from the distance and the 
latency between the electrodes. Modified from 10. 
 
Propagation of SD. It is believed that the rise in [K+]e and glutamate act as chemical signals 
diffusing to and depolarizing adjacent cells, and in this way the depolarization slowly 
spreads. The massive rise in [K+]e to levels sufficient to depolarize neighboring cells is the 
figure 2. Repre entative tracings of electrocorticogram (ECoG) and extracellular DC potential 
during a cortical SD wave in rat brain, triggered by 1M KCl briefly applied on to the occipital 
cortex, and recorded by two intracortical glass microelectrodes placed in series with the KCl 
application site. SD is character zed by transient depression of cortical el ctrical activity and a 
slow DC shift 20-30 mV in amplitude lasting less than 1 min. When triggered by an intense stimulus 
that simultaneously depolarizes a minimum critical volume of brain tissue, SD spreads centrifugally 
to be detected first at the proximal (e1), and after a latency, at the distal (e2) microelectrode. In 
otherwise normal tissue, eCoG activity starts to recover a few minutes after the onset of SD, but 
may take up to 10 min to return to normal. Th  peed of propagati n is calculated f om the distance 
and the latency between the electrodes. Modified from 10.
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Chapter 1
within a minute. The process is in part energy-dependent and strongly stimulates 
O
2
 and glucose consumption. Therefore, in severely hypoperfused (i.e., ischemic) 
tissue, restoration of homeostasis is delayed, with deleterious consequences on 
tissue viability.
SD and migraine. Since the discovery of SD decades ago, similarities between 
the electrophysiological properties of SD and the neurological signs and 
symptoms during migraine aura suggested a causative link between the two.59-61 
experimental evidence also suggests that SD can trigger headache by activating 
the trigeminovascular system.11,62-67 Although whether an asymptomatic SD triggers 
migraine headache without a perceived aura is still debated, suppression of SD 
susceptibility by migraine prophylactic drugs as a class effect supported this notion 
since these drugs have been equally efficacious in migraine with or without a 
perceived aura. Therefore, SD is now considered a potential therapeutic target in 
migraine, and experimental models of SD susceptibility are increasingly being used 
in migraine drug screening.
SD susceptibility. The ease with which SD can be initiated and sustained is often 
termed SD susceptibility, and can be used as an experimental surrogate for migraine 
(with aura) susceptibility. Indeed, modulation of SD susceptibility by drugs appears to 
be the basis for migraine prophylaxis.68 There are several experimental models that can 
be used to measure SD susceptibility.69 The most common attributes used to define SD 
susceptibility are: i) the threshold stimulus intensity that triggers an SD (i.e., electrical 
charge measured in Coulombs, or KCl concentration threshold) determined by 
sequential stimuli of stepwise escalating intensity until an SD is triggered, ii) the 
frequency of SDs triggered during continuous constant suprathreshold stimulus 
for up to an hour (i.e., topical high concentration of KCl), and iii) the propagation 
speed of SD. 
3.  ISCHEMIC STROKE
Definition of the problem. Ischemic stroke is an acute cerebrovascular catastrophe 
and a leading cause of death and disability worldwide.70 It is caused by occlusion 
of an artery supplying the brain or spinal cord. Despite intense research into the 
pathophysiology and treatment of ischemic stroke, the only proven and widely 
adopted therapeutic modality is thrombolysis to achieve reperfusion in a timely 
manner. Brain tissue is highly sensitive to ischemia. Infarction ensues unless 
reperfusion is achieved within a few hours after cerebral arterial occlusion. Therefore, 
the therapeutic efficacy and safety window of thrombolysis is limited to only 4.5 hours 
after stroke onset.71 
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Ischemic core. Cerebral arterial occlusion typically creates a focal perfusion defect within 
its territory (Figure 3). Some degree of collateral blood flow reaches the focal ischemic 
tissue via surrounding patent arteries. However, efficacy of collateral flow drops as a 
function of distance, creating an inverted bell-shaped gradient of blood flow from the 
relatively well-perfused periphery towards the severely ischemic center. Irreversible 
ischemic injury (i.e., infarct) starts in the center and gradually expands over minutes to 
days into the periphery. energy shortage in the severely ischemic center results in failure 
of Na+/K+ ATPase, gradual increase in extracellular potassium concentrations ([K+]
e
). Within 
a few minutes after the arterial occlusion, when [K+]
e
 reaches a critical threshold of ~12 mM 
(from a normal resting level of ~3-4 mM), neurons develop a sudden onset catastrophic 
loss of resting membrane potential (V
m
), termed anoxic depolarization (AD), which marks 
the ischemic core. The process is analogous to the triggering of SD as described above, 
with the critical distinction being tissue inability to restore the transmembrane ionic 
gradients because of ongoing ischemia. In that sense, AD is a persistent form of SD that 
can become permanent. It is generally believed that AD that continues longer than ~10-15 
minutes results in irreversible cell injury and eventual death by necrosis and/or apoptosis. 
Ischemic penumbra. Surrounding the core, there is sufficient collateral flow to maintain 
the resting V
m
, but neural activity and synaptic transmission are suppressed via intrinsic 
protective mechanisms creating a ring of electrical silence (Figure  3). This ‘still-viable 
tissue at risk for infarction’ is called ischemic penumbra. The spatiotemporal evolution of 
injury in penumbra is complex. Depending on residual tissue perfusion and the intrinsic 
tissue sensitivity to ischemia, portions of penumbra succumb to AD, and get incorporated 
into the ischemic core over time. Therefore, ischemic core gradually expands into the 
penumbra (Figure 4). A critical factor that facilitates ischemic injury, expands the infarct 
and worsens the neurological outcome is the occurrence of spontaneous spreading 
depression waves within the peri-infarct tissue, called peri-infarct depolarizations.
 
Figure 3. The hemodynamic status and membrane potential of acute focal ischemic brain tissue showing the 
definitions of ischemic penumbra and core. Vm, membrane potential. 
 
Ischemic core. Cerebral arterial occlusion typically creates a focal perfusion defect within its 
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process is analogous to the triggering of SD as described above, with the critical distinction 
being tissue inability to restore the transmembrane ionic gradients because of ongoing 
ischemia. In that sense, AD is a persistent form of SD that can become permanent. It is 
generally believed that AD that continues longer than ~10-15 minutes results in irreversible 
cell injury and eventual death by necrosis and/or apoptosis.  
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resting Vm, but neural activity and synaptic transmission are suppressed via intrinsic 
protective mechanisms creating a ring of electrical silence (Figure 3). This ‘still-viable tissue 
at risk for infarction’ is called ischemic penumbra. The spatiotemporal evolution of injury in 
penumbra is complex. Depending on residual tissue perfusion and the intrinsic tissue 
sensitivity to ischemia, portions of penumbra succumb to AD, and get incorporated into the 
ischemic core over time. Therefore, ischemic core gradually expands into the penumbra 
(Figure 4). A critical factor that facilitates ischemic injury, expands the infarct and worsens 
the neurological outcome is the occurrence of spontaneous spreading depression waves 
within the peri-infarct tissue, called peri-infarct depolarizations. 
 
 
Figure 4. Ischemic core gradually expands into the penumbra because of persistent ischemia and the 
occurrence of peri-infarct depolarizations. 
 
figure 3. The hemodynamic status and embrane potential of acute focal ischemic brain 





Peri-infarct depolarizations. In addition to AD, ischemic brain also develops 
spontaneous recurrent peri-infarct spreading depolarization waves (PIDs) that 
originate at the boundary and propagate throughout the ischemic and non-ischemic 
tissue. When PIDs enter the non-ischemic tissue, they are electrophysiologically 
indistinguishable from SD, the substrate of migraine aura, suggesting that PIDs 
are analogous to SDs (Figure 5). The local rise in [K+]
e
 and the hypoxic suppression 
of Na+/K+-ATPase in ischemic brain serve as the strongly depolarizing stimuli that 
trigger PIDs, analogous to the topical KCl or electrical stimulation to trigger 
SDs. Importantly, occurrence of PIDs have been shown in human brain as well.72 
Therefore, SDs and PIDs represent a mechanistic overlap between migraine 
and stroke. 
 
Figure 3. The hemodynamic status and membrane potential of acute focal ischemic brain tissue showing the 
definitions of ischemic penumbra and core. Vm, membrane potential. 
 
Ischemic core. Cerebral arterial occlusion typically creates a focal perfusion defect within its 
territory (Figure 3). Some degree of collateral blood flow reaches the focal ischemic tissue 
via surrounding patent arteries. However, efficacy of collateral flow drops as a function of 
distance, creating an inverted bell-shaped gradient of blood flow from the relatively well-
perfused periphery towards the severely ischemic center. Irreversible ischemic injury (i.e., 
infarct) starts in the center and gradually expands over minutes to days into the periphery. 
Energy shortage in the severely ischemic center results in failure of Na+/K+ ATPase, gradual 
increase in extracellular potassium concentrations ([K+]e). Within a few minutes after the 
arterial occlusion, when [K+]e reaches a critical threshold of ~12 mM (from a normal resting 
level of ~3-4 mM), neurons develop a sudden onset catastrophic loss of resting membrane 
potential (Vm), termed anoxic depolarization (AD), which marks the ischemic core. The 
process is analogous to the triggering of SD as described above, with the critical distinction 
being tissue inability to restore the transmembrane ionic gradients because of ongoing 
ischemia. In that sense, AD is a persistent form of SD that can become permanent. It is 
generally believed that AD that continues longer than ~10-15 minutes results in irreversible 
cell injury and eventual death by necrosis and/or apoptosis.  
 
Ischemic penumbra. Surrounding the core, there is sufficient collateral flow to maintain the 
resting Vm, but neural activity and synaptic transmission are suppressed via intrinsic 
protective mechanisms creating a ring of electrical silence (Figure 3). This ‘still-viable tissue 
at risk for infarction’ is called ischemic penumbra. The spatiotemporal evolution of injury in 
penumbra is complex. Depending on residual tissue perfusion and the intrinsic tissue 
sensitivity to ischemia, portions of penumbra succumb to AD, and get incorporated into the 
ischemic core over time. Therefore, ischemic core gradually expands into the penumbra 
(Figure 4). A critical factor that facilitates ischemic injury, expands the infarct and worsens 
the neurological outcome is the occurrence of spontaneous spreading depression waves 
within the peri-infarct tissue, called peri-infarct depolarizations. 
 
 
Figure 4. Ischemic core gradually expands into the penumbra because of persistent ischemia and the 
occurrence of peri-infarct depolarizations. 
 
figure 4. Ischemic core gradually expands into the penumbra because of persistent ischemia 
and the occurrence of peri-infarct depolarizations.
trigger SDs. Importantly, occurrence of PIDs have been shown in human brain as well.72 
Therefore, SDs and PIDs represent a mechanistic overlap between migraine and stroke.  
 
Figure 5. Recurrent peri-infarct injury depolarizations (PIDs; four negative deflections on the tracing) recorded 
during filament occlusion of the middle cerebral artery by an intracortical glass micropipette placed outside the 
ischemic tissue in a representative mouse. These PIDs are indistinguishable from SDs triggered by intense 
depolarization in otherwise normal cortex. Lower right panel is the summary of 10 experiments, where each 
horizontal line shows the beginning and end of electrophysiological recordings after the onset of ischemia, and 
each circle represents a PID. Grey shaded area shows the approximate location of the perfusion defect upon 
arterial occlusion. Recurrent PIDs appear spontaneously throughout the recording period in all mice. 
 
Acute infarct progression on MRI. Ionic changes and cell swelling in tissue that has 
undergone AD cause a characteristic decrease in apparent diffusion coefficient (ADC) of 
water on diffusion-weighted MRI (DWI) as the MRI signature of core infarction (Figure 6). 
Perfusion-weighted MRI (PWI) outlines the total tissue at risk for infarction. Therefore, the 
mismatch between DWI and PWI lesion volumes is a measure of viable tissue at risk for 
infarction (i.e., penumbra). Ischemic penumbra is the primary target of all acute stroke 
rescue interventions. The volume of penumbra present at any given time is a good measure 
of how much tissue is available that can be rescued from ischemic infarction. 
 
 
Figure 6. Acute MRI of a typical middle cerebral artery stroke. Diffusion-weighted imaging (DWI) shows the 
infarcted tissue (yellow), whereas perfusion-weighted imaging (PWI; measured by mean transit time, MTT, blue) 
delineates the hypoperfused tissue. The DWI/PWI mismatch (blue tissue outside the yellow) is a surrogate MRI 
measure of ischemic penumbra, defined as ‘still-viable tissue at risk for infarction’. Day 7 T2 MRI shows the final 
infarct volume in this patient. 
 
4. CLINICAL ASSOCIATION BETWEEN MIGRAINE AND STROKE:  
 
Migraine has traditionally been viewed as a benign chronic episodic condition. However, 
accumulating evidence suggests that migraine with aura, can be associated with increased 
risk for stroke and white matter lesions.73-79  
 
Observational data. Abundant data from retrospective and population- or hospital-based 
case-control studies, as well as small and large population-based prospective studies 
including tens of thousands of subjects, have firmly established a link between migraine and 
6 hour DWI 
Final infarct (Day-7 T2) 
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DWI/PWI (yellow/blue) 
figure 5. Recurrent peri-infarct injury depolarizations (PIDs; four negative deflections on the 
tracing) recorded during fil ment occlusion of th  middle cerebral artery by an intracortical 
glass micropipette placed outside the ischemic tissue in a representative mouse. These 
PIDs are indistinguishable from SDs triggered by intense depolarization in otherwise normal 
cortex. Lower right panel is the summary of 10 experiments, where each horizontal line shows 
the beginning and end of electrophysiological recordings after the onset of ischemia, and each 
circle represents a PID. Grey shaded area shows the approximate location of the perfusion defect 
upon arterial occlusion. Recurrent PIDs appear spontaneously throughout the rec rding period 
in all mice.
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Acute infarct progression on MRI. Ionic changes and cell swelling in tissue that 
has undergone AD cause a characteristic decrease in apparent diffusion coefficient 
(ADC) of water on diffusion-weighted MRI (DWI) as the MRI signature of core 
infarction (Figure 6). Perfusion-weighted MRI (PWI) outlines the total tissue at risk 
for infarction. Therefore, the mismatch between DWI and PWI lesion volumes is a 
measure of viable tissue at risk for infarction (i.e., penumbra). Ischemic penumbra 
is the primary target of all acute stroke rescue interventions. The volume of 
penumbra present at any given time is a good measure of how much tissue is 
available that can be rescued from ischemic infarction.
trigger SDs. Importantly, occurrence of PIDs have been shown in human brain as well.72 
Therefore, SDs and PIDs represent a mechanistic overlap between migraine and stroke.  
 
Figure 5. Recurrent peri-infarct injury depolarizations (PIDs; four negative deflections on the tracing) recorded 
during filament occlusion of the middle cerebral artery by an intracortical glass micropipette placed outside the 
ischemic tissue in a representative mouse. These PIDs are indistinguishable from SDs triggered by intense 
depolarization in otherwise normal cortex. Lower right panel is the summary of 10 experiments, where each 
horizontal line shows the beginning and end of electrophysiological recordings after the onset of ischemia, and 
each circle represents a PID. Grey shaded area shows the approximate location of the perfusion defect upon 
arterial occlusion. Recurrent PIDs appear spontaneously throughout the recording period in all mice. 
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Figure 6. Acute MRI of a typical middle cerebral artery stroke. Diffusion-weighted imaging (DWI) shows the 
infarcted tissue (yellow), whereas perfusion-weighted imaging (PWI; measured by mean transit time, MTT, blue) 
delineates the hypoperfused tissue. The DWI/PWI mismatch (blue tissue outside the yellow) is a surrogate MRI 
measure of ischemic penumbra, defined as ‘still-viable tissue at risk for infarction’. Day 7 T2 MRI shows the final 
infarct volume in this patient. 
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Migraine has traditionally been viewed as a benign chronic episodic condition. However, 
accumulating evidence suggests that migraine with aura, can be associated with increased 
risk for stroke and white matter lesions.73-79  
 
Observational data. Abundant data from retrospective and population- or hospital-based 
case-control studies, as well as small and large population-based prospective studies 
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figure 6. Acute MRI of a typical middle cerebral artery stroke. Diffusion-weighted imaging (DWI) 
shows the infarcted tissue (yellow), whereas perfusion-weighted imaging (PWI; measured by mean 
transit time, MTT, blue) delineates the hypoperfused tissue. The DWI/PWI mismatch (blue tissue 
outside the yellow) is a surrogate MRI measure of ischemic penumbra, defined as ‘still-viable tissue at 
risk for infarction’. Day 7 T2 MRI shows the final infarct volume in this patient. Courtesy of Dr. Hakan Ay.
4. CLINICAL ASSOCIATION BET WEEN MIGRAINE AND STROKE
Migraine has traditionally been viewed as a benign chronic episodic condition. 
However, accumulating evidence suggests that migraine with aura, can be associated 
with increased risk for stroke and white matter lesions.73-79 
Observational data. Abundant data from retrospective and population- or hospital-
based case-control studies, as well as small and large population-based prospective 
studies including tens of thousands of subjects, have firmly established a link between 
migraine and ischemic stroke.77,80,81 The odds ratio (OR) for ischemic stroke is ~2 among 
migraineurs (95% confidence interval [CI] 1.72-2.43). Important insights are: 
I. The association is explained by migraine with aura alone (OR 2.5, 95% CI 1.5-4.1), 




II. The association is stronger in women (OR 2.9, 95% CI 2.4-3.5),77 and in subjects 
younger than 45 (OR 2.7, 95% CI 1.4-5.0),
III. The risk is higher in patients who experience active migraine attacks (OR 1.9, 95% 
CI 1.2-3.1), and not in those with just a history of migraine without recent attacks,82
IV. The risk is higher in those who experience >12 attacks per year (OR 1.7, 95% 
CI 1.1-2.8).83 
Neuroimaging. A number of neuroimaging studies over the past decade revealed a 
higher prevalence of subclinical brain lesions in migraineurs, including infarcts and 
white matter hyperintensities, suggesting acute or chronic ischemic disease. CAMeRA 
(Cerebral Abnormalities in Migraine and epidemiological Risk Analysis) was a cross-
sectional, population-based MRI lesion prevalence study in subjects between ages 
30 and 60 (mean age 48; 161 migraine with aura, 134 migraine without aura and 140 
matched controls) randomly selected from the Genetic epidemiology of Migraine 
study. Data suggested an increased risk of subclinical posterior circulation infarct-like 
lesions, mostly located in the cerebellum, in migraineurs compared to controls (OR 7.1, 
95% CI 0.9-55).78,84 Important insights are:
I. The risk was substantially higher in migraineurs with aura (OR 13.7, 95% CI 1.7-112),
II. The risk was also higher with frequent migraine attacks (≥1 attack/month) (OR 15.8, 
95% CI 1.8-140),
III. The risk was independent of triptan use or vascular risk factors,
IV. In the 9-year follow up of the same cohort, none of the lesions disappeared, and 
new posterior circulation lesions were found in 5% of migraineurs compared with 
none in control subjects.85 
The conclusions of CAMeRA study were later independently confirmed in the 
Age Gene/environment Susceptibility Reykjavik study,86 and in the population-based 
epidemiology of Vascular Aging study (780 subjects, mean age of 69).87 Clinical 
contrasts between migraine and stroke make this association highly intriguing:
1. Unlike the perceived benign nature of migraine (i.e., no imminent risk of injury), 
stroke is: (i) an acute and often catastrophic cerebrovascular event, (ii) the leading 
cause of acquired physical disability in adults in the US,88 and (iii) the second leading 
cause of mortality worldwide.70 
2. Stroke is predominantly a disease of the elderly, while migraine prevalence peaks 
around age 40. 
3. Stroke risk is higher in males than females of reproductive age, whereas migraine is 
higher in females of reproductive age and increases stroke risk most prominently 
in this group.
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Investigation of the mechanisms underlying the association between migraine and 
stroke can impact hundreds of millions of people worldwide.
5.  TRANSGENIC ANIMAL MODEL S Of HUMAN MIGRAINE 
SYNDROMES
Modeling susceptibility to migraine. In order to elucidate the mechanisms linking 
migraine with aura and stroke, animal models are needed. While animal models of stroke 
are plenty, animal models of migraine with aura are relatively scarce. Migraine is an inherited 
disease.89 Genetic determinants of migraine susceptibility, occurrence and severity range 
from rare monogenic inherited conditions (e.g., a single mutation is sufficient to cause 
disease in a patient) with large effect sizes to common polygenic influences (e.g., multiple 
polymorphisms are needed to cause disease in a patient) with small effect sizes. While 
the latter (i.e., common variants with small effects) is difficult to model experimentally, 
transgenic mouse models expressing human migraine mutations have been generated 
that recapitulate the clinical features of monogenic inherited conditions characterized by 
migraine with aura as well as ischemic stroke (e.g., CADASIL90, 91). Among these are mutant 
mouse models of familial hemiplegic migraine (FHM).
familial hemiplegic migraine. Hemiplegic migraine is a rare monogenic form of 
migraine with aura characterized by motor weakness during the attacks sometimes 
accompanied by sensory, aphasic, visual and basilar symptoms, that can be sporadic, 
or familial (autosomal dominant), linked to genes involved in ion regulation (Table 1). 
Auras are often severe and prolonged, and a third of patients can experience a 
decrease in level of consciousness and even coma, which may be prolonged.92 The 
net result of all FHM mutations identified to date is dysregulation of membrane ionic 
equilibrium and hyperexcitability, predicting enhanced susceptibility to SD as the 
overarching theme and the overlapping feature between migraine and stroke. FHM 
has been used as a model for more common forms of migraine with aura because 
of shared clinical features and trigger factors, female preponderance, and because 
two thirds of FHM patients and their first-degree relatives also suffer from attacks of 
common migraine with and without aura.
Table 1. Familial hemiplegic migraine genes identified to date. Modified from Russell and Ducros, 2011.92
fHM1 fHM2 fHM3
Chromosome 19p13 1q23 2q24
Gene CACNA1A ATP1A2 SCN1A





Catalytic α2 subunit of a 
glial and neuronal Na+/K+ 
ATPase







familial hemiplegic migraine type 1. FHM1 is caused by mutations in the pore-
forming α
1A
 subunit of neuronal Ca
V
2.1 (P/Q-type) voltage-gated Ca2+ channels 
(Figure 7). Mutations shift the voltage-current relationship of the channel to the left 
so that channels open at more negative membrane potentials (i.e., upon smaller 
membrane depolarizations), and stay open longer, increasing the Ca2+ influx. Ca
V
2.1 
channels are major regulators of presynaptic glutamate release. The net result is 
increased presynaptic Ca2+ entry and glutamate release resulting in enhanced cerebral 
excitability93 that may be shared with more common forms of migraine.13 Among the 
FHM1 mutations identified to date, the S218L missense mutation confers stronger 
gain of Ca
V
2.1 channel function and a more severe clinical phenotype with prolonged 
auras that can progress to coma.94,95 In contrast, the R192Q mutation is associated with 
modest gain of Ca
V
2.1 channel function and pure hemiplegic auras.96
figure 7. fHM1 mutations and the Ca
V
2.1 gain-of-function. The two missense mutations studied 
as part of this thesis are also shown (S218L and R192Q). Blue arrows show the direction of change by 
the S218L mutation with an allele dosage effect. Modified from Pietrobon, 2005.97
6.  OUTLINE Of THE THESIS
The overall hypothesis. The central hypothesis states that susceptibility to SD 
determines both the susceptibility to migraine with aura and the susceptibility to 
hypoxic/ischemic injury in the same direction. Therefore, factors that enhance the 
susceptibility to SD increase the likelihood of migraine with aura as well as ischemic 
stroke. Such factors that can modulate the susceptibility to SD may include genes, 
hormones and pharmacological agents. 
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Figure 8. The central hypothesis. 
 
The hypothesis predicts that genetic, hormonal and pharmacological modulators that 
enhance or suppress SD susceptibility will render the brain more or less susceptible to 
ischemic injury, respectively (Figure 8). As such, SD is hypothesized to be the missing link 
between migraine and ischemic stroke. In order to test the hypothesis in a logical sequential 
manner, it is first necessary to identify and characterize a set of factors that modulate the 
susceptibility to SD that mimic the clinical observations of susceptibility to migraine aura 
(Figure 8, step 1), and then study the impact of those factors on outcome of a cerebral 
ischemic event (Figure 8, step 2). 
 
The aim of this thesis is to investigate how genetic, hormonal and pharmacological 
modulators of SD susceptibility will influence the susceptible to ischemic injury. To this end 
we will unravel underlying mechanisms of SD susceptibility and susceptibility to ischemic 
injury by making use of two transgenic mouse models of migraine that carry migraine-
relevant gene mutations in voltage-gated CaV2.1 Ca2+ channels (Chapters 2 and 3) and will 
review all relevant clinical and experimental data from the literature (Chapter 4).    
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The hypothesis predicts that genetic, hormonal and pharmacological modulators 
that enhance or suppress SD susceptibility will render the brain more or less susceptible 
to ischemic injury, respectively (Figure 8). As such, SD is hypothesized to be the 
missing link between migraine and ischemic stroke. In order to test the hypothesis 
in a logical sequential manner, it is first necessary to identify and characterize a set of 
factors that modulate the susceptibility to SD that mimic the clinical observations of 
susceptibility to migraine aura (Figure 8, step 1), and then study the impact of those 
factors on outcome of a cerebral ischemic event (Figure 8, step 2).
The aim of this thesis is to investigate how genetic, hormonal and pharmacological 
modulators of SD susceptibility will influence the susceptible to ischemic injury. To this 
end we will unravel underlying mechanisms of SD susceptibility and susceptibility to 
ischemic injury by making use of two transgenic mouse models of migraine that carry 
migraine-relevant gene mutations in voltage-gated Ca
V
2.1 Ca2+ channels (Chapters 2 
and 3) and will review all relevant clinical and experimental data from the literature 
(Chapter 4).
In Chapter 2, we describe the genetic and gonadal hormone modulation of cortical 
SD susceptibility using state-of-the-art in vivo electrophysiological studies under full 
systemic physiological monitoring and maintenance in mice. To characterize the 
genetic modulation, we utilize two transgenic (knock-in) mouse models of FHM1 
expressing the Cacna1a R192Q or S218L missense mutation in Ca
V
2.1 voltage-gated 
(P/Q-type) Ca2+ channels. As mentioned above, the magnitude of single channel gain-
of-function is larger in S218L mutants compared with R192Q, and with homozygous 
mutants compared with heterozygotes. Therefore, the use of two mutations and three 
genotypes (wild-type controls, heterozygous and homozygous mutants) allows a 
graded modulation the SD susceptibility. Chapter 2A also dissects the female gonadal 
hormone modulation of CSD susceptibility by gonadectomy (i.e., ovariectomy) and 
hormone replacement, and draws parallels between the clinical symptomatology of 
FHM and the neurological signs displayed by FHM1 mutant mice after an SD. Because 
higher SD susceptibility in female mutants can in part be due to an inhibitory effect of 
male gonadal hormones on SD in male mice, in Chapter 2B we investigate the effect of 
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an allele dosage effect. Modified from Pietrobon, 2005.97 
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In Chapter 2, we describe the genetic and gonadal hormone modulation of cortical SD 
susceptibility using state-of-the-art in vivo electrophysiological studies under full systemic 
physiological monitoring and maintenance in mice. To characterize the genetic modulation, 
we utilize two transgenic (knock-in) mouse models of FHM1 expressing the Cacna1a 
R192Q or S218L missense mutation in CaV2.1 voltage-gated (P/Q-type) Ca2+ channels. As 
mentioned above, the magnitude of single channel gain-of-function is larger in S218L 
mutants compared with R192Q, and with hom zygous mutants compared with 
heterozygotes. Therefore, the use of two mutat ons and three genotypes (wild-type controls, 
heterozygous and homozygou  muta ts) allows a graded modulation the SD susceptibility. 
Chapter 2A also dissects the female gonadal hormone modulation of CSD susceptibility by 
gonadectomy (i.e., ovariectomy) and hormone replacement, and draws parallels between 
the clinical symptomatology of FHM and the neurological signs displayed by FHM1 mutant 
mice after an SD. Because higher SD susceptibility in female mutants can in part be due to 
an inhibitory effect of male gonadal hormones on SD in male mice, in Chapter 2B we 
investigate the effect of androgens on SD once again using gonadectomy (i.e., 
orchiectomy). Ischemic events are not limited to cortex; therefore, in Chapter 2C we study 
the SD susceptibility in subcortical structures, including striatum, th lamus and 
hippocampus, and its gene ic and gonadal hormone modulation, with the same graded 
approach usin  different mutants, genotypes a d sexes as described above. Altogether, 
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Chapter 1
androgens on SD once again using gonadectomy (i.e., orchiectomy). Ischemic events 
are not limited to cortex; therefore, in Chapter 2C we study the SD susceptibility in 
subcortical structures, including striatum, thalamus and hippocampus, and its genetic 
and gonadal hormone modulation, with the same graded approach using different 
mutants, genotypes and sexes as described above. Altogether, studies in Chapter 2 set 
the stage to investigate the same genetic and hormonal modulators on the outcome 
of cerebral ischemic events in Chapter 3.
In Chapter 3, we build upon the data obtained in Chapter 2 and investigate how 
SD modulators impact the outcome of cerebral ischemic events. In Chapter 3A, we 
test the impact of genetic susceptibility to SD on susceptibility to ischemic injury 
by making use of FHM1 knock-in mouse models. By comparing the R192Q and S218L 
mutants, different genotypes (heterozygotes vs. homozygotes) and sexes, we get an 
opportunity to study the correspondence between SD susceptibility and ischemic 
sensitivity across a wide range of phenotypes. Chapter 3B tests the opposite effect, 
i.e., decreased SD susceptibility, using chronic treatment by migraine prophylactic 
drugs known to suppress SD. By studying two drugs and comparing the effects of 
chronic treatment (i.e., mimicking migraine prophylaxis) to acute effects of a single 
dose, we once again get an opportunity to study a wide range of effect size. And finally 
in Chapter 3C, we take the first step towards clinical translation in a retrospective 
case-control study, by testing whether a history of migraine, particularly migraine 
with aura, accelerates infarction of ischemic penumbra in acute human stroke as well. 
Lastly, Chapter 4 puts the data generated in this thesis and all relevant clinical and 
experimental data from the literature together into a comprehensive review to form a 
synthesis that can explain the clinical association between migraine and stroke. Novel 
hypotheses and potential experimental approaches to test them are proposed to 
elucidate potential mechanisms.
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Familial hemiplegic migraine type 1 (FHM1) is an autosomal dominant subtype of 
migraine with aura that is associated with hemiparesis. As with other types of migraine, 
it affects women more frequently than men. FHM1 is caused by mutations in the 
CACNA1A gene, which encodes the α
1A
 subunit of Ca
v
2.1 channels; the R192Q mutation 
in CACNA1A causes a mild form of FHM1, whereas the S218L mutation causes a severe, 
often lethal phenotype. Spreading depression (SD), a slowly propagating neuronal and 
glial cell depolarization that leads to depression of neuronal activity, is the most likely 
cause of migraine aura. Here, we have shown that transgenic mice expressing R192Q or 
S218L FHM1 mutations have increased SD frequency and propagation speed; enhanced 
corticostriatal propagation; and, similar to the human FHM1 phenotype, more severe 
and prolonged post-SD neurological deficits. The susceptibility to SD and neurological 
deficits is affected by allele dosage and is higher in S218L than R192Q mutants. Further, 
female S218L and R192Q mutant mice were more susceptible to SD and neurological 
deficits than males. This sex difference was abrogated by ovariectomy and senescence 
and was partially restored by estrogen replacement, implicating ovarian hormones in 
the observed sex differences in humans with FHM1. These findings demonstrate that 
genetic and hormonal factors modulate susceptibility to SD and neurological deficits 
in FHM1 mutant mice, providing a potential mechanism for the phenotypic diversity of 
human migraine and aura. 
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INTRODUCTION
Spreading depression (SD) is characterized by an intense depolarization of neuronal 
and glial membranes that propagates in brain tissue at a rate of approximately 3 mm/
min.1,2 evoked when local extracellular K+ concentrations exceed a critical threshold, 
SD is associated with disruption of membrane ionic gradients, and massive K+ efflux and 
glutamate release; both are believed to depolarize adjacent neurons and glia, thereby 
facilitating its spread. There is growing evidence from animal experiments, suggesting 
that cortical SD (CSD) is the electrophysiological event underlying migraine aura and 
a possible trigger of headache mechanisms.3-5 In humans, evidence for a causal role 
of SD in the aura comes from functional MRI performed during migraine with aura 
attacks.6,7 
SD is also implicated in the pathophysiology of familial hemiplegic migraine (FHM), 
an autosomal dominant subtype of migraine with aura associated with hemiparesis.8 
The aura and headache features are otherwise identical to those in the common, 
multi-factorial forms of migraine. This and the fact that the majority of FHM patients 
also experience attacks of common migraine with or without aura9 make FHM a valid 
model for studying the pathogenesis of common, complex types of migraine. 
Thus far, 3 FHM genes have been identified.10 The FHM1 CACNA1A gene encodes 
the pore-forming α
1A
-subunit of neuronal, voltage-gated Ca
v
2.1 (previously known as 
P/Q-type) calcium channels.11,12 Two knock-in FHM1 mouse models, carrying the human 
pathogenic R192Q or S218L missense mutation, were generated.13,14 In patients, the 
R192Q mutation causes pure FHM without other associated neurological features,12 
whereas the S218L mutation causes a severe migraine phenotype with excessive 
and often fatal cerebral edema.15 When expressed in transfected cultured neurons, 
both mutations shift channel opening toward more negative membrane potentials 
and delay channel inactivation; the S218L mutation causes more pronounced single-
channel gain of function than R192Q.14,16 As a result, channels open with smaller 
depolarization and stay open longer, allowing more Ca2+ to enter presynaptic 
terminals. FHM1 mouse models exhibit a reduced threshold for electrically evoked 
CSD and increased SD velocity.13,17
Gonadal hormones are important modulators of migraine18 and cortical 
excitability.19-21 In migraine with aura, the incidence of attacks reportedly increases 
during periods of high circulating estrogen.18,22,23 Higher plasma estrogen 
concentrations were measured during normal menstrual cycle in migraineurs with 
aura.24 Whereas the prevalence of migraine is similar in boys and girls before puberty 
(4%), after puberty it rises to about 3-fold higher in adult females (25%) than in males 
(8%).25,26 A female preponderance is also described for familial (5:2 ratio) and sporadic 
(4.25:1 ratio) hemiplegic migraine.9,27,28 
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In this study, we investigated the modulating effect of different allelic mutations, 
gene dosage, and gonadal hormones on SD susceptibility and subsequent neurological 
deficits as surrogates for migraine aura in mouse models of FHM1. We found that both 
FHM1 mutant strains exhibited enhanced SD susceptibility, and SD induced severe and 
prolonged unilateral motor deficits akin to the human FHM phenotype. Furthermore, 
both SD susceptibility and severity of neurological deficits were modulated by: (a) 
the degree of gain of function caused by allelic mutations, (b) allele dosage, and (c) 
female gonadal hormones. Our data provide a potential mechanism for the severe 
and prolonged neurological deficits in FHM patients and underscore that genetic 
and hormonal factors contribute to the phenotypic diversity of human migraine 
syndromes. 
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mutations shift channel opening toward more negative membrane potentials and delay 
channel inactivation; the S218L mutation causes more pronounced single-channel gain of 
function than R192Q (14, 16). As a result, channels open with smaller depolarization and 
stay open longer, allowing more Ca2+ to enter presynaptic terminals. FHM1 mouse models 




Figure 1. Enhanced CSD susceptibility in FHM1 mutant mice. (A) Representative 
electrophysiological recordings showing increased frequency of slow (DC) potential shifts 
during repetitive CSDs in male and female homozygous R192Q or S218L mutants compared 
with WT mice evoked by topical KCl application (300 mM) for 30 minutes. The number of CSDs 
was substantially higher in FHM1 mutant strains compared with WT controls and in female 
mutants versus males. Calibration bars: vertical, 20 mV; horizontal, 10 minutes. (B) The impact 
of R192Q and S218L mutations, allele dosage, and sex on CSD frequency and propagation 
speed (upper and lower graphs, respectively). Higher CSD frequencies and propagation 
speeds were found in both FHM1 mutants, with values higher in S218L than in R192Q mutants 
and an allele dosage relation. CSD frequency was greater and propagation faster in females 
compared with males in both FHM1 mutant strains. No sex difference was found in WT mice. 
Covariance analysis revealed that 82% of variation in CSD frequency and 93% of variation in 
CSD propagation speed were explained by the independent variables mutation, genotype, and 
sex (see Methods). Numbers of mice per group are shown within the bars. HET, heterozygous; 
HOM, homozygous. Data are mean ± standard deviation. **P < 0.001, *P < 0.01 versus male 
in CSD frequency and propagation speed; †P < 0.001 versus WT and homozygous mutant; ‡P 
< 0.001 versus WT and heterozygous mutant; §P < 0.001 versus corresponding R192Q 
genotype.  
figure 1. ed  cepti ilit  in fHM1 mutant mice. (A) Repr sentative 
electr siol i l i s i  increase  frequency of slow (DC) potential shifts 
during r titi  Ds in ale and female homozygous R192Q or S218L mutants compared with 
WT mice evoked by topical KCl application (300 mM) for 30 minutes. The number of CSDs was 
substantially higher in FHM1 mutant strains compared with WT controls and in female mutants 
versus males. Calibration bars: vertical, 20 mV; horizontal, 10 minutes. (B) The impact of R192Q 
and S218L mutations, allele dosage, and sex on CSD frequency and propagation speed (upper and 
lower graphs, respectively). Higher CSD frequencies and propagation speeds were found in both 
FHM1 mutants, with values higher in S218L than in R192Q mutants and an allele dosage relation. 
CSD frequency was greater and propagation faster in females compar d with males in both FHM1 
mutant strains. No sex differ nce was found in WT m ce. Covariance analysis revealed that 82% of 
variation in CSD frequ ncy and 93% of variation in CSD propagation speed were explained by the 
independent variables utation, genotype, and sex (see Methods). Numbers of mice per group 
are shown within the bars. HeT, heterozygous; HOM, homozygous. Data are mean ± standard 
deviation. **P < 0.001, *P < 0.01 versus male in CSD frequency and propagation speed; †P < 0.001 
versus WT and homozygous mutant; ‡P < 0.001 versus WT and heterozygous mutant; §P < 0.001 
versus corresponding R192Q genotype. 
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RESULTS 
CSD susceptibility in fHM1 mutant mice is modulated by Ca
v
2.1 gain of function, 
allele dosage, and ovarian hormones. SD susceptibility was assessed by: (a) counting 
the number of evoked SDs during continuous topical KCl (300 mM) application and (b) 
measuring the propagation speed of SDs between 2 recording electrodes. The values 
in the different strains were compared. In WT mice, epidural KCl evoked repetitive CSDs 
(9.5 ± 1.0 SDs/h) with a propagation speed of 2.8 ± 0.2 mm/min. Both the frequency 
and the propagation speed were increased in the R192Q mutants and even more so in 
the S218L mutants (Figure 1). Furthermore, heterozygous mice of both FHM1 mutant 
strains showed SD frequencies and propagation speeds intermediate between those 
in WT and homozygous mutant mice, indicating an allele dosage effect. The duration 
or amplitude of SDs after KCl application did not differ among the groups (Table 1). 
The electrocorticogram did not show seizure activity in mutant mice during these SD 
recordings under anesthesia. 
SD susceptibility (i.e., frequency and propagation speed) was strikingly higher 
in females than in males of both FHM1 mutant strains but not in WT mice (Figure 1). 
When tested in R192Q mutant mice, the sex difference was abrogated by ovariectomy, 
implicating effects of female gonadal hormones in adult brain, rather than a perinatal 
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(9.5 ± 1.0 SDs/h) with a propagation speed of 2.8 ± 0.2 mm/min. Both the frequency and 
the propagation speed were increased in the R192Q mutants and even more so in the 
S218L mutants (Figure 1). Furthermore, heterozygous mice of both FHM1 mutant strains 
showed SD frequencies and propagation speeds intermediate between those in WT and 
homozygous mutant mice, indicating an allele dosage effect. The duration or amplitude of 
SDs after KCl application did not differ among the groups (Table 1). The 
electrocorticogram did not show seizure activity in mutant mice during these SD recordings 
under anesthesia.  
 
SD susceptibility (i.e., frequency and propagation speed) was strikingly higher in females 
than in males of both FHM1 mutant strains but not in WT mice (Figure 1). When tested in 
R192Q mutant mice, the sex difference was abrogated by ovariectomy, implicating effects 
Table 1. Electrophysiological measures of CSD and systemic physiological parameters 
in FHM1 mutant mice. Values are mean ± standard deviation. CSD duration was measured 
at half amplitude. Because the duration, but not the amplitude, gradually decreased upon 
repetitive SDs in all groups, both the duration of first CSD and the average of all CSDs are 
presented. Group differences are not statistically significant (1-way ANOVA). Estrogen: 0.075 
mg/pellet 21-day release. Mean arterial blood pressure (MABP) and arterial partial pressure 
of oxygen (pO2) and carbon dioxide (pCO2) are expressed in mmHg, averaged over 1-hour 
recordings. n, number of mice; Ovx, ovariectomized; HET, heterozygous; HOM, homozygous. 
Table 1. Electrophysiological measures of CSD and systemic physiological parameters in fHM1 
mutant mice. Values are mean ± standard deviation. CSD duration was measured at half amplitude. 
Because the duration, but not the amplitude, gradually decreased upon repetitive SDs in all groups, 
both he duratio  of first CSD and t  average of all CSDs are presented. Group differences are 
not statistically significant (1-way ANOVA). e rogen: 0.075 mg/pellet 21-day release. Mean arterial 
blood pressure (MABP) and arterial partial pressure of oxygen (pO
2
) and carbon dioxide (pCO
2
) are 
expressed in mmHg, averaged over 1-hour recordings. n, number of mice; Ovx, ovariectomized; 
HeT, heterozygous; HOM, homozygous.
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organizational effect of gonadal hormones or chromosomal sex per se, as modulators 
of cortical excitability (Figure 2). Consistent with these findings, SD frequencies and 
propagation speeds were significantly reduced in senescent female R192Q mutant 
mice after putative cessation of estrous cycling and reduced gonadal hormone 
production (Figure 2). Chronic estrogen replacement by subcutaneous implantation 
of pellets containing 0.075 mg 17β-estradiol (3-week release) was associated with a 
small increase in SD susceptibility in ovariectomized R192Q mutant, but not in WT, 
mice (13 ± 1 vs. 16 ± 1 SDs/h in control and estrogen-treated homozygous R192Q 
mutant, n = 5 and 6, respectively; P < 0.01). A lower dose of estrogen (0.025 mg/pellet) 
was ineffective in both WT and homozygous R192Q mutant mice (data not shown). 
Neither gonadectomy nor advanced age influenced SD susceptibility in WT mice using 
the described protocols (Figure 2). These data suggest that female gonadal hormones 
modulate SD susceptibility only in mice that have a genetic predisposition. 
fHM1 mutant mice develop severe and prolonged motor deficits after SD that are 
modulated by gene dosage and sex. Prior to SD induction, both WT and FHM1 mutant 
strains appeared phenotypically normal and did not exhibit neurological deficits when 
assessed using the wire grip test and neurological examination protocols. In WT mice, 
a single SD induced by brief topical application of 300 mM KCl caused only mild deficits 
that lasted less than 10 minutes in the wire grip test and only a mild and short-lasting 
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S218L mutant mice (Figure 4, A and B). No seizure ctivity was observed in these 
recordings under anesthesia. These data indicated that delayed electrophysiological 
recovery of cortical synaptic function was not the cause of prolonged and severe unilateral 
motor deficits after CSD in FHM1 mutant mice.  
 
 
Corticostriatal propagation of SD is facilitated in FHM1 mutant mice. CSD occasionally 
propagates into subcortical structures in rodent brain (29, 30). We therefore tested 
whether prolonged post-SD neurological deficits such as hemiplegia and circling were 
associated with enhanced subcortical spread into the striatum. In WT mice, CSDs did not 
reach the striatum (Figure 5; see Methods for experimental conditions). In contrast, CSDs 
Figure 2 Gonadal hormone–mediated modulation of CSD susceptibility in female FHM1 
mutant mice. The impact of ovariectomy and senescence on CSD susceptibility in WT and 
homozygous R192Q mutant mice. Both ovariectomy (3–4 months of age; gray) and 
senescence (13 months of age; white) reduced CSD frequency (left panel) and propagation 
speed (right panel) in homozygous female R192Q to the level of male mutants (see Figure 
1B). Ovariectomy (n = 5) and aging (n = 7) had similar effects in heterozygous female R192Q 
mice (data not shown). In WT mice, gonadectomy or senescence did not alter CSD 
susceptibility. Experiments were performed 3 weeks after ovariectomy. Numbers of mice for 
each group are shown within the bars. Ovx, ovariectomized. Data are mean ± standard 
deviation. *P < 0.001, #P < 0.01 versus WT; †P < 0.001 versus naive young female mice of the 
same genotype.  
figure 2. Gonadal hormone–mediated modulation of CSD susceptibility in female fHM1 mutant 
mice. The impact of ovariectomy and senescence on CSD susceptibility in WT and homozygous 
R192Q mutant mice. Both ovariectomy (3–4 months of age; gray) a d senescence (13 months of age; 
white) reduced CSD frequency (left panel) and propagation speed (right panel) in homozygous 
female R192Q to the level of male muta ts (see Figure 1B). Ovariectomy (n = 5) and aging (n = 7) had 
similar effects in heterozygous female R192Q mice (data not shown). In WT mice, gonadectomy 
or senescenc  did not alter CSD susceptibility. experi nts wer  p rforme  3 weeks after 
ovariectomy. Numbers of mice for each group are shown within the bars. Ovx, ovariectomized. 
Data are mean ± standard deviation. *P < 0.001, #P < 0.01 versus WT; †P < 0.001 versus naive young 
female mice of the same genotype. 
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hemiparesis that completely recovered before the first neurological assessment at 
5 minutes after SD induction (Figure 3A). In contrast, a single SD caused hemiplegia 
with leaning and circling in both R192Q and S218L mutant mice (Figure 3, Supplemental 
Figure 1, and Supplemental Videos 1–13, available at http://www.jci.org/articles/
view/36059#sd). In the wire grip test, they were initially unable to move along the wire 
and fell more often than WT mice. S218L mutants were more severely impaired, and 
unlike R192Q mice, some remained unconscious for up to 10 minutes after a single SD. 
Homozygous FHM1 mutant mice were impaired more than heterozygotes, indicating 
an allele dosage relation (Figure 3). Interestingly, FHM1 mutants showed 1 or more 
transient episodes of neurological deterioration after full or partial recovery during 
the 60- to 80-minute monitoring period (Supplemental Figure 1e). 
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readily propagated into the striatum in FHM1 mutant mice (Figure 5A). Corticostriatal SD 
propagation was more frequent and arose with shorter latency in S218L compared with 
R192Q mutant mice (P < 0.05), homozygotes compared with heterozygotes of both mutant 
strains (P < 0.01), and female homozygous (but not heterozygous) mutants compared with 
males (P < 0.01; Figure 5B and Table 2). SD did not propagate to thalamus and 
hippocampus under our experimental conditions (n = 7 heterozygous female and 
homozygous male S218L mice; n = 2 WT mice; data not shown). Therefore, corticostriatal 
SD propagation corresponded well to the severity of post-SD neurological deficits and was 
modulated by: (a) the degree of ion channel dysfunction; (b) allele dosage; and (c) sex. 
These data implicate corticostriatal SD propagation as a likely explanation for the more 
severe motor deficits in FHM1 mutant mice.  
 
figure 3. Prolonged and severe neurological deficits after SD in fHM1 mutant mice. Time 
course of neurological deficits in WT and FHM1 mutant mice after a single SD (A) or 9 SDs over 
1 hour (B), as assessed by wire grip score and latency as well as neurological score. (A) Impact of 
allelic mutations and allele dosage. In WT mice, deficits were mild and short-lasting in wire grip 
test and undetectable by neurological scoring (triangles). FHM1 mutants developed severe and 
prolonged deficits (P < 0.01 versus WT). These deficits were markedly more severe and prolonged 
in homozygous S218L (black circles) than in homozygous R192Q mutants (gray circles; P < 0.01) or 
heterozygous S218L mutants (squares; P < 0.01 in wire grip test, P < 0.05 in neurological scoring). 
n  = 13, 7, 6, and 3 WT, homozygous R192Q, heterozygous S218L, and homozygous S218L mutant 
mice, respectively. (B) Sex differences. In WT mice, deficits were mild and completely recovered 
within 45 minutes after 9 SDs. In contrast, R192Q mutant mice developed severe and prolonged 
deficits that lasted 80 minutes or more after 9 SDs (P < 0.01 versus WT). Importantly, female mutant 
mice (circles) were more severely affected than males (squares; P < 0.01). Deficits did not differ 
between WT males and females; therefore, data were pooled (triangles). n = 15, 6, and 7 WT, male 
R192Q, and female R192Q mutant mice, respectively. error bars were omitted for clarity but were 
less than 25% of mean. 
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All 3 homozygous S218L mutant mice developed generalized seizures 45, 55, and 75 
minutes after a single SD. Two of the mice died immediately after the seizure due to 
respiratory arrest; the third mouse survived the seizure and completely recovered at 
80 minutes. Seizures were not observed in heterozygous S218L or homozygous R192Q 
mutant mice during recovery from SD. The deficits in heterozygous S218L mutant 
mice in the absence of overt seizure activity suggest that the clinical phenotype was 
most likely due to SD and not seizure activity. 
Compared with a single SD, multiple SDs (9 in 1 hour) caused more severe motor 
deficits. In WT mice, deficits in the wire grip test were detectable for 30 minutes after 
the last SD (Figure 3B), whereas multiple SDs caused even more severe deficits in 
R192Q mutants. Moreover, female R192Q mutant mice developed more severe and 
longer-lasting deficits than males (Figure 3B). 
Recovery of cortical evoked potentials after SD is not delayed in fHM1 mutant 
mice. To test whether prolonged neurological deficits were due to a slower recovery 
of cortical electrophysiological function, we recorded somatosensory evoked 
potentials in the whisker barrel cortex after a single SD. evoked potentials were 
abolished after SD but reemerged within approximately 2 minutes and completely 
recovered to pre-SD baseline levels within 10 minutes (Figure 4A). The recovery rate 
was identical in WT and R192Q or S218L mutant mice (Figure 4, A and B). No seizure 
activity was observed in these recordings under anesthesia. These data indicated that 
delayed electrophysiological recovery of cortical synaptic function was not the cause 
of prolonged and severe unilateral motor deficits after CSD in FHM1 mutant mice. 
Corticostriatal propagation of SD is facilitated in fHM1 mutant mice. CSD 
occasionally propagates into subcortical structures in rodent brain.29,30 We therefore 
tested whether prolonged post-SD neurological deficits such as hemiplegia and circling 
were associated with enhanced subcortical spread into the striatum. In WT mice, 
CSDs did not reach the striatum (Figure 5; see Methods for experimental conditions). 
In contrast, CSDs readily propagated into the striatum in FHM1 mutant mice (Figure 
5A). Corticostriatal SD propagation was more frequent and arose with shorter latency 
in S218L compared with R192Q mutant mice (P < 0.05), homozygotes compared with 
heterozygotes of both mutant strains (P < 0.01), and female homozygous (but not 
heterozygous) mutants compared with males (P < 0.01; Figure 5B and Table 2). SD did 
not propagate to thalamus and hippocampus under our experimental conditions (n = 7 
heterozygous female and homozygous male S218L mice; n = 2 WT mice; data not shown). 
Therefore, corticostriatal SD propagation corresponded well to the severity of post-SD 
neurological deficits and was modulated by: (a) the degree of ion channel dysfunction; 
(b) allele dosage; and (c) sex. These data implicate corticostriatal SD propagation as a 
likely explanation for the more severe motor deficits in FHM1 mutant mice. 
39
fHM1 mutant mice develop delayed recurrent SDs after a single KCl-induced SD. 
In order to test whether prolonged neurological deficits were caused by recurrent 
SDs, we recorded from cortex and striatum simultaneously for 60 minutes after one 
initial SD induced by brief topical KCl application that was followed by extensive 
saline wash. In all FHM1 knock-in mice, 1 or more recurrent SDs were observed 
throughout the recording period (range, 1-55 minutes after the initial SD, n = 6 
heterozygous female and 2 homozygous male S218L mutants and n = 3 homozygous 
female R192Q mutants; Supplemental Figure 3). None of the WT mice showed SD 
recurrence. As suggested by their latency, recurrent SDs appeared to originate from 
cortex and consistently spread into striatum. In a few instances, there was evidence 
for cortico-striato-cortical reentrant SDs. In the absence of prior SD induction, we 
did not observe spontaneous SDs during 60-minute recordings in mutant or WT 
strains (n = 6). 
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channel mutations) and physiological factors (gonadal hormones) modulating 
susceptibility to migraine also modulate SD susceptibility. Enhanced SD susceptibility 
shows a clear relation to the degree of single-channel gain of function caused by S218L 
and R192Q mutations and is associated with more severe and prolonged neurological 
deficits after SD, consistent with the clinical phenotypes observed in FHM1 patients. Both 
enhanced SD susceptibility (i.e., frequency and propagation speed) and neurological 
deficits are linked to the propensity of corticostriatal SD propagation and are modulated 
by the interaction of allelic mutations, gene dosage, and gonadal hormones.  
 
 
Figure 4 The recovery of whisker pad stimulation–evoked cortical field potentials. (A) 
Representative tracings showing field potentials in a female WT (top), homozygous female 
R192Q mutant (middle), and heterozygous female S218L mutant mouse (bottom), evoked by 
electrical stimulation of the whisker pad (black triangles) and recorded from the whisker barrel 
field using extracellular glass micropipettes (400 μm depth, layer IV). Evoked potentials 
ranging from 2 to 4 mV in amplitude at baseline (column a) were abolished upon arrival of SD 
at the recording site (column b) and gradually recovered within less than 10 minutes (columns 
c–e), as shown in the time course graph in B. Calibration bars: vertical, 1 mV; horizontal, 20 
ms. (B) The time course of recovery of somatosensory evoked field potentials (SSEP) after a 
single SD (time 0).The AUC for each evoked field potential (mV • ms) was expressed as 
percent of pre-SD baseline. The rate of recovery of cortical evoked field potentials did not differ 
among WT and FHM1 mutant mice. Recovery of peak amplitudes also did not differ among 
groups (data not shown). Numbers of mice are indicated in the graph. Male and female WT 
mice did not differ; therefore, pooled data are shown. Error bars were omitted for clarity.  
figure 4. The recovery of whisker pad stimulation–evoked cortical field potentials. (A) 
Representative tracings showing field potentials in a female WT (top), homozygous female R192Q 
mutant (middle), and heterozygous female S218L mutant mouse (bottom), evoked by electrical 
stimulation of the whisker pad (black triangles) and recorded from the whisker barrel field using 
xtracellular glass micropipettes (400 μm depth, layer IV). evoked potentials ranging from 2 to 
4 mV in amplitude at b seline (column a) were abolished upon arrival of SD at the recordi g site 
(column b) and gradually recovered within less than 10 i utes (columns c–e), as shown in the time 
course graph i  B. Calibration bars: vertical, 1 mV; horizontal, 20 ms. (B) The time co rse of recovery 
of somatosensory evoked field potentials (SSeP) after a single SD (time 0).The AUC for each evoked 
field potential (mV • ms) was expressed as percent of pre-SD baseline. The rate of recovery of 
cortical evoked field potentials did not differ among WT and FHM1 mutant mice. Recovery of peak 
amplitudes also did not differ among groups (data not shown). Numbers of mice are indicated in the 




figure 5. facilitated corticostriatal SD propagation in fHM1 mutant mice. (A) Representative 
extracellular DC potential shifts recorded simultaneously from cortex and striatum in female WT and 
homozygous R192Q and S218L mutant mice. SD was not observed to propagate into the striatum in any 
of the WT mice. A substantial proportion of CSDs propagated into the striatum in R192Q and to a greater 
extent in the S218L mutant. Calibration bars: vertical, 20 mV; horizontal, 10 minutes. (B) The frequency 
of SDs during continuous topical KCl application (300 mM) to the occipital cortex. CSD frequency (gray 
bars) was substantially higher in S218L and to a lesser extent in R192Q mutant mice than WT. They were 
higher in females compared with males and homozygous FHM1 mutants compared with heterozygotes 
(see Figure 1). CSDs readily propagated into striatum (black bars) in both FHM1 mutant strains, but 
never in the WT. Striatal propagation was more frequent in S218L (lower graphs) compared with R192Q 
mutants (upper graphs) and in females (right) compared with males (left), with an allele dosage relation 
(see Table 2 for latencies between cortical and striatal SDs). Covariance analysis revealed that 83% of the 
variance of striatal SD frequency was explained by the independent variables mutation, genotype, and 
sex (see Methods). n = 3–8 mice per group as shown within each bar. Data are mean ± standard deviation. 




Figure 5 Facilitated corticostriatal SD propagation in FHM1 mutant mice. (A) 
Representative extracellular DC potential shifts recorded simultaneously from cortex and 
striatu  in female WT and homozygous R192Q and S218L mutant mice. SD was not observed 
to propagate into the striatum i  any of the WT ice. A substantial proportion of CSDs 
propagated into the striatum in R192Q nd to a greater extent in the S218L mutant. Calibration 
bars: vertical, 20 mV; horizontal, 10 minutes. (B) The frequency of SDs during continuous 
topical KCl application (300 mM) to the occipital cortex. CSD frequency (gray bars) was 
substantially higher in S218L and to a lesser extent in R192Q mutant mice than WT. They 
were higher in females compared with males and homozygous FHM1 mutants compared with 
heterozygotes (see Figure 1). CSDs readily propagated into striatum (bl ck bars) in both FHM1 
mutant strains, but never in the WT. Striatal propagat on w s more freque t in S218L (low r 
graphs) compared with R192Q mutants (upper graphs) and in females (right) compared with 
males (left), with an allele dosage relation (see Table 2 for latencies between cortical and 
striatal SDs). Covariance analysis revealed that 83% of the variance of striatal SD frequency 
was explained by the independent variables mutation, genotype, and sex (see Methods). n = 
3–8 mice per group as shown within each bar. Data are mean ± standard deviation. *P < 0.01 
versus male; †P < 0.001, §P < 0.05 versus heterozygous mutants; ‡P < 0.01 versus R192Q 
males.  
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The frequency of SDs evoked by topical KCl application and their propagation speed were 
determined as previously described with minor modifications (4). KCl-evoked CSDs were 
dete ted b sed on the characteristic slow DC potential shift and ECoG suppression. The 
frequency of evoked CSDs was determined over 30 min tes on each hemisphere. CSD 
frequencies obtained from the right and left hemispheres did not statistically differ in any 
experimental group and were averaged to calculate the CSD frequency in each mouse. 
Propagation speed was calculated from the distance between the 2 recording electrodes 
divided by the latency between the first CSDs recorded at these sites. The DC shift 




Epidural application of NaCl (300 mM) did not trigger SD or cause neurological deficits in 
sham-operated knock-in controls (n = 2 homozygous female R192Q mutant mice; data 
not shown). In subgroups of WT and FHM1 mutant mice, histopathological assessment of 
the KCl application site after the experimental recordings did not reveal any evidence of 
cortical injury in H&E-stained frozen sections (data not shown).  
Ovariectomy and estrogen replacement. The impact of diminished gonadal hormone 
production on SD susceptibility was studied using ovariectomized (3–4 months old) or 
senescent (13 months old, after cessation of estrous cycle) homozygous R192Q mutant 
Table 2 Corticostriatal propagation latency of SD. Values are mean ± standard deviation, 
expressed in minutes. AP < 0.01 versus heterozygote; BP < 0.01 vs. male; CP < 0.01 versus 
R192Q. See Figure 5 for the number of mice in each group.  
Table 2. Corticostriatal propagation latency of SD. Values are mean ± standard deviation, 
expressed in minutes. AP < 0.01 versus heterozygote; BP < 0.01 vs. male; CP < 0.01 versus R192Q. See 
Figure 5 for the number of mice in each group. 
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DISCUSSION 
Migraine susceptibility is modulated by genetic, physiological, and environmental 
factors. Here, we provide experimental evidence showing that genetic (Ca
v
2.1 
voltage-gated Ca2+ channel mutations) and physiological factors (gonadal hormones) 
modulating susceptibility to migraine also modulate SD susceptibility. enhanced SD 
susceptibility shows a clear relation to the degree of single-channel gain of function 
caused by S218L and R192Q mutations and is associated with more severe and prolonged 
neurological deficits after SD, consistent with the clinical phenotypes observed in 
FHM1 patients. Both enhanced SD susceptibility (i.e., frequency and propagation 
speed) and neurological deficits are linked to the propensity of corticostriatal SD 
propagation and are modulated by the interaction of allelic mutations, gene dosage, 
and gonadal hormones. 
The Ca
v
2.1 calcium channels are important modulators of SD.31,32 The first evidence 
that linked Ca
v
2.1 channel mutations to a CSD phenotype was described in tottering 
and leaner mice. These naturally occurring mouse mutants have loss-of-function 
mutations in their Ca
v
2.1 channels and showed an increase in SD threshold.33 In a 
subsequent study, van den Maagdenberg and colleagues13 demonstrated a reduced 
threshold for SD induced by electrical stimulation in R192Q FHM1 mutant mice. The 
increased SD frequency and propagation speed following epidural KCl application in 
R192Q mutant mice in the present study are in line with these results. Consistent with 
more negative opening voltages and a greater increase in the single-channel opening 
probability associated with S218L mutation, SD susceptibility was even higher in this 
mutant, suggesting incremental modulation of the phenotype by allelic mutations.13,14,16 
Because excitatory neurotransmitters promote SD via NMDA receptors,34-38 we 
speculate that FHM1 mutations facilitate the initiation and propagation of SDs by 
increasing presynaptic Ca2+ influx and subsequent glutamate release. Although 
augmented neurotransmitter release has been shown at the neuromuscular junctions 
of R192Q mutant mice,13,39 this remains to be tested in central synapses. 
Sex hormones. Our data establish the importance of female gonadal hormones as 
modulators of genetically driven enhanced SD susceptibility. Ovarian hormones, rather 
than sex chromosome-related developmental differences in synaptic organization 
and structure, were implicated in aged female mice and after ovariectomy. These 
findings may be clinically relevant, since migraine improves at menopause in two-
thirds of patients.40 The frequency of migraine attacks decreases after age 50, both 
in patients with FHM and those with more typical migraine subtypes.9 estradiol did 
partially restore SD susceptibility when administered chronically to ovariectomized 
R192Q mutant mice. Clinically, estrogen reportedly increases cortical excitability 
in humans during transcranial magnetic stimulation,41 and high doses increase the 
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incidence of aura during hormone replacement therapy.42-44 Moreover, higher 
levels of estrogen are associated with an increase in seizure frequency in females.45 
experimentally, seizure thresholds are decreased during peak estrogen levels,46 
and amygdala kindling is increased.47 estrogen augments excitatory glutamatergic 
neurotransmission by upregulating NMDA receptor expression, downregulating 
glutamate uptake by astrocytes, and increasing the number of dendritic spines, which 
are densely populated with NMDA receptors.19-21 A large body of evidence suggests 
that estrogen modulates nociceptive processing as well,48,49 so that enhanced SD 
susceptibility is only one mechanism by which estrogen may impact migraine. 
Clinical and epidemiological data on hormonal modulation of FHM are sparse. In a 
population-based study, the female/male ratio was 5:2; males and females did not differ 
in age of onset or in symptoms of aura and headache.9 In one case report, a 48-year-old 
woman with hemiplegic migraine ceased to experience any further neurological signs 
during migraine attacks after ovariectomy.50 Hence, available evidence supports the 
notion that female gonadal hormones aggravate the hemiplegic migraine phenotype 
as well. 
The lack of gonadal hormone modulation of SD in WT mice we observed argues 
against a simple additive effect between genetic and hormonal factors and suggests 
that gonadal hormones modulate SD susceptibility predominantly in brains made 
susceptible by gene mutations. The precise nature of the interactions between 
gonadal hormones and mutant Ca
v
2.1 channels remains to be determined. It has been 
shown, however, that estrogen upregulates expression of some voltage-gated Ca2+ 
channels (e.g., L- and T-type) in hypothalamus and pituitary.51-53 expression levels of the 
α
1A
 subunit of P/Q-type channels show sexual dimorphism in anterior pituitary (higher 
in females than in males) and fluctuate during estrous cycle, suggesting a direct 
modulation by female hormones.54 Furthermore, Ca
v
2.1 channels undergo extensive 
alternative splicing that shows sexual dimorphism.55 Therefore, female hormones may 
enhance the impact of genotype on SD phenotype via increased expression or by 
favoring alternative splicing patterns that enhance mutant channel activity. 
It should be noted that Brennan et al. recently reported that SD thresholds are 
reduced by approximately 50% in WT female mice compared with males.56 Using the 
SD frequency model, we did not detect sex differences in the WT strain, despite 95% 
power to detect a 25% difference between the means in our model (α = 0.05). We 
also did not detect a threshold difference using direct epidural cortical electrical 
stimulation (140 μm tip diameter, 200 μm tip separation, 4.3 kΩ tip resistance) very 
similar to that used by Brennan et al.56 (electrical SD threshold, 413 ± 168 [females] vs. 
460 ± 124 [males] μC, n = 11 and 8, respectively; P = 0.7). At present, we do not have 
an explanation for the discrepant results. Nevertheless, consistent with our data, the 
propagation speed, SD duration, and number of successful SD inductions did not differ 
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between WT males and females in their study, and the studies agree that gonadal 
hormones play an important part in modulating SD susceptibility. 
Motor deficits. Motor deficits (i.e., contralateral hemiplegia with leaning and circling) 
were significantly more severe and prolonged in FHM1 mutant mice, as compared with 
the WT strain, lasting 20 minutes or more after induction of a single SD. As can be 
expected from single-channel kinetics,14 the deficits were more severe in S218L than 
in R192Q mutant mice, and often experiments were terminated by fatal generalized 
seizures. Delayed electrophysiological recovery of cortical function did not explain 
the post-SD deficits (Figure 4). Instead, we believe that the propagation of CSD into 
the striatum in FHM1 mutants may have been responsible. The frequency of striatal 
SDs (as well as their propagation speed from cortex to striatum) was greater in the 
homozygous mutants, in female mutant mice, and in the S218L strain, i.e., the one with 
the most severe calcium channel dysfunction.14 
Striatal SDs are associated with contralateral circling and hemiparesis.57-59 CSDs 
did not propagate into the striatum in WT mice, consistent with the absence of 
severe neurological deficits. CSD spreads into the striatum through the amygdala 
as SD propagation is impeded in tissues such as white matter with less than a critical 
density of neurons.1,29,30,60-62 Consistent with this, direct thalamic and hippocampal 
electrophysiological recordings failed to detect concurrent SD propagation into 
these structures in either WT or FHM knock-in mouse. In rats, the proportion of CSD 
propagating into striatum reportedly varied between 4% and 60% in different studies, 
depending on the strain and the use and type of anesthesia, and subcortical propagation 
of CSD could be facilitated pharmacologically (e.g., with pyrrolopyrimidine BW 58271) 
or physiologically (e.g., in undernourished rats).30,59,60 To our knowledge, this has not 
been studied in mice at this level of detail. Our data suggest that FHM1 mutations 
facilitate corticostriatal SD propagation. The anesthetic regimen used in our model 
may explain the complete lack of corticostriatal SD propagation in WT mice.63,64 
Post-SD neurological deficits were not only more severe in the mutant strains but 
also lasted longer than in WT mice. Indeed, mutants showed one or more episodes of 
transient neurological worsening, delaying the neurological recovery after a single 
KCl-induced SD. Prolonged deficits and episodes of transient worsening were linked 
to recurrent and possibly reentrant SDs in FHM1 mutants. It should also be noted 
that SD causes severe and long-lasting tissue hypoperfusion65 and hypoxia in mice.66 
It remains to be tested whether the hemodynamic and metabolic impact of SD is 
more severe in FHM1 mice and whether this contributes to the prolonged post-SD 
neurological deficits. 
Seizures. Recurrent SDs observed in FHM1 mutants might have directly caused or 
predisposed to delayed seizures in the S218L knock-in. Homozygous female S218L 
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knock-in mice developed generalized seizures 45-75 minutes after a single SD. 
Interestingly, the incidence of premature death at a young age (i.e., <20 weeks, both 
males and females) was higher in mice of both knock-in strains, in some cases linked 
to apparently spontaneous seizures (our unpublished observations), suggesting 
that FHM1 mutations predispose to seizures without an experimentally triggered 
SD. SD may also render the cortex transiently hyperexcitable. For example, SD 
enhances excitatory postsynaptic field potentials as well as the repetition rate and 
amplitude of spontaneous rhythmic potentials 20-90 minutes after its induction; it 
augments long-term potentiation in human neocortical slices.67,68 SD is followed 
by hyperexcitability in rat neocortex and spinal cord after transient depression 
of neuronal activity.69,70 Last but not least, SD can directly precipitate seizure-like 
electrocorticogram activity, as first demonstrated by Leão.2 Consistent with our 
findings, epilepsy is more frequent in FHM patients than in the general population, with 
seizures occurring either during FHM attacks71-74 or interictally.75-78 epilepsy has been 
reported in many patients carrying FHM1 mutations.10,71,79-82 For example, 2  patients 
harboring the S218L mutation have developed seizures at the onset of severe attacks 
associated with coma.15,83 
In summary, data showing enhanced SD susceptibility and prolonged neurological 
deficits after SD in genetic mouse models of migraine strengthen the link between 
SD and the migraine aura. Furthermore, they provide mechanistic insight by 
implicating recurrent SDs and facilitated propagation of SD into subcortical 
tissues. The modulation of SD susceptibility, neurological deficits, and subcortical 
propagation by specific FHM1 mutations (i.e., R192Q vs. S218L mutation), genotype 
(i.e., heterozygous vs. homozygous), and gonadal hormones underscores the complex 
synergistic interactions between genetic and hormonal factors determining migraine 
susceptibility. 
METHODS 
Experimental groups. experimental groups are summarized in Table 1. A total of 337 
mice were used in this study. Male and female FHM1 mutant mice, homozygous or 
heterozygous for R192Q or S218L mutation in the mouse Cacna1a gene (encoding the 
α
1A
 pore-forming subunit of Ca
v
2.1 channels), were compared with WT littermates. 
In addition, R192Q mutants were backcrossed onto C57BL6/J mice (Charles River 
Laboratories) for more than 8 generations. None of the measured endpoints differed 
between WT littermates of R192Q mutant and C57BL6/J control mice (data not 
shown). Therefore, data from WT littermates of R192Q mutants and C57BL6/J control 
mice were pooled for the analysis. The S218L mutants were compared with their 
littermates only. 
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 migraine mouse models were generated by a gene 
targeting approach in which the endogenous Cacna1a gene was modified. In the 
R192Q mice,13 we modified the CGG triplet (arginine) of codon 192 to CAG (glutamine) 
using in vitro mutagenesis to introduce the human FHM1 mutation R192Q.12 The 
targeting vector that was used for generating the S218L mice contained the mutant 
TTA (leucine) instead of the original TCA (serine) triplet of codon 218; thus creating 
the S218L mutation that had previously been found in patients.15 This targeting vector 
also contained a PGK-driven neomycin-resistance cassette that was flanked by loxP 
sites in the endogenous HindIII site that is located 537 nucleotides upstream of exon 
5. Chimeras were obtained by injecting correctly targeted e14 eS cells into C57BL/6J 
blastocysts according to standard procedures in order to generate a transgenic line of 
mice. In mice that were used for the experiments, the cassette was deleted by crossing 
these transgenic mice with mice of the eIIA-Cre deleter strain,84 which express Cre 
recombinase driven by the eIIA early promoter. For both the R192Q and S218L mice, 
heterozygous mice (>96% C57BL/6J background) were subsequently interbred to 
provide litters containing all 3 possible genotypes that were used for the experiments. 
Litters were genotyped after weaning by PCRs specific for the respective transgenic 
line, essentially as described previously.13 All experiments were carried out with the 
investigator blinded for genotype, and confirmatory genotyping was done after the 
experiment. All animal experiments were approved by the Massachusetts General 
Hospital Subcommittee on Research Animal Care and performed in accordance with 
the NIH Guide for the care and use of laboratory animals (NIH publication no. 85-23. 
Revised 1985). 
General surgical and electrophysiological procedures. Mice were housed under 
diurnal lighting conditions and allowed food and tap water ad libitum. To assess 
SD susceptibility under full systemic physiological monitoring, femoral artery was 
catheterized for blood sampling and measurement of mean arterial pressure and 
trachea intubated for mechanical ventilation (SAR-830; CWe), under isoflurane 
anesthesia (2.5% induction, 1% maintenance, in 70% N2O/30% O2). Arterial blood 
gases and pH were measured once every 20 minutes during each experiment in 25 μl 
samples (Corning 178 blood gas/pH analyzer; Ciba Corning Diagnostic Corp.) and 
maintained within normal limits by adjusting ventilation parameters (Table 1). Mice 
were then placed in a stereotaxic frame (David Kopf Instruments), and 3 burr holes 
were drilled under saline cooling at the following coordinates on both sides (mm 
from bregma): 3.5 mm posterior, 2 mm lateral (2 mm diameter for KCl application 
onto occipital cortex); 1.5 mm posterior, 2 mm lateral (1 mm diameter, recording 
site 1); 0.5 mm anterior, 2 mm lateral (1 mm diameter, recording site 2). The dura was 
kept intact to minimize trauma. Two glass capillary microelectrodes were placed to 
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record extracellular steady (DC) potential and electrocorticogram (eCoG) at a depth 
of 300 μm. For striatal recordings, the electrode at recording site 2 was lowered to 
a depth of 3 mm into the striatum. A third electrode was simultaneously inserted at 
2 mm posterior, 1.2 mm lateral from bregma, at depths of 3 and 1.2 mm from the pial 
surface for thalamic and hippocampal recordings, respectively. Recording sites were 
later confirmed by tracking the electrode placement (Supplemental Figure 2). An 
Ag/AgCl reference electrode was placed subcutaneously in the neck. Recording sites 
were covered with mineral oil after electrode placement to prevent cortical drying. 
After surgical preparation, the occipital cortex was allowed to recover for 20 minutes 
under saline irrigation. A cotton ball (2 mm diameter) soaked with 300 mM KCl was 
placed on the dura and replaced every 15 minutes to maintain steady KCl concentration 
during stimulation. In order to test whether occipital epidural KCl application causes 
SD in the striatum via direct diffusion, in a subgroup of FHM1 mutant mice we evoked 
SD by pinprick on the occipital cortex and observed reproducible propagation of 
SD into striatum with the same latency as after topical KCl application (n = 3 female 
R192Q mutant mice; data not shown). All data were continuously recorded using a data 
acquisition system for off-line analysis (PowerLab; ADInstruments). 
The frequency of SDs evoked by topical KCl application and their propagation 
speed were determined as previously described with minor modifications.4 KCl-
evoked CSDs were detected based on the characteristic slow DC potential shift and 
eCoG suppression. The frequency of evoked CSDs was determined over 30 minutes on 
each hemisphere. CSD frequencies obtained from the right and left hemispheres did 
not statistically differ in any experimental group and were averaged to calculate the 
CSD frequency in each mouse. Propagation speed was calculated from the distance 
between the 2 recording electrodes divided by the latency between the first CSDs 
recorded at these sites. The DC shift amplitude and duration at half-maximal amplitude 
were averaged for all CSDs in each experiment. 
epidural application of NaCl (300 mM) did not trigger SD or cause neurological 
deficits in sham-operated knock-in controls (n = 2 homozygous female R192Q mutant 
mice; data not shown). In subgroups of WT and FHM1 mutant mice, histopathological 
assessment of the KCl application site after the experimental recordings did not reveal 
any evidence of cortical injury in H&e-stained frozen sections (data not shown). 
Ovariectomy and estrogen replacement. The impact of diminished gonadal hormone 
production on SD susceptibility was studied using ovariectomized (3–4 months old) or 
senescent (13 months old, after cessation of estrous cycle) homozygous R192Q mutant 
mice. Because the sex effect on SD phenotype appeared in both heterozygous and 
homozygous mutants (Figure 1), further experiments exploring post-SD neurological 
deficits (see below) were performed on homozygous mutants only. Ovaries were 
exteriorized, ligated, and removed via bilateral dorsal approach in young adult mice 
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(3-4 months old) under isoflurane anesthesia. In addition, subgroups of ovariectomized 
mice were chronically treated with estrogen via subcutaneous implantation (dorsal 
scapular) of 21-day slow-release pellets (Innovative Research of America) containing 
17β-estradiol 3-benzoate to achieve constant plasma estrogen levels corresponding 
to the proestrus stage of cycle (0.025 mg/pellet) or higher-than-normal estradiol 
concentration (0.075 mg/pellet).85-90 SD susceptibility was tested 3  weeks after 
ovariectomy with or without estrogen replacement (i.e., empty pellet implantation). 
The C57BL/6J background of FHM1 mutant mice has a gonadal hormone profile of 
aging very similar to that observed in menopausal women: prolonged cycles with 
delayed preovulatory rise of estrogen progress to acyclicity, lower estrogen levels, 
and hypergonadotrophic hypogonadism;91,92 decreased nuclear estrogen receptors 
and a nuclear translocation defect of estrogen-receptor complex have also been 
described as in humans.93-95 
Neurological testing. In order to minimize the confounding effect of invasive surgical 
procedures on neurological testing, arterial and tracheal catheterizations were not 
performed, and freely breathing mice were anesthetized via a face mask during the 
SD induction procedure. Neurological deficits were assessed either after 1 SD or after 
9 SDs induced over 1 hour. In the 1-SD group, mice were briefly anesthetized, and KCl 
(300 mM) was topically applied (typically for less than 1 minute) on the parietooccipital 
cortex until an SD was recorded in the frontal cortex as described above, followed 
by extensive saline wash of cortical surface. In the 9-SD group, KCl (300 mM) was 
briefly applied in the same manner approximately every 7.5 minutes, and SD induction 
confirmed at the frontal recording site. Motor deficits were assessed at predefined 
time points after induction of the last SD in a blinded fashion. Mice fully awakened 
from anesthesia usually within 3 minutes in the 1-SD group; therefore, neurological 
assessments were started 5 minutes after SD induction and carried out every 5 minutes 
until full reversal of deficits. Because full awakening was delayed in the 9-SD group 
for up to 15-20 minutes in all groups, first neurological assessment was carried out 
30 minutes after the last SD and then repeated at 45, 80, and 120 minutes. The severity 
of deficits and high mortality after a single SD in S218L mutant mice precluded testing 
of the 9-SD paradigm in this strain. There was no difference among WT and FHM1 
mutant strains in the time required for full recovery of neurological function after 
10 minutes of isoflurane anesthesia (data not shown). 
We relied exclusively upon motor performance, since preliminary studies of 
sensory deficits and neglect (e.g., corner test) did not reliably detect deficits in this 
model (data not shown). Motor deficits were assessed using 2 independent tests. The 
5-point neurological scale is most commonly used to quantify unilateral motor deficits 
after stroke. The deficits are scored as: 0 (no neurological deficit: normal), 1 (mild 
neurological deficit: failure to extend forepaw fully), 2 (moderate neurological deficit: 
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circling), 3 (severe neurological deficit: falling to one side), 4 (very severe neurological 
deficit: no spontaneous walking, depressed level of consciousness), as previously 
described.96 The wire grip test is used to assess coordination and fine movement of 
the digits based on the ability of the mouse to remain on the wire and successfully 
climb down the pole and scored as: 0, unable to remain on wire more than 30 seconds; 
1, holds on wire more than 30 seconds, but not with both sets of paws on wire; 2, holds 
on to the wire with all paws but not the tail; 3, uses the tail along with all paws but does 
not move on wire; 4, moves along the wire on all 4 paws plus tail; 5, moves along the 
wire on all 4 paws plus tail and ambulates down one of the posts used to support the 
wire. Besides the wire grip score, we also recorded the latency to fall off the wire; if 
the mouse stayed on the wire for more than 60 seconds, or climbed down the pole 
successfully, it was scored as 60 seconds.97 
Somatosensory evoked potentials. Two cranial windows (1 mm diameter) were 
drilled under saline cooling over the right whisker barrel cortex (posterior 1.3 mm, 
lateral 3.7 mm from bregma) and occipital cortex (posterior 4 mm, lateral 2 mm 
from bregma). The dura was kept intact. A glass micropipette electrode filled with 
150 mM NaCl was inserted to a depth of 400 μm. Somatosensory evoked potentials 
as well as the extracellular steady (DC) potential were recorded using a differential 
amplifier (eX-1; Dagan Corp.) and stored using a data acquisition system for off-line 
analysis (PowerLab 200; ADInstruments). An Ag/AgCl reference electrode was also 
placed subcutaneously in the neck, and the cortex was covered with a thin layer 
of mineral oil to prevent drying. Somatosensory potentials in the whisker barrel 
cortex were evoked by electrical stimulation of the entire whisker pad (single 
square pulse, 0.2 ms duration, 700 μA, 0.1 Hz; S48, Grass Technologies; and A395 
Linear Stimulus Isolator/Constant Current Unit, WPI) via 2 needle electrodes 
placed in the contralateral whisker pad (5 mm electrode separation). In preliminary 
experiments, we determined that nitrous oxide in inhalation gas potently suppressed 
somatosensory evoked potentials. Therefore, in these experiments, we replaced 
nitrous oxide with nitrogen. 
Whisker pad stimulation typically evoked a monophasic negative field potential at 
this recording depth (Figure 4). After acquiring 50 such evoked potentials at baseline, 
a CSD was triggered using brief occipital epidural KCl application and confirmed by 
the characteristic DC potential shift at the recording site in whisker barrel cortex. In 
order to avoid multiple CSDs, the KCl application site was immediately washed with 
saline upon detection of the SD at the recording site. experiments with multiple SDs 
were excluded from analysis. Both the amplitude of negative peak and the area under 
the field potential curve were measured before, during, and after SD and expressed as 
percent of baseline. 
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Statistics. Data were analyzed using SPSS software package (version 11.0). The 
impact of independent variables allelic mutations (R192Q vs. S218L), allele dosage 
(WT, heterozygous, homozygous), and sex (male vs. female) on the dependent 
variables cortical and striatal SD frequency and propagation speed were tested using 
3-way ANOVA (Figures 1 and 5). The impact of independent variables R192Q mutation 
(WT vs. R192Q) and gonadal status (normal, ovariectomized, and senescent) on 
the dependent variables CSD frequency and propagation speed were tested using 
2-way ANOVA (Figure 2). The time course of neurological deficits and recovery of 
somatosensory evoked potentials after SD were tested among experimental groups 
using 2-way ANOVA for repeated measures (Figures 3 and 4). electrophysiological 
measures of CSD (Table 1), systemic physiological data (Table 1), and the impact 
of estrogen replacement in ovariectomized FHM1 mutant mice (see Results) 
were compared among experimental groups using 1-way ANOVA. Corticostriatal 
propagation latencies were compared using 3-way ANOVA (Table 2). In addition, 
using pooled data from all mice and a general linear model of covariance analysis 
(ANACOVA), we tested for an effect of the independent variables mutation, genotype, 
and sex (fixed factors) on the dependent variables cortical and striatal SD frequency 
and propagation speed. Data are presented as mean ± standard deviation. P < 0.05 
was considered statistically significant. 
ACKNOWLEDGMENTS 
This work was supported by the Deutsche Forschungsgemeinschaft (Ha5085/1-1 
to K. eikermann-Haerter), National Institute of Neurological Disorders and 
Stroke (1R01NS061505 to C. Ayata; 2P01NS35611 to M.A. Moskowitz), Netherlands 
Organization for Scientific Research (903-52-291 and Vici 918.56.602 to M.D. Ferrari), 
eU “eUROHeAD” grant (LSHM-CT-2004-504837 to M.D. Ferrari, A.M.J.M. van den 
Maagdenberg), and the Centre for Medical Systems Biology (CMSB) in the framework 
of the Netherlands Genomics Initiative (NGI). We would like to thank elkan Halpern 
and Tobias Kurth for statistical guidance, Lynda Banzi for assistance with videos, Mike 
Whalen and Zerong you for assistance with neurological deficit assessment, and 





Organization for Scientific Research (903-52-291 and Vici 918.56.602 to M.D. Ferrari), EU 
“EUROHEAD” grant (LSHM-CT-2004-504837 to M.D. Ferrari, A.M.J.M. van den 
Maagdenberg), and the Centre for Medical Systems Biology (CMSB) in the framework of 
the Netherlands Genomics Initiative (NGI). We would like to thank Elkan Halpern and 
Tobias Kurth for statistical guidance, Lynda Banzi for assistance with videos, Mike Whalen 
and Zerong You for assistance with neurological deficit assessment, and Jianhua Qiu for 
histological imaging.  
Supplementary material 
 
Supplemental figure 1. Prolonged and more severe neurological deficits after SD in fHM1 
mutant mice. Representative photographs demonstrating the wire grip and neurological deficits 
after a single SD in female wild type and homozygous R192Q and S218L mutant mice. In wire grip 
test, wild type mice showed minimal deficits soon after SD (A), while S218L mutant mice continued 
to fall off the wire for prolonged periods (B). Neurological examination showed leaning (C) and 
circling (D) in R129Q and S218L mutant mice. SD was evoked in the right hemisphere in all mice. (E) 
Graphs showing the time course of neurological deficits (only wire grip latency shown) from four 
representative FHM1 knockin mice. One or more episodes of transient neurological deterioration 
(red arrows) were observed after full or partial recovery in 7/7 homozygous female R192Q knockin, 
4/6 homozygous male R192Q knockin, 3/3 homozygous female S218L knockin, and 4/5 heterozygous 
female S218L knockin. Vertical dashed line indicates a non-fatal generalized seizure that occurred 






Supplemental Figure 1. Prolonged and more severe neurological deficits after SD in 
FHM1 mutant mice. Representative photographs demonstrating the wire grip and 
neurological deficits after a single SD in female wild type and homozygous R192Q and S218L 
mutant mice. In wire grip test, wild type mice showed minimal deficits soon after SD (a), while 
S218L mutant mice continued to fall off the wire for prolonged periods (b). Neurological 
examination showed leaning (c) and circling (d) in R129Q and S218L mutant mice. SD was 
evoked in the right hemisphere in all mice. (e) Graphs showing the time course of neurological 
deficits (only wire grip latency shown) from four representative FHM1 knockin mice. One or 
more episodes of transient neurological deterioration (red arrows) were observed after full or 
partial recovery in 7/7 homozygous female R192Q knockin, 4/6 homozygous male R192Q 
knockin, 3/3 homozygous female S218L knockin, and 4/5 heterozygous female S218L 
knockin. Vertical dashed line indicates a non-fatal generalized seizure that occurred shortly 
after the 40 min assessment time point.  
 
Supplemental Figure 2. Electrophysiological recording sites. Representative coronal 
gross brain sections showing the SD recording sites in cortex (C), striatum (S), thalamus (T), 
and hippocampus (H). The dark vertical stains (arrows) show the electrode tracks labeled 
using Coomassie Brilliant Blue.  
Supplemental figure 2. Electrophysiological recording sites. Representative coronal gross brain 
sections showing the SD recording sites in cortex (C), striatum (S), thalamus (T), and hippocampus 




Supplemental Figure 3. Recurrent SD in FHM1 mutant mice. Representative tracings from 
S218L knockin mice (homozygous male and heterozygous female shown) showing 
spontaneous recurrent SDs (black dots) after an initial SD induced by brief topical KCl (red 
arrows, 300 mM) application immediately followed by extensive saline wash. (A) The initial 
KCl-induced cortical SD (upper tracing) propagates into striatum (lower tracing). Approximately 
50 minutes after this initial SD, a recurrent SD spontaneously appeared in the cortical electrode 
followed by the striatal electrode. Extreme care was taken to avoid cortical drying, mechanical 
stimulation or trauma during these recordings. (B) In some experiments, the initial SD was 
followed in rapid succession by a striatal and a recurrent cortical SD, suggesting a cortico-
striato-cortical reentrant SD. Vertical bars indicate 20 mV. Horizontal bars indicate 10 min (A) 
or 2 min (B).  
Supplemental figure 3. Recurrent SD in fHM1 mutant mice. Representative tracings from S218L 
knockin mice (homozygous male and heterozygous female shown) showing spontaneous recurrent 
SDs (black dots) after an initial SD induced by brief topical KCl (red arrows, 300 mM) application 
immediately followed by extensive saline wash. (A) The initial KCl-induced cortical SD (upper 
tracing) propagates into striatum (lower tracing). Approximately 50 minutes after this initial SD, a 
recurrent SD spontaneously appeared in the cortical electrode followed by the striatal electrode. 
extreme care was taken to avoid cortical drying, mechanical stimulation or trauma during these 
recordings. (B) In some experiments, the initial SD was followed in rapid succession by a striatal and 
a recurrent cortical SD, suggesting a cortico-striato-cortical reentrant SD. Vertical bars indicate 
20 mV. Horizontal bars indicate 10 min (A) or 2 min (B). 
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Supplemental Movies (available at http://www.jci.org/articles/view/36059#sd):
1. Representative homozygous female R192Q mutant mouse with circling behavior 5 
min after a single SD. 
2. Representative homozygous female R192Q mutant mouse from Supplemental 
Movie 1, with subsequent full recovery at 50 min. 
3. Representative wild type female mouse with normal gait 5 min after a single SD. 
4. Representative heterozygous female S218L mutant mouse with circling behavior 
5 min after a single SD. 
5. Representative heterozygous female S218L mutant mouse from Supplemental 
Movie 5, with subsequent recovery at 70 min. 
6. Representative heterozygous female S218L mutant mouse with left hemiparesis 
15 min after a single SD. Note the weakness of left forearm and paw grip. In wild 
type mice no weakness was demonstrated even at the earliest assessment point 
(5 min). 
7. Representative homozygous female R192Q mutant mouse with wire grip deficits 
10 min after a single SD. 
8. Representative homozygous female R192Q mutant mouse from Supplemental 
Movie 7 with wire grip deficits 20 min after a single SD. 
9. Representative homozygous female S218L mutant mouse with wire grip deficits 
35 min after a single SD. 
10. Representative homozygous female S218L mutant mouse from Supplemental 
Movie 9 with wire grip deficits 70 min after a single SD. 
11. Representative homozygous female S218L mutant mouse from Supplemental 
Movies 9 and 10 with recovery of wire grip deficits at 100 min. 
12. Representative wild type female mouse with normal wire grip performance 5 min 
after a single SD. 
13. Representative wild type female mouse with normal wire grip performance 5 min 
after a single SD. 
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Familial hemiplegic migraine type 1 (FHM1), a severe migraine with aura variant, is 
caused by mutations in the CACNA1A gene. Mutant mice carrying the FHM1 R192Q 
mutation exhibit increased propensity for cortical spreading depression (CSD), a 
propagating wave of neuroglial depolarization implicated in migraine aura. The CSD 
phenotype is stronger in female R192Q mutants and diminishes after ovariectomy. 
Here, we show that orchiectomy reciprocally increases CSD susceptibility in R192Q 
mutant mice. Chronic testosterone replacement restores CSD susceptibility by an 
androgen receptor-dependent mechanism. Hence, androgens modulate genetically-




Familial hemiplegic migraine (FHM) is an autosomal dominant subtype of migraine with 
aura associated with transient hemiparesis. Aura and headache features are otherwise 
identical to those in common forms of migraine.1 FHM1 is caused by missense mutations 
in the CACNA1A gene, which encodes the pore-forming α
1A
-subunit of neuronal Ca
v
2.1 
voltage-gated Ca2+ channels (VGCC).2 When expressed in transfected cultured neurons, 
FHM1 mutations shift channel opening toward more negative membrane potentials 
and delay channel inactivation. Channels open with smaller depolarization and stay 
open longer, allowing more Ca2+ to enter presynaptic terminals.3,4 Increased action 
potential-evoked Ca2+ influx has been shown to enhance excitatory neurotransmission 
at pyramidal cell synapses of FHM1 mutant mice.5 Accordingly, mutant mice carrying 
the FHM1 R192Q mutation show enhanced susceptibility to cortical spreading 
depression (CSD), the electrophysiological correlate of migraine aura, and a possible 
trigger of migraine headache mechanisms.4,6-8 CSD is characterized by an intense 
depolarization of neuronal and glial membranes propagating at a rate of ~3mm/
minute. evoked when extracellular K+ concentrations exceed a critical threshold, CSD 
is associated with massive K+ and glutamate efflux, depolarizing adjacent neurons and 
glia and facilitate CSD spread. 
Gonadal hormones are important modulators of migraine and cortical excitability.9,10 
Incidence of common types of migraine both with or without aura is three-fold higher 
in females (25%) than in males (8%).11 A female preponderance has also been described 
for familial (5:2) and sporadic (4.25:1) hemiplegic migraine.1,12 
Brennan et al.13 recently reported that KCl and electrical stimulation thresholds for 
CSD induction are both reduced by approximately 50% in wild-type (WT) female mice 
compared to males. We found a similar increase in CSD susceptibility in female FHM1 
knockin mice compared to males; the sex difference was abrogated by ovariectomy 
and partly restored by estradiol replacement, suggesting that estrogens modulate 
CSD susceptibility.7 Although the female preponderance of migraine has been largely 
attributed to ovarian sex steroids, anecdotal evidence suggests a role for testosterone 
and its synthetic derivatives in suppressing migraine in both men and women.14-16 Here, we 
provide in vivo experimental evidence for androgenic suppression of CSD susceptibility, 
as a surrogate model for migraine aura. The data suggest that male and female gonadal 
hormones exert reciprocal effects on CSD susceptibility, and that androgens may 
contribute to the lower prevalence of FHM and common types of migraine in males. 
MATERIAL S AND METHODS 
experimental groups and the number of mice in each group are shown in the Table 
(n = 106). Adult (4-8 months) or senescent (11-13 months) male FHM1 knockin mice, 
homozygous for the R192Q mutation that was introduced in the mouse Cacna1a gene 
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by a gene-targeting approach,4 were compared to WT littermates and C57BL6/J mice. 
All experiments were carried out with the investigator blinded for the genotype, and 
confirmatory genotyping was done after the experiment. 
experiments were conducted in accordance with the U.S. Public Health Service’s 
Policy on Humane Care and Use of Laboratory Animals, and were approved by the 
institutional review committee. The femoral artery was catheterized for blood sampling 
and measurement of mean arterial pressure, and the trachea was intubated for 





). Arterial blood gases and pH were measured every 20 minutes and 
maintained within normal limits by adjusting ventilation (Table). Mice were placed in a 
stereotaxic frame and burr holes were drilled at the coordinates described previously.7 
Two glass capillary microelectrodes were placed to record extracellular steady (DC) 
potential and electrocorticogram at a depth of 300  μm. After surgical preparation, 
the occipital cortex was allowed to recover for 20 minutes under saline irrigation. 
The frequency of CSDs evoked by epidural KCl application (300mM for 30 minutes) 
was determined, as previously described.7 The propagation speed, amplitude, and 
duration of the first CSD were also measured. 
Orchiectomy was performed under brief isoflurane anesthesia 3 weeks prior to 
CSD susceptibility testing. Subcutaneous testosterone pellets (0.1  mg/pellet, 21-day 
release; Innovative Research of America, Sarasota, FL) were implanted into the dorsal 
neck and shoulder region on the day of orchiectomy. The pellets restore physiological 
circulating levels of testosterone for at least 21 days, but may cause an early peak 
in plasma levels during the first week after implantation. In order to test whether 
testosterone replacement exerts its effects on CSD via androgen receptors, a subgroup 
of orchiectomized testosterone-replaced mice also received pellets containing 
the androgen receptor antagonist, flutamide (25 or 50  mg/pellet, 21-day release; 
Innovative Research of America). In addition, acute effects of testosterone propionate 
(1.2 mg per mouse in 0.1 ml of β-cyclodextrin injected subcutaneously; Sigma, St. Louis, 
MO) were tested 1 hour before electrophysiological recording in castrated mice. The 
effectiveness of orchiectomy, testosterone, and flutamide treatments was confirmed 
by measuring the prostate and seminal vesicle weights after sacrifice. 
Data were analyzed using SPSS (version 11.0; SPSS, Inc., Chicago, IL). Using a 
general linear model of covariance analysis (ANACOVA), we tested for an effect of 
the independent variables genotype, age, orchiectomy, testosterone treatment 
(acute, chronic) and flutamide treatment (25mg, 50mg) on the dependent variables 
CSD frequency and propagation speed. Other electrophysiological measures of 
CSD and systemic physiological data were compared among groups using one-way 
analysis of variance (ANOVA). Data are presented as mean ± standard deviation 
(SD), and p < 0.05 was considered statistically significant. 
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Table. Electrophysiological Measures of CSD, and Systemic Physiological Parameters. Values 
are mean ± SD. CSD duration was measured at one-half amplitude. The duration and the amplitude 
of only the first CSD are shown. Systemic physiological parameters were averaged over 1 hour 
recording duration. CSD = cortical spreading depression; SD = standard deviation; BW = body weight; 
Orx = orchiectomized mice; T
Chronic
 = testosterone 0.1mg pellet for 21 days; T
Acute
 = single 1.2mg dose of 
testosterone administered 1 hour prior to CSD testing; F
25/50
 = flutamide 25 or 50mg/pellet for 21 days; 
BP = mean arterial blood pressure; pH
a




 = arterial partial pressure 




 = arterial partial pressure of oxygen; WT = wild-type; R192Q = homozygous 
R192Q knockin mice; Aged = 11-13 months old.
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chronic) and flutamide treatment (25mg, 50mg) on the dependent variables CSD 
frequency and propagation speed. Other electrophysiological measures of CSD and 
systemic physiological data were compared among groups using one-way analysis of 
variance (ANOVA). Data are presented as mean ± standard deviation (SD), and p < 0.05 




Continuous epidural KCl application evoked repetitive CSDs in all mice (Figure). Both 
the frequency and the propagation speed of CSDs were significantly higher in R192Q 
mutants compared to the WT, as reported previously.7 Orchiectomy further increased 
CSD frequency (by 40%) and to a lesser extent the propagation speed in R192Q 
mutants, but not in WT mice. Chronic testosterone replacement for 21 days completely 
Table. Electrophysiological Measures of CSD, and Systemic Physiological 
Parameters. Values are mean ± SD. CSD duration was measured at one-half amplitude. 
The duration and the amplitude of only the first CSD are shown. Systemic physiological 
parameters were averaged over 1 hour recording duration. CSD = cortical spreading 
depression; SD = standard deviation; BW = body weight; Orx = orchiectomized mice; TChronic 
= testosterone 0.1mg pellet for 21 days; TAcute = single 1.2mg dose of testosterone 
administered 1 hour prior to CSD testing; F25/50 = flutamide 25 or 50mg/pellet for 21 days; BP 
= mea  arterial blood pressure; pHa = acidity of arterial blood; paCO2 = arterial partial 
pressure of carbon dioxide; paO2 = arterial partial pressure of oxygen; WT = wild-type; 
R192Q = homozygous R192Q knockin mice; Aged = 11-13 months old. 
RESULTS 
Continuous epidural KCl application evoked repetitive CSDs in all mice (Figure). 
Both the frequency and the propagation speed of CSDs were significantly higher in 
R192Q mutants compared to the WT, as reported previously.7 Orchiectomy further 
increased CSD frequency (by 40%) and to a lesser extent the propagation speed in 
R192Q mutants, but not in WT mice. Chronic testosterone replacement for 21 days 
completely prevented the orchiectomy-induced increase in CSD susceptibility 
in R192Q mutant mice (Figure; Table). In contrast, a single dose of testosterone 
propionate administered 1 hour before electrophysiological recordings had no effect 
(16 ± 2 CSDs/hour, 4.3 ± 0.3 mm/minute; p > 0.05 vs. orchiectomized controls). The CSD 
suppression by chronic testosterone replacement was prevented by cotreatment with 
androgen receptor antagonist flutamide (50 mg pellet); a lower dose of flutamide was 
ineffective (25 mg pellet; data not shown). Aging (11-13 months) had no effect on CSD 
frequency and propagation speed in either WT or R192Q mutant mice, consistent with 
the mainte ance of plasma testosterone levels during a ng in this WT background 
strain.17 In WT mice, gonadectomy or testosterone replacement did not significantly 
alter CSD susceptibility, suggesting that in our model androgens modulate CSD 
susceptibility only if the latter is genetic lly enhanced. The CSD duration and 





We showed that testosterone, acting via androgen receptors, suppresses genetically-
enhanced CSD susceptibility. CSD suppression required chronic androgen 
replacement. We recently showed that estradiol augmented genetically-enhanced 
CSD susceptibility in FHM1 knockin mice.7 To the extent that mice homozygous for 
the FHM1 allele represent the human condition, the data suggest that estrogen and 
androgen exert reciprocal effects on CSD susceptibility, providing a dual mechanism 





We showed that testosterone, acting via androgen receptors, suppresses genetically-
enhanced CSD susceptibility. CSD suppression required chronic androgen replacement. 
Figure. Androgenic modulation of CSD in R192Q mutant mice. (A) Representative 
electrophysiological recordings from male wild-type (WT) and homozygous R192Q mutant 
mice showing repetitive CSDs evoked by topical KCl application (300mM) for 30 minutes. (B) 
Graphic representation of CSD frequency and propagation speed in WT and R192Q mutant 
mice. Naive R192Q mutant mice developed higher frequency of CSDs compared to WT. 
Orchiectomy (Orx) further increased CSD frequency in the R192Q mutant, which was 
restored to the level of naive R192Q mutants by chronic testosterone replacement (T). The 
androgen receptor blocker flutamide (F) completely abolished the effects of testosterone 
replacement. Vertical bar = 20mV; horizontal bar = 4 minutes. Data are mean ± SD; *p < 
0.001 vs. naive and Orx+T R192Q mutant; †p < 0.001 vs. WT. Numbers of mice for each 
group are shown in the Table.  
figure. Androgenic modulation of CSD in R192Q mutant mice. (A) Representative 
electrophysiological recordings fr m male wild-type (WT) and ho ozygous 192Q mutant mice 
showing repetitive CSDs evoked by topical KCl application (300 mM) for 30 minutes. (B) Graphic 
representation of CSD frequency and propagation speed in WT and R192Q mutant mice. Naive 
R192Q mutant mice developed higher frequency of CSDs compared to WT. Orchiectomy (Orx) 
further increased CSD frequency in the R192Q mutant, which was restored to the level of naive 
R192Q mutants by chronic testosterone repl cement (T). The androgen receptor blocker flutamide 
(F) completely abolished the effects of testosterone replacement. V rtical bar = 20 mV; h rizontal 
bar = 4 minutes. Data are mean ± SD; *p < 0.001 vs. naive and Orx+T R192Q mutant; †p < 0.001 vs. WT. 
Numbers of mice for each group are shown in the Table. 
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Observational studies suggest that methyltestosterone and danazol, a 
synthetic testosterone derivative, may decrease attack frequency and severity in 
migraineurs.14-16,18,19 As androgens are known to downregulate estrogen receptor 
expression20 and danazol also inhibits ovarian sex hormone production, it is unclear 
whether the clinical effects of danazol are a direct result of androgen receptor 
activation or secondary to suppression of estrogen actions on excitability.10,21,22 
Complete cessation of migraine with aura attacks was reported in men treated with 
gonadotrophins for infertility, further implicating androgens secreted by the testes.23 
In a small cohort of male-to-female transsexuals, the prevalence of migraine with aura 
increased during anti-androgen combined with estrogen therapy to levels similar to 
that seen in females.24 
Unlike estrogens, the influence of androgens on neuronal structure and function 
has not been studied in detail. There are data suggesting that androgens modulate 
both presynaptic and postsynaptic mechanisms. For example, orchiectomy enhances 
spontaneous acetylcholine release (ie, increased frequency of miniature endplate 
potentials) at the neuromuscular junction possibly related to altered expression and 
function of VGCCs (eg, Ca
v
2.2).25 Although a specific modulation of Ca
v
2.1 channels has 
not been reported, similar mechanisms may be operational at the glutamatergic central 
synapses. Postsynaptic glutamate receptors, particularly the N-methyl-D-aspartic 
acid (NMDA) subtype, are critical for the propagation of CSD. The nonaromatizable 
androgen, 5-α-dihydrotestosterone (5αDHT), modulates NMDA responses in a 
complex manner in hippocampal slices from orchiectomized rats: despite larger 
NMDA-induced currents, irreversible depolarization and cell death at high NMDA 
concentrations were significantly inhibited by 5αDHT.26 The latter effect required 
5αDHT exposure times of 8 hours or more, implicating transcriptional mechanisms. 
There is a well-established bidirectionally increased risk of comorbidity of 
migraine and epilepsy, suggesting shared underlying mechanisms.27 Interestingly, 
there is a clinical association between androgen deficiency and epilepsy.28 Consistent 
with this, androgens possess anticonvulsant activity in rodents by acutely enhancing 
γ-aminobutyric acid type A (GABA
A
) receptor activity independent of androgen 
receptors.29 However, we found that acute testosterone administration did not 
suppress CSD, and that suppression by chronic testosterone treatment was abolished 
by the androgen receptor blocker flutamide. Taken together with previous data 
suggesting that barbiturates do not significantly suppress CSD,30 it is unlikely that 
GABAergic mechanisms play a significant role in androgenic CSD suppression. 
In our study, orchiectomy and testosterone modulated CSD only in FHM1 mutant 
mice, and not in the WT. The mechanisms of interaction between gonadal hormones 
and the mutant Ca
v
2.1 channels are not known; however, the need for chronic treatment 
with testosterone implicates mechanisms linked to gene expression and, possibly, 
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ultrastructural changes. Presynaptic, postsynaptic and astrocytic mechanisms may 
all be involved in the interaction between gonadal hormones and FHM1 mutations. 
The clear female preponderance in clinical migraine strongly suggests a reciprocal 
modulation of yet unidentified polygenetic migraine susceptibility factors by androgen 
and estrogen.
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Familial hemiplegic migraine type 1, a monogenic migraine variant with aura, is linked 
to gain-of-function mutations in the CACNA1A gene encoding Ca
V
2.1 channels. The 
S218L mutation causes severe channel dysfunction, and paroxysmal migraine attacks 
can be accompanied by seizures, coma and hemiplegia; patients expressing the 
R192Q mutation exhibit hemiplegia only.  Familial hemiplegic migraine knock-in mice 
expressing the S218L or R192Q mutation are highly susceptible to cortical spreading 
depression, the electrophysiological surrogate for migraine aura, and develop severe 
and prolonged motor deficits after spreading depression. The S218L mutants also 
develop coma, seizures and sometimes die. To investigate underlying mechanisms for 
these symptoms, we used multielectrode electrophysiological recordings, diffusion-
weighted MRI, and c-fos immunohistochemistry to trace spreading depression 
propagation into subcortical structures. We showed that unlike the wild type, cortical 
spreading depression readily propagated into subcortical structures in both familial 
hemiplegic migraine type 1 mutants. Whereas the facilitated subcortical spread 
appeared limited to the striatum in R192Q, hippocampal and thalamic spread was 
detected in the S218L mutants with an allele-dosage effect.  Both strains exhibited 
increased susceptibility to subcortical spreading depression and reverberating 
spreading depression waves. Altogether, these data show that spreading depression 
propagates between cortex, basal ganglia, diencephalon, and hippocampus in 
genetically susceptible brains, which could explain the prolonged hemiplegia, coma, 
and seizure phenotype in this variant of migraine with aura. 
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INTRODUCTION
Familial hemiplegic migraine (FHM) is a monogenic subtype of migraine with aura 
characterized by transient neurological signs and symptoms including hemiparesis, 
aphasia, seizures, and coma. Different aura signs and symptoms can coexist, typically 
transforming into each other (e.g., visual followed by sensory and motor), and resolve 
in the order they appear.1 FHM type 1 (FHM1) is caused by missense mutations in the 
CACNA1A gene (e.g., R192Q, S218L) encoding the poreforming α
1A
 subunit of neuronal 
voltage-gated Ca
V
2.1 channels.2,3 In cultured neurons, FHM1 mutations shift channel 
opening toward more negative membrane potentials and delay channel inactivation. 
Channels open with smaller depolarization and stay open longer,4,5 presumably 
allowing more Ca2+ to enter presynaptic terminals, resulting in enhanced glutamate 
release. Consistent with this, excitatory neurotransmission is enhanced in pyramidal 
cell synapses of R192Q knock-in mice.6
Spreading depression (SD), widely viewed as the electrophysiological event 
underlying migraine aura, is an intense wave of neuronal depolarization that 
propagates (~3 mm/min) by way of gray matter contiguity, regardless of functional 
divisions. SD is characterized by massive K+ efflux, Ca2+ influx, and glutamate release, 
which are believed to depolarize adjacent neurons and glia, thereby facilitating its 
spread. The transmembrane ionic and water shifts also lead to characteristic apparent 
diffusion coefficient (ADC) changes on diffusion-weighted magnetic resonance 
imaging (MRI), and upregulation of the immediate-early gene c-fos, as surrogate 
measures of intense neuronal depolarization. Mutant mouse models expressing 
the pathogenic R192Q or S218L FHM1 mutation exhibit increased susceptibility to 
cortical SD.6-9 The S218L mutation shows larger gain-of-function, in vitro, and higher 
SD susceptibility, in vivo, compared with the R192Q variant.7-9  In contrast to pure 
hemiplegic migraine associated with the R192Q mutation, attacks in patients carrying 
the S218L mutation are sometimes accompanied by coma or stupor and generalized 
seizures.2,10 Accordingly, experimentally induced cortical SD induces pure hemiplegia 
in R192Q mutant mice, whereas S218L mutants additionally develop coma and often 
fatal seizures.8.9
experimental SD produces seizures and coma when evoked in hippocampus 
or thalamus, respectively.11 We investigated whether the severe clinical phenotype 
observed only with the S218L mutation could be caused by subcortical SD involving 
hippocampus and thalamus. We now provide evidence for enhanced subcortical SD 
susceptibility in FHM1 mutant mice that facilitates SD propagation bidirectionally 
between cortex, hippocampus, and thalamus in the S218L mutant strain. Our findings 
suggest a role for subcortical SD as a potential mechanism to explain hemiplegia, 




Experimental groups. A total of 75 male and female wild-type (WT) or FHM1 knock-in 
mice [homozygous (HOM) R192Q, or HOM or heterozygous (HeT) S218L]7 were used 
(n = 44 for electrophysiological recordings, n = 22 for c-fos immunostaining, n = 4 for 
MRI, and n = 5 for laser speckle flowmetry). R192Q mutant mice were compared with 
their WT littermates or C57BL/6J mice,on which the mutants were backcrossed for >10 
generations. Because none of the end points differed between WT littermates and 
C57BL/6J mice, data from WT strains were pooled. S218L mutant mice were compared 
with their WT littermates. In female mice, we did not control for the estrus stage as 
we did not observe high variability in SD susceptibility in randomly tested female mice 
in our previous study.9 To test whether enhanced glutamatergic activity contributes 
to subcortical spread in FHM1 mutants, a separate group of female WT and S218L 
HOM mice was treated with guanosine (7.5 mg/kg, i.p., 30 min before SD induction), 
an anticonvulsant that enhances astrocytic glutamate uptake and suppresses 
glutamatergic transmission.12-15 All experiments were performed with the investigator 
blinded to genotype, followed by confirmatory genotyping.
General surgical preparation. experimental procedures were approved by the 
institutional review committee. Mice were housed under diurnal lighting conditions and 
allowed food and tap water ad libitum. The femoral artery was catheterized for blood 
pressure (BP) monitoring, and the trachea was intubated for mechanical ventilation 





). Arterial blood gases and pH were measured every 20 min and 
maintained within normal limits by adjusting the ventilation. Systemic physiological 
parameters did not differ among groups (supplemental Table 1, see Notes). There was 
no mortality during these experiments. 
Electrophysiology. Mice were placed in a stereotaxic frame, and burr holes were 
drilled (Fig. 1). Up to four glass microelectrodes were placed to simultaneously record 
extracellular steady (DC) potential and fast neuronal activity (electrocorticogram) at 
the following coordinates (posterior, lateral, and ventral from bregma; in mm): cortex: 
3.5, 1, 0.3; striatum: -0.5, 2, 3; hippocampus: 1.8, 1.2, 1.2; thalamus: 1.8, 1.2, 3. Table 2 
shows the numbers of mice and SD recordings in each experimental group. In a subset 
of S218L HOM mice, simultaneous bilateral recordings from cortex (n = 9), hippocampus 
(n = 3), or thalamus (n = 4) were obtained to examine contralateral spread. In a separate 
group, SD induced cortical blood flow changes were measured simultaneously in both 
hemispheres using laser speckle imaging to detect contralateral cortical spread (n = 5), as 
described previously.16 Because isoflurane and N
2
O, but not pentobarbital, suppress SD 
susceptibility,17 after surgical preparation anesthesia was switched to pentobarbital, and 




, for all experiments. Pentobarbital 
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figure 1.  Electrophysiological recording sites. SD was triggered by brief topical KCl (300 mM) 
application onto parietal cortex and recorded with up to four glass micropipettes (arrowheads) placed 
into cortex (c), striatum (s), hippocampus (h), thalamus (t). [Adapted from Allen Mouse Brain Atlas 
(Internet), 2009. Seattle: Allen Institute for Brain Science. Available at http://mouse.brain-map.org].
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anticonvulsant that enhances astrocytic glutamate uptake and suppresses glutamatergic 
transmission.12-15 All experiments were performed with the investigator blinded to 
genotype, followed by confirmatory genotyping. 
General surgical preparation. Experimental procedures were approved by the 
institutional review committee. Mice were housed under diurnal lighting conditions and 
allowed food and tap water ad libitum. The femoral artery was catheterized for blood 
pressure (BP) monitoring, and the trachea was intubated for mechanical ventilation 
(SAR-830; CWE) under isoflurane anesthesia (2.5% induction, 1% maintenance in 70% 
N2O/30% O2). Arterial blood gases and pH were measured every 20 min and maintained 
within normal limits by adjusting the ventilation. Systemic physiological parameters did 
not differ among groups (supplemental Table 1, see Notes). There was no mortality 
during these experiments.  
 
 
Figure 1.  Electrophysiol gical recording sites. SD was triggered by brief topical KCl 
(300 mM) application onto parietal cortex and recorded with up to four glass micropipettes 
(arrowheads) placed into cortex (c), striatum (s), hippoca pus (h), thalamus (t). [Adapted 
from Allen Mouse Brain Atlas (Internet), 2009. Seattle: Allen Institute for Brain Science. 
Available at http://mouse.brain-map.org]. 
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Table 1. Propagation rate of cortical SDs into subcortical structures. Structures were 
recorded in random order. Values indicate the proportion of CSDs propagating into indicated 
subcortical structures while recording from that structure and the proportion of mice that 
showed subcortical propagation into indicated structures. *p < 0.05 versus WT; †p < 0.05 
versus R192Q HOM; ‡p < 0.05 versus S218L HET; +p < 0.05 and #p = 0.06 versus untreated 
S218L female HOM. NR, Not recorded. 
Table 2. Latency between KCl application and the onset of SD. Values indicate the 
latency (seconds) between topical cortical KCl application and SD onset in indicated 
structures. Only two cortical SDs were recorded in striatum in S218L female WT treated with 
guanosine; individual values are shown. *p < 0.01 versus WT; †p < 0.05 versus S218L HET; 
#p = 0.10 versus S218L female HOM. Values are mean ± SD. 
Table 1. Propagation rate of cortical SDs into subcortical structures. Structures were recorded 
in random order. Values indicate the proportion of CSDs propagating into indicated subcortical 
structures while recording from that structure and the proportion of mice that showed subcortical 
propagation into indicated structures. *p < 0.05 versus WT; †p < 0.05 versus R192Q HOM; ‡p < 0.05 
versus S218L HeT; +p < 0.05 and #p = 0.06 versus untreated S218L female HOM. NR, Not recorded.
was chosen over urethane because it all wed us to better maintain a normal systemic 
physiological state in prolonged experiments performed in this study. After 30 min, 
one SD was induced through a parietal window (1.5 mm diameter, 2.5 mm posterior, 
and 3 mm lateral from bregma) by an pidural cotton ball (1.5 mm) soaked with 300 mM 
KCl. After the onset of the DC shift, KCl was removed by extensive saline wash. Fifteen 
minutes were allowed between each SD induction whether induced by topical KCl or 
mechanically during electrode insertion.18 In a separate group of mice, we induced the 
cortical SD by a single pin prick and obtained similar data (not shown). 
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Magnetic resonance imaging. MRI was performed in S218L HOM mice (n = 4) using 
a 9.4T horizontal bore (Magnex Scientific) scanner with a custom-made surface-
radiofrequency coil, under pentobarbital anesthesia. The ADC was measured with 
a sequence of four diffusion-weighted echoplanar images (weighting along Z 
direction, b = 0 –1287.9 s/mm2; echo time, 20 ms; repetition time, 5000 ms; field of 
view, 14 mm; slice thickness, 0.50 mm; matrix, 64 X 64). Sixteen contiguous coronal 
slices were acquired to cover cerebrum with a temporal resolution of 20 s. After 
surgical preparation and the onset of sequential MRI, cortical SD (CSD) was evoked 
by topical application of 300 mM KCl on the parietal cortex via a polyethylene tubing 
mounted above an open cranial window. Ten seconds after topical application of 
300 mM KCl, cortex was washed with saline via a separate polyethylene tubing, to 
minimize cortical exposure to high levels of K+. Imaging was continued for 15 min 
after CSD induction. 
c-fos immunostaining. Under pentobarbital anesthesia, one cortical SD was induced 
every 15 min for a total of three cortical SDs and was electrophysiologically confirmed 
(n = 6, 4, and 12 female WT, R192Q HOM, and S218L HOM mutants, respectively). 
Three hours after the induction of the first cortical SD, mice were deeply anesthetized 
and transcardiac perfusion fixed. Sham animals underwent the same procedure, 
duration, and form of anesthesia, but cotton balls soaked with saline instead of KCl 
were placed on the cortex. Brains were postfixed in 2.5% paraformaldehyde, and 
30 μm cryosections were immunostained for c-fos19 and qualitatively examined at two 
coronal levels through (1) the striatum and septal nuclei and (2) the hippocampus, 
thalamus, and amygdala. 
Data analysis. Data were analyzed using SPSS (version 11.0; SPSS). Using pooled data 
from all mice and a general linear model of variance analysis, we tested for an effect 
of independent-variable mutation and genotype (fixed factors) on physiological 
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Table 1. Propagation rate of cortical SDs into subcortical structures. Structures were 
recorded in random order. Values indicate the proportion of CSDs propagating into indicated 
subcortical structures while recording from that structure and the proportion of mice that 
showed subcortical propagation into indicated structures. *p < 0.05 versus WT; †p < 0.05 
versus R192Q HOM; ‡p < 0.05 versus S218L HET; +p < 0.05 and #p = 0.06 versus untreated 
S218L female HOM. NR, Not recorded. 
Table 2. Latency between KCl application and the onset of SD. Values indicate the 
latency (seconds) between topical cortical KCl application and SD onset in indicated 
structures. Only two cortical SDs were recorded in striatum in S218L female WT treated with 
guanosine; individual values are shown. *p < 0.01 versus WT; †p < 0.05 versus S218L HET; 
#p = 0.10 versus S218L female HOM. Values are mean ± SD. 
Table 2. Latency between KCl application and the onset of SD. Values indicate the latency (seconds) 
between topical cortic l KCl application and SD o se  in indi ated structures. Only two cortical SDs 
were recorded in striatum in S218L female WT treated with guan sine; i dividual values are shown. 
*p < 0.01 versus WT; †p < 0.05 versus S218L HeT; #p = 0.10 versus S218L female HOM. Values are mean ± SD.
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parameters of dependent variables, latency between KCl application and occurrence 
of SD, and duration and amplitude of SD in the respective structures. The incidence of 
subcortical SD and mechanical SD induction in respective structures were compared 
among groups using the χ2 test. Data are presented as mean ± SD. p < 0.05 was 
considered statistically significant. Strong statistical trends (0.05 ≤ p ≤ 0.10) were 
also shown.
figure 2.  Subcortical propagation of cortical SD into hippocampus and thalamus in S218L 
mutant mice. Representative microelectrode recordings show SD propagation from cortex into 
striatum and hippocampus or thalamus in HeT or HOM S218L mutants but not in WT mice. Thalamic 
or hippocampal propagation was not found in R192Q HOM mice (see Table 2). Hippocampal SDs were 
often prolonged compared with other structures. Thalamic SDs were often multiphasic, sometimes 
coalescing into a prolonged depolarization. The multiphasic waveformmaybe attributable to 
multiple corticothalamic propagation pathways arriving sequentially at the thalamic recording site 




Electrophysiology. Topical application of 300 mM KCl consistently induced cortical SD 
(Fig. 2). In WT mice, only 20-30% of cortical SDs propagated into the striatum, and none 
propagated into the hippocampus or the thalamus (Table 1). In R192Q mutant mice, 
over 70% of cortical SDs propagated into the striatum but not into other subcortical 
structures. In contrast, all cortical SDs propagated into the striatum, and a substantial 
proportion propagated into the hippocampus in S218L mutant mice, with an allele-
dosage effect. Moreover, propagation into thalamus was found only in S218L HOM mice. 
The subcortical propagation rate did not significantly differ between male and female 
S218L HOM mice. Guanosine (7.5 mg/kg, administered intraperitoneally 30 min before 
SD recordings) suppressed hippocampal and thalamic spread in female S218L HOM 
mice. In contrast, striatal spread was not affected in either WT or S218L HOM. 
Consistent with the faster propagation speed reported previously,8,9 the latency between 
Figure 2.  Subcortical propagatio  of c rtical SD into hippocampus and thalamus in 
S218L mutant mice. Representative microelectrode recordings show SD propagation from 
cortex into stri tum and hippocampus or thalamus in HET or HOM S218L mutants but not in 
WT ice. Thalamic or hippocamp l propagation was not found in R192Q HOM mice (see 
Table 2). Hippocampal SDs wer  often prolonged c mpared with other structures. Thalamic 
SDs were ften multiphasic, sometim s coalescing into  prolonged depolarization. The 
multiphasic w veformmaybe attributable to multiple corticothalamic propagation pathways 
arriving sequentially at the thalamic recording site or caused by circling within thalamic 
nuclei. 
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cortical and subcortical SD was significantly shorter in both FHM1 mutants compared 
with WT (Table 2). Although the overall morphology of SDs differed between cortex and 
subcortical structures, SD amplitudes and durations were comparable among WT and 
FHM1 mutants within each structure (Table 3).  
An SD was occasionally evoked in cortex or subcortical structures during electrode 
insertion. These mechanical SDs occurred with higher incidence in FHM1 mutants 
compared with WT (Table 4), and when evoked in cortex, they spread into subcortical 
structures similar to KCl-induced SDs. Moreover, when directly evoked in a subcortical 
structure (i.e., via electrode insertion), mechanical SDs did reciprocally spread into the 
cortex and other subcortical structures, suggesting that cortico-subcortical propagation 




Table 3. Amplitudes and duration  of SD. Values are mean ± SD. *p < 0.05 versus R192Q 
HOM; †p < 0.05 and #p = 0.10 versus female S218L HOM. 
Table 3. Amplitudes and durations of SD. Values are mean ± SD. *p < 0.05 versus R192Q HOM; 




Electrophysiology. Topical application of 300 mM KCl consistently induced cortical 
SD (Fig. 2). In WT mice, only 20-30% of cortical SDs propagated into the striatum, and 
none propagated into the hippocampus or the thalamus (Table 1). In R192Q mutant 
mice, over 70% of cortical SDs propagated into the striatum but not into other 
subcortical structures. In contrast, all cortical SDs propagated into the striatum, and a 
substantial proportion propagated into the hippocampus in S218L mutant mice, with 
an allele-dosage effect. Moreover, propagation into thalamus was found only in S218L 
HOM mice. The subcortical propagation rate did not significantly differ between male 
and female S218L HOM mice. Guanosine (7.5 mg/kg, administered intraperitoneally 
30 min before SD recordings) suppressed hippocampal and thalamic spread in female 
S218L HOM mice. In contrast, striatal spread was not affected in either WT or S218L 
HOM. Consistent with the faster propagation speed reported previously,8,9 the latency 
between cortical and subcortical SD was significantly shorter in both FHM1 mutants 
compared with WT (Table 2). Although the overall morphology of SDs differed between 
cortex and subcortical structures, SD amplitudes and durations were comparable 
among WT and FHM1 mutants within each structure (Table 3). 
An SD was occasionally evoked in cortex or subcortical structures during electrode 
insertion. These mechanical SDs occurred with higher incidence in FHM1 mutants 
compared with WT (Table 4), and when evoked in cortex, they spread into subcortical 
structures similar to KCl-induced SDs. Moreover, when directly evoked in a subcortical 
structure (i.e., via electrode insertion), mechanical SDs did reciprocally spread into 
the cortex and other subcortical structures, suggesting that cortico-subcortical 
propagation can be bidirectional (Fig. 3; Table 4). 
In all S218L HOM mutants (n = 7), we observed repetitive cortical SD waves 
after a single KCl application despite a vigorous saline wash (median, three SDs; 
interquartile range, two to five SDs) (Fig. 4). None of the other groups showed 
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cortical and subcortical SD was significantly shorter in both FHM1 mutants compared 
with WT (Table 2). Although the overall morphology of SDs differed between cortex and 
subcortical structures, SD amplitudes and durations were comparable among WT and 
FHM1 mutants within each structure (Table 3).  
An SD was occasionally evoked in cortex or subcortical structures during electrode 
insertion. These mechanical SDs occurred with higher incidence in FHM1 mutants 
compared with WT (Table 4), and when evoked in cortex, they spread into subcortical 
structures similar to KCl-induced SDs. Moreover, when directly evoked in a subcortical 
structure (i.e., via electrode insertion), mechanical SDs did reciprocally spread into the 
cortex and other subcortical structures, suggesting that cortico-subcortical propagation 




Table 3. Amplitudes and durations of SD. Values are mean ± SD. *p < 0.05 versus R192Q 
HOM; †p < 0.05 and #p = 0.10 versus female S218L HOM. 
Table 4. Incidence of mechanical SD and reciprocal spread of subcortical SD into cortex. Values 
indicate the proportion of electrode insertions and the proportion of mice that showed a mechanical 
SD and reciprocal spread. *p < 0.05, ^p = 0.09, $p = 0.05, and @p = 0.06 versus WT; †p < 0.05 versus S218L 
HeT and R192Q HOM; ‡p < 0.05 and #p = 0.06 versus S218L HOM female.
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repetitive SDs. Recurrent cortical SDs occurred after 19 and 38% of all SD inductions 
in male and female S218L HOM mice, respectively, and spread into the striatum (43 
and 31%), hippocampus (0 and 11%), and thalamus (33 and 10%) in clusters. Inter-SD 
intervals were relatively regular, suggesting reverberating SD waves (average 
inter-SD intervals were 126 ± 20 and 118 ± 22 s in cortex, 202 ± 40 and 229 ± 54 s in 
striatum, 86 ± 16 and 174 s in hippocampus, and 144 ± 64 and 187 s in thalamus in male 
and female S218L HOM, respectively). Importantly, striatal but not hippocampal 
or thalamic propagation was required for recurrent SDs to occur, suggesting that 
they were reentry waves between cortex and striatum, as described previously.20
Cortical SD propagation into the contralateral cortex was not detected (n = 2 
cortical SDs in two female and n = 5 cortical SDs in five male S218L HOM). These 
results using bilateral electrophysiological recordings were also confirmed using 
full-field laser speckle imaging to detect SD-evoked cortical blood flow changes 
(n = 5 cortical SDs in five S218L HOM mice) (supplemental Fig. 1 and supplemental 
Movie 1, http://www2.massgeneral.org/NCS/Supplemental_Online_Movie.mpeg).21 
Hippocampal SDs were similarly limited to the ipsilateral hemisphere (n = 3 
hippocampal SDs in three S218L HOM mice). In contrast, all thalamic SDs (n = 4 
thalamic SDs in four S218L HOM mice) propagated into the contralateral thalamus 
with a latency of 13 ± 3 s between bilateral thalamic electrodes (~2.4 mm apart).
Last, we detected large-amplitude (1-2 mV) and rhythmic (up to 7 Hz) spike activity, 
reminiscent of epileptiform afterdischarges, within 1–2 min after the recovery of an 
SD in S218L mutants only (Figs. 2, 4). Spike activity was present in all four structures 
recorded, displayed an allele-dosage effect, and was more frequent in female mutants 
compared with males (supplemental Table 2, see Notes). Sustained seizure activity was 
never observed under our recording conditions.
figure 3.  Reverse propagation of subcortical SD into cortex in S218L HOM mutants. A 
representative tracing shows a thalamic SD triggered during glass micropipette insertion in 
S218L HOM mice (dashed line) that preceded slow potential changes in the striatum and cortex, 
suggesting that SDs can propagate from thalamus to cortex as well.
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mice) propagated into the contralateral thalamus with a latency of 13 ± 3 s between 
bilateral thalamic electrodes (~2.4 mm ap rt).
Last, we detected l rge-amplitude (1-2 mV) and rhyth ic (u  to 7 Hz) spike activity, 
reminiscent of epileptiform afterdischarges, within 1–2 min after the recovery of an SD in 
S218L mutants only (Figs. 2, 4). Spike activity was present in all four structures recorded, 
displayed an allele-dosage effect, and was more frequent in female mutants compared 
with males (supplemental Table 2, see Notes). Sustained seizure activity was never 
observed under our recording conditions. 
 
 
Figure 3.  Reverse propa ation of subcortical SD into cortex in S218L HOM mutants. 
A repr sentative tracing hows a thal mic SD triggered during glass micropipette insertion in 
S218L HOM mice (dashed line) that preceded slow potential changes in the striatum and 
cortex, suggesting that SDs can propagate from thalamus to cortex as well. 
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Chapter 2C
MRI. We consistently observed a wave of reduced ADCs, slowly propagating into the 
striatum and the hippocampus after topical KCl application on to the parietal cortex in all 
mice (n = 4 female S218L HOM) (Fig. 5; supplemental Table 3, see Notes). In two animals 
only, we detected spread into the thalamus, which propagated into the contralateral 
thalamus in both cases. SD-related ADC changes consistently propagated in a lateral-
to-medial direction within the striatum and in a medial-to-lateral direction within the 
hippocampus. It was not possible to precisely determine the propagation pathways 
because of the relatively rapid SD propagation in S218L HOM mice (~7 mm/min)8,9 
compared to the slow MRI acquisition time and repetition rate (once every 20 s).
c-fos expression. Compared with sham controls and contralateral cortex, ipsilateral 
cortical c-fos expression was increased in all mice after cortical SD (Fig. 6). c-fos was 
upregulated in the striatum in all 12 S218L HOM and 3 of 4 R192Q HOM mice but in 
only 1 of 6 WT mice. c-fos upregulation was found in hippocampus (10 of 12 mice), 
and in thalamus and lateral hypothalamic area (3 of 12 mice), in S218L HOM mutants 
only. Consistent with the electrophysiological data, cortical, striatal, and hippocampal 
c-fos upregulation was strictly unilateral, whereas thalamic c-fos upregulation was 
bilateral. In addition, all FHM1 mutants showed strong ipsilateral c-fos upregulation in 
amygdala, basal forebrain nuclei, nucleus accumbens, and the septal nuclei, as well as 
in regions interposed among these structures, whereas in WT there was only a slight 
figure 4.  Recurrent cortical and subcortical SDs in S218L HOM mutants. (A,B) Representative 
microelectrode recordings show clusters of SD in cortex, striatum, and hippocampus (A) or 
thalamus (B) after a single brief epidural KCl application (dashed line) in
S218L HOM mice. The arrowhead shows a typical large-amplitude spike burst observed only in the 
S218L HOM mutant strain. These afterdischarges usually lasted < 1 min and started within a few 





MRI. We consistently observed a wave of reduced ADCs, slowly propagating into the 
striatum and the hippocampus after topical KCl application on to the parietal cortex in all 
mice (n = 4 female S218L HOM) (Fig. 5; supplemental Table 3, see Notes). In two 
animals only, we detected pr ad into th  thalamus, which pro ed into the 
contralateral thalamus in both cases. SD-related ADC changes consistently propagated 
in a lateral-to-medial direction within the striatum and in a medial-to-lateral direction 
within the hippocampus. It was not possible to precisely determine the propagation 
pathways because of the relatively rapid SD propagati n in S218L HOM mice (~7 
mm/min)8,9 compared to the slow MRI acquisition time and repetition rate (once every 20 
s). 
Figure 4.  R u re t cortical and ubcortical SDs in S218L HOM mutants. A,B, 
Representative micro lectrode recordings show clusters of SD i  cortex, striatum, and 
hippocampus (A) or thalamus (B) after a single brief epidural KCl application (dashed line) in 
S218L HOM mice. The arrowhead shows a typical large-amplitude spike burst observed only 
in the S218L HOM mutant strain. These afterdischarges usually lasted < 1 min and started 
within a few minutes after the recovery of slow potential shift. 
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c-fos staining present in three of six mice in the amygdala and in two of six in the 
septal nuclei only (Fig. 6). In sham controls, staining was very light and did not differ 
between WT and S218L HOM (n = 3 each; data not shown), thereby ruling out an effect 
of anesthesia.
Cardiovascular physiology. Thalamic SDs were associated with abrupt BP transients 
75% of the time in all S218L HOM mice. These BP transients lasted ~1 min and were 
hypertensive, increasing BP > 25% without accompanying changes in heart rate (Fig. 7). 
Such BP fluctuations never occurred when a cortical SD failed to propagate into 
thalamus and thus were present only in S218L HOM mice. 
figure 5.  Diffusion-weighted MRI of SD 
propagation. Serial magnetic resonance images 
in a representative S218L HOM mouse show ADC 
changes during cortical SD (orange) spreading 
into striatum (blue), hippocampus (red), and 
dorsomedial thalamus (green). Three consecutive 
coronal slices are shown over time (acquired at 
20 s interval; voxel dimensions: 0.5, 0.2, 0.2 mm). 
The top row shows average baseline ADC maps 
to serve as an anatomical reference. Arrows 
indicate the SD wavefront. Striatal ADC changes 
corresponding to SD propagation typically 
occurred in a lateral-to-medial direction, whereas 
changes in hippocampus propagated in a medial-
to-lateral direction. Hippocampal ADC changes 






The mechanisms underlying the signs and symptoms of severe aura in FHM patients are 
poorly understood. We recently reported that after an SD, S218L mutant mice exhibit 
neurological signs highly reminiscent of clinical attacks in FHM1 patients carrying 
this mutation, including hemiplegia, coma, and seizures, whereas the R192Q mutant 
mice developed pure hemiplegia.9,10 Here, we present evidence that SD propagation 
is enhanced in subcortical structures in the S218L mutant mouse, facilitating the 





The mechanisms underlying the signs and symptoms of severe aura in FHM patients are 
poorly understood. We recently reported that after an SD, S218L mutant mice exhibit 
Figure 6.  Enhanced c-fos expression in cortex and subcortical structures in S218L 
mutant mice. c-fos immunohistochemistry in coronal sections taken from representative WT 
and S218L HOM mice 3 h after three consecutive cortical SDs triggered 15 min apart is 
shown. Coronal sections were taken from two different levels (striatum and hippocampus) in 
whole brain. Both the number of labeled cells plus staining intensity were increased in S218L 
mutant brain compared with wild type. Higher-magnification images show that c-fos was 
expressed throughout cortex in both strains, although this increase appeared more 
prominent in the S218L HOM mutant. c-fos expression was upregulated in striatum (S) in all 
mutants (n = 12) but only one WT mouse (n = 6). c-fos upregulation in hippocampus (H) or 
thalamus (T) was observed in the mutants only. Mutants also showed c-fos upregulation in 
septal nuclei (SN; 100%), hypothalamus (HT; 50%), and amygdala (A; 100%). c-fos 
expression was observed in cells bridging contiguous structures such as striatum and 
amygdala, striatum and septal nuclei, and thalamus and hypothalamus (arrows). Scale bar, 
500 µm. 
figure 6.  Enhanced c-fos expression in cortex and subcortical structures in S218L mutant mice. 
c-fos immunohistochemistry in coronal sections taken from representative WT and S218L HOM 
mice 3 h after three c nsecutive cortical SDs triggered 15 min apart is shown. Coronal sections were 
taken from two different levels (striatum and hippocampus) in whole brain. Both the number of 
labeled cells plus staining intensity were increased in S218L mutant brain compared with wild type. 
Higher-magnification images show that c-fos was expressed throughout cortex in both strains, 
although this increase appeared more prominent in the S218L HOM mutant. c-fos expression was 
upregulated in striatum (S) in all mutants (n = 12) but only one WT mouse (n = 6). c-fos upregulation 
in hippocampus (H) or thalamus (T) was observed in the m tants only. Mutants lso showed c-fos 
upregulation in septal nuclei (SN; 100%), hypothalam s (HT; 50%), and amygdala (A; 100%). c-fos 
expression was observed in cells bridging contiguous structures such as striatum and amygdala, 
striatum and septal nuclei, and thalamus and hypothalamus (arrows). Scale bar, 500 μm.
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predisposing to reverberating SD waves. The widespread SD propagation provides 
a novel mechanism for the severe neurological dysfunction during FHM1 attacks. 
Furthermore, cortical SDs propagated into striatum more consistently in S218L than 
R192Q mutants, and thalamic and hippocampal SDs were observed only in S218L 
mutants with an allele-dosage relationship. Hence, the propensity of SD to traverse 
barriers with low neuronal density and high white matter content corresponds to the 
strength of gain of function in S218L and R192Q mutant Ca
V
2.1 channels.8
Although striatal propagation of cortical SD has been reported in rats,20,22 
propagation into the hippocampus and the thalamus appears to be a manifestation of 
genetically enhanced SD susceptibility in FHM1 mutants. SD propagation requires high 
neuronal and synaptic density and is impeded by the presence of large extracellular 
space and an abundance of astrocytes and myelin.23-25 Consequently, white matter and 
areas with lower neuronal density (e.g., subiculum) serve as natural barriers against 
SD propagation. Whereas thick white matter bundles such as corpus callosum are 
impervious to SD, the extracellular K+ and glutamate surge may still permeate thinner 
white matter tracts and areas with low neuronal density to rekindle the process on the 
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threshold is, the more likely the ionic and neurotransmitter fluxes to evoke SD on the 
other side of the barrier and the more widespread the SD propagation, explaining both 
the allele-dosage effect and the hippocampal and thalamic spread exclusively in the 
S218L mutants. Also supporting a role for glutamate in subcortical spread, guanosine, 
which inhibits glutamatergic hyperexcitability by stimulating astrocytic glutamate 
uptake,12,14 suppressed hippocampal and thalamic spread in FHM1 mutants. 
 
 
Figure 7.  Thalamic SDs were associated with transient hypertension. Representative 
electrophysiological tracings are shown with simultaneous arterial BP recordings in an S218L 
HOM mutant. A, When an SD propagated into thalamus, transient hypertensive episodes 
were observed in S218L HOM mice. B, In the absence of thalamic SD, BP increases did not 
occur, even when SD propagated into the striatum. Hence, hypertensive episodes were 
never observed in R192Q mutant mice. 
figure 7.  Thalamic SDs were associated with transient hypertension. Representative 
electrophysiological tracings are shown with simultaneous arterial BP recordings in an S218L 
HOM mutant. (A) When an SD propagated into thalamus, transient hypertensive episodes were 
observed in S218L HOM mice. (B) In the absence of thalamic SD, BP increas s did not occur, even 




other side of the barrier. FHM1 mutations augment Ca
v
2.1 current density after weak 
depolarization and enhance presynaptic Ca2+ influx and glutamate release, thereby 
lowering the depolarization threshold for SD induction.5,6,8,9 The S218L mutation causes 
larger Ca
v
2.1 gain of function and a lower SD threshold than R192Q. The lower the SD 
threshold is, the more likely the ionic and neurotransmitter fluxes to evoke SD on the 
other side of the barrier and the more widespread the SD propagation, explaining both 
the allele-dosage effect and the hippocampal and thalamic spread exclusively in the 
S218L mutants. Also supporting a role for glutamate in subcortical spread, guanosine, 
which inhibits glutamatergic hyperexcitability by stimulating astrocytic glutamate 
uptake,12,14 suppressed hippocampal and thalamic spread in FHM1 mutants.
In our previous work using combined isoflurane and nitrous oxide anesthesia, 
subcortical SD propagation rates were much lower in both WT and FHM1 mutant 
mice.9 Isoflurane together with nitrous oxide is known to suppress SD susceptibility.17 
To avoid this confound, in the present study we used pentobarbital anesthesia, 
which has the least suppressive effect on CSD compared with other anesthetics that 
have been tested,17,26 and detected widespread subcortical propagation in the FHM1 
mutants. However, compared with the awake state, pentobarbital may still increase 
SD threshold.27,28 Therefore, in unanesthetized FHM1 mutants, SDs might propagate 
even farther and exhibit longer-lasting reentrant patterns between different cortical 
and subcortical structures.
Results using diffusion-weighted MRI and c-fos immunoreactivity as surrogates of 
SD propagation were consistent with the electrophysiological data and reflected SD 
propagation into striatum, hippocampus, and thalamus of S218L mutant mice. Diffusion-
weighted MRI is an established method to map SD propagation in which transient 
ADC reductions spatiotemporally correlate with the electrophysiological changes 
during SD.29 enhanced expression of the c-fos also shows spatial correspondence to 
SD propagation.19,30 Although subcortical c-fos expression might reflect increased 
corticosubcortical efferent activity during a cortical SD, more typically, cortical SD 
leads to suppression of glucose metabolism in subcortical structures,31 suggesting 
that suppression of neuronal activity (e.g., cortex) in the wake of SD has the opposite 
effect on efferent input to target structures.
Despite observing afterdischarges in the wake of an SD in the S218L mutant, we 
believe contiguous spread, rather than seizure activity, was responsible for subcortical 
SD occurrence. First, the SD latencies between cortical and subcortical structures 
were longer than expected if evoked synaptically via corticofugal axonal projections.32 
Second, ADC reductions were slow and contiguous between cortex and subcortical 
structures, which is not consistent with seizure activity.33
We observed transient BP elevations during SD in S218L HOM mice. Because the 
occurrence of these hypertensive episodes was tightly linked to thalamic SDs (i.e., 
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never observed in the absence of a thalamic SD), and because hypothalamic nuclei 
showed diffuse c-fos upregulation, we speculate that BP transients were triggered by 
direct propagation of SD into the hypothalamus, rather than upstream modulation of 
hypothalamic autonomic output by SD in amygdala. It should be noted that although 
SD is limited to gray matter nuclei, the associated ionic shifts can influence conduction 
in white matter bundles embedded in gray matter, causing additional signs and 
symptoms unrelated to the involved gray matter.34-36
Probable subcortical propagation pathways. Amygdala is a likely path for 
cortico-subcortical SD propagation because of its lower proportion of myelin 
and direct gray matter contiguity with striatum, entorhinal and piriform cortices, 
and basal forebrain nuclei.20,22,23,37-39 Subiculum may be an alternative pathway into 
hippocampus, despite its diminished neuronal density.23 Human brain, of course, has 
a greater abundance of white matter than rodents. Nevertheless, these anatomical 
relationships are preserved in mammalian brains. For example, human entorhinal 
cortex still forms a gray matter bridge between hippocampus and neocortex. 
Amygdala, phylogenetically the oldest part of basal ganglia, is immediately anterior 
and superior to hippocampus, in contiguity with striatum, claustrum, uncus, and 
subiculum. Therefore, we speculate that in highly susceptible FHM1 patients (e.g., 
S218L carriers), cortical SD may propagate into subcortical tissues and possibly 
reverberate within and/or among the cortex and gray matter nuclei, leading to 
a prolonged and severe clinical state including encephalopathy and coma. It is 
equally plausible that SD may originate within the susceptible subcortical nuclei 
in FHM1 patients de novo. Changes in glucose metabolism and ADC have been 
detected in subcortical structures using diffusion-weighted MRI and 18F-2-fluoro-2-
deoxy-D-glucose positron emission tomography during FHM attacks.40,41
Speculations on subcortical SD and the clinical features of fHM. Many of the 
FHM1 aura symptoms and signs can be linked to dysfunction in subcortical structures. 
For example, hemiparesis can be caused by SD within the basal ganglia, as shown in 
experimental animals.11,42,43 One-third of FHM1 patients develop severe attacks with 
transient impairment of consciousness ranging from stupor to sometimes fatal coma, 
more commonly associated with a subset of mutations including S218L.10,40,44-49 Thalamic 
SD may be the mechanism for the depressed level of consciousness in FHM1 patients, 
because bilateral thalamic dysfunction can cause stupor and coma,50 and we observed 
bilateral thalamic SD in S218L HOM mutants. Hippocampus is highly susceptible to 
SD,23 and SD has been observed in human hippocampus.51,52 Importantly, hippocampal 
SD can trigger seizure activity. Clinically, 20% of FHM patients carrying the S218L 
mutation develop seizures during attacks.1 Similarly, we observed generalized seizures 
in S218L HOM mice after a cortical SD.9 Hippocampal dysfunction may be associated 
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with amnesia, and limbic disturbances such as dysphoria, yawning, and fluid retention 
can occur during migraine attacks.53 Amygdala may also play a role in the development 
of complex neuropsychiatric, autonomic, and neuroendocrine symptoms during 
an attack.54
Conclusion. Our data show that SD is a remarkable phenotype in FHM1 mutant 
mice. Both S218L and R192Q mutants show enhanced striatal SD as a possible cause 
for transient hemiplegia in FHM1. In addition, the S218L mutant shows widespread SD 
propagation in the forebrain, including thalamus and hippocampus, two findings that 
may explain coma and seizures during some attacks in patients carrying the S218L 
mutation. Therefore, subcortical SD, either arising de novo or propagating from 
cortex, might account for the severe attacks with hemiplegia, coma, and seizures in 
FHM1 patients.
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Supplemental Figure 1 and Movie 1.  Cortical SD-induced blood flow changes 
imaged using laser speckle flowmetry showing the absence of propagation into 
contralateral cortex. Cerebral blood flow tracings from the ipsilateral and contralateral 
cortices during cortical SD in a representative S218L HOM mouse. Green arrowheads 
indicate brief topical KCl applications (300 mM) 10 minutes apart. Each black dot 
indicates a cortical SD.  The second KCl application triggers three consecutive SDs in 
this highly susceptible mutant.  The first cortical SD is associated with an initial profound 
hypoperfusion followed by a transient normalization, as previously described (Ayata et 
al., 2004b).  Each subsequent SD is associated with monophasic hyperemia 
superimposed on the oligemic baseline in the wake of the first SD.  Despite multiple 
Supplemental figure 1 and Movie 1. Cortical SD-induced blood flow changes imaged using 
laser speckle flowmetry showing the absence of propagation into contralateral cortex. 
Cerebral blood flow tracings from the ipsilateral and contralateral cortices during cortical SD in a 
representative S218L HOM mouse. Green arrowheads indicate brief topical KCl applications (300 
mM) 10 minutes apart. each black dot indicates a cortical SD.  The second KCl application triggers 
three consecutive SDs in th s highly susceptible mutant.  The first cortical SD is a sociat d with 
an initial profound hypoperfusion followed by a transient normalization, as previously described 
(Ayata et al., 2004b).  each subsequent SD is associated with monophasic hyperemia superimposed 
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tracing). Inset shows the position of the imaging field for laser speckle flowmetry and the regions 
of interest used to quantify the flow changes. Supplemental Movie (http://www2.massgeneral.org/
ncs/Supplemental_Online_Movie.mpeg) shows a representative full field laser speckle contrast 
imaging of SD-induced cortical blood flow changes in an S218L HOM mutant mouse. Imaging 
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Background: Migraine is an independent risk factor for stroke. Mechanisms underlying 
this association are unclear. Familial hemiplegic migraine (FHM), a migraine subtype 
that also carries an increased stroke risk, is a useful model for common migraine 
phenotypes because of shared aura and headache features, trigger factors, and 
underlying glutamatergic mechanisms. 
Methods and Results: Here, we show that FHM type 1 (FHM1) mutations in Ca
V
2.1 
voltage-gated Ca2+ channels render the brain more vulnerable to ischemic stroke. 
Compared with wild-type mice, 2 FHM1 mutant mouse strains developed earlier onset 
of anoxic depolarization and more frequent peri-infarct depolarizations associated 
with rapid expansion of infarct core on diffusion-weighted magnetic resonance 
imaging and larger perfusion deficits on laser speckle flowmetry. Cerebral blood 
flow required for tissue survival was higher in the mutants, leading to infarction with 
milder ischemia. As a result, mutants developed larger infarcts and worse neurological 
outcomes after stroke, which were selectively attenuated by a glutamate receptor 
antagonist. 
Conclusions:  We propose that enhanced susceptibility to ischemic depolarizations 
akin to spreading depression predisposes migraineurs to infarction during mild 
ischemic events, thereby increasing the stroke risk. 
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INTRODUCTION
Migraine is the most common neurological condition affecting young to middle-age 
adults. Up to one third of migraineurs experience transient neurological symptoms 
called aura. Migraine, particularly with aura, is associated with increased stroke risk 
both during and between attacks, especially in women.1-4 The biological basis for this 
association is unknown. Stroke risk is also increased in familial hemiplegic migraine 
(FHM), a monogenic migraine subtype with hemiplegic auras in addition to the 
common aura forms.5 FHM is a useful model for common migraine with aura because 
of shared clinical features and trigger factors, female preponderance, and because two 
thirds of FHM patients and their first-degree relatives also have attacks of common 
migraine with or without aura.6,7 Neuronal network hyperexcitability and enhanced 
glutamate release have been implicated in both FHM and common forms of migraine.8 
FHM type 1 (FHM1) is caused by mutations in the CACNA1A gene, which encodes the 
pore-forming α
1A
 subunit of neuronal Ca
V
2.1 voltage-gated Ca2+ channels.9 Presynaptic 
Ca
V
2.1 channels are major regulators of excitatory neurotransmitter release. FHM1 
mutant channels open with smaller depolarizations and stay open longer,10 which 
augments presynaptic Ca2+ entry and glutamate release, thereby enhancing brain 
excitability.11 Transgenic mice expressing the human R192Q or S218L FHM1 mutation 
show an increased susceptibility to spreading depression, the electrophysiological 
substrate for migraine, and display characteristic clinical features of FHM such as 
transient hemiplegia.12-14 Glutamatergic mechanisms and hyperexcitability also have 
been implicated in the pathogenesis of common forms of migraine.15,16 Genetic support 
for this link was recently obtained in a genome-wide association study identifying the 
astrocyte elevated gene 1 (AEG1), encoding a regulator of glial glutamate transporter 
eAAT2, as the first migraine gene.16 
Glutamate excitotoxicity also plays a pivotal role in the pathogenesis of 
stroke. Therefore, we hypothesized that genetic mutations conferring cerebral 
hyperexcitability and migraine susceptibility increase the vulnerability to ischemic 
stroke, as 1 mechanism to explain the migraine-stroke association. We tested this 
hypothesis using Ca
V
2.1 S218L and R192Q transgenic mouse models of FHM1. The 
results reveal electrophysiological and hemodynamic mechanisms that accelerate 
hyperacute stroke evolution and worsen ischemic outcome in FHM1 mutants and 
suggest a pivotal role for enhanced glutamatergic transmission in increasing the 
vulnerability to ischemic stroke in susceptible migraineurs. 
METHODS
Experimental Animals. experimental procedures were approved by the institutional 
review boards. A total of 267 male and female mice were used. Transgenic knock-in 
Cacna1a migraine mouse models homozygous (HOM) or heterozygous (HeT) for 
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R192Q or S218L FHM1 mutations were generated by a gene targeting approach.14 The 
R192Q mutant strain was compared with C57BL6/J, backcrossed for 10 generations. The 
S218L mutants were compared with their wild-type (WT) littermates. Because stroke 
risk is highest in young adult migraineurs, mice were studied between 2 and 6 months 
of age. All experiments were carried out by blinded investigators, and confirmatory 
genotyping was done. 




, and blood pressure were 
measured via a femoral artery catheter under isoflurane anesthesia (2.5% induction, 
1.5% maintenance, in 70% N
2
O and 30% O
2
; Supplemental Table 1). Rectal temperature 
was controlled at 37°C during ischemia, and intermittent monitoring was continued 
for 6 hours in a subset of mice. 
Transient filament Occlusion of the Middle Cerebral Artery. A nylon monofilament 
was inserted into the internal carotid artery via the external carotid artery followed 
by reperfusion after 30 or 60 minutes under isoflurane anesthesia (2.5% induction, 
1.5% maintenance, in 70% N
2
O and 30% O
2
) and laser Doppler monitoring. Mice were 
placed in a temperature-controlled incubator with easy access to food and water. 
Neurological outcomes were scored 24 hours after reperfusion with a 5-point scale: 0, 
normal; 1, forepaw monoparesis; 2, circling to left; 3, falling to left; 4, no spontaneous 
walking and depressed consciousness; and 5, death. Infarct volume was calculated 
by integrating the infarct area in ten 1-mm-thick 2,3,5-triphenyltetrazolium chloride 
(TTC)-stained coronal sections. Infarct volumes were calculated by subtracting 
the volume of ipsilateral noninfarcted tissue from the contralateral hemisphere. 
Ischemic swelling volumes were calculated by subtracting the volume of contralateral 
hemisphere from the volume of ipsilateral hemisphere. Glutamatergic mechanisms 
were tested by administering MK-801 (1 mg/kg IP; Sigma, St Louis, MO) 15 minutes 
before filament occlusion of the middle cerebral artery (fMCAO). 
Magnetic Resonance Imaging. Apparent diffusion coefficient maps were acquired 
under isoflurane anesthesia with a 9.4-T magnetic resonance imaging (MRI) scanner 
(Bruker Biospin, Inc, Billerica, MA) 30 and 60 minutes after fMCAO (repetition time/echo 
time, 3000/27 milliseconds; b, 154 and 1294 s/mm2; in-plane resolution, 180 x 180 μm2; 
slice thickness, 1 mm; number of averaging, 8). Means and SDs of the apparent diffusion 
coefficient in the cortex, striatum, hippocampus, and thalamus were extracted from 
the normal hemisphere, and thresholds were defined as mean minus 2 SDs to calculate 
lesion volumes. Normal systemic physiological parameters were confirmed under 
simulated MRI conditions in a separate group of mice (not shown). 
Electrophysiological Recordings. After fMCAO, isoflurane-anesthetized mice were 
intubated and ventilated, and the femoral artery was catheterized for blood pressure 
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and blood gas monitoring. Two intracortical glass micropipettes were placed, and 
extracellular recordings (depth, 250 μm) were started within 15 minutes after the onset 
of ischemia and continued for ≈2 hours. 
Receptor Autoradiography. The density and distribution of glutamate and GABAA 
receptors and glutamate reuptake sites were assessed on 10-μm frozen sections with 
tritium-sensitive storage phosphor screens (Ge Healthcare) as described.17 
Laser Speckle flowmetry. Spontaneously breathing mice (S218L HOM) were 
anesthetized with isoflurane as above, and the femoral artery was catheterized for 
blood pressure and gas measurements. Mice were placed in a stereotaxic frame; a 
temporal burr hole (2-mm diameter) was drilled above the zygomatic arch; and the 
distal middle cerebral artery was occluded with a microvascular clip for 60 minutes. 
Cortical perfusion was imaged during distal middle cerebral artery occlusion with 
laser speckle flowmetry through intact skull.18 Cerebral blood flow (CBF) changes were 
calculated for each pixel relative to the preischemic baseline, and the area of cortex 
with residual CBF ≤30% was determined by thresholding. Neurological outcomes and 
infarcts were assessed 48 hours later as described above. In addition, the CBF threshold 
for tissue viability was estimated by superimposing the images of CBF and infarct. In the 
R192Q HOM strain, mice were intubated and ventilated to ensure normal arterial blood 
gas values, precluding survival for neurological and infarct assessment in this strain. 
Anatomic Analysis of the Circle of Willis and Pial Collaterals. Mice were 
transcardially perfused with carbon black. The diameter of cerebral arteries, patency 
of the posterior communicating artery, and number of pial arterial anastomoses 
between the anterior, posterior, and middle cerebral arteries and their distance from 
midline were determined. 
Absolute Resting CBf. Mice were anesthetized with α-chloralose (50 mg/kg) and 
ventilated. The femoral artery and external jugular vein were cannulated. Arterial 
blood was withdrawn continuously (0.3 mL/min). N-isopropyl-[methyl-1,3-14C]-p-
iodoamphetamine (1 μCi) was injected in 0.1 mL saline over 10 seconds. Twenty seconds 
after injection, the animal was decapitated, and the blood withdrawal was terminated 
simultaneously. The brain was removed, frozen, and dissected. CBF was calculated from 
the radioactivity in tissue and blood measured by liquid scintillation spectrometry. 
Statistical Analysis. Data were analyzed with SPSS (version 11.0) and are presented 
as mean ± Se or median and interquartile range. We used the χ2 test to compare 
proportions, ANOVA to compare mean values of continuous measures according to 
genotypes, and general linear models for repeated measures to compare mean values 
over time according to genotypes. Comparisons of disability scores were performed 
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by the use of nonparametric rank tests; cumulative peri-infarct depolarization (PID) 
incidence was compared by the log-rank test; and PID frequency versus the area of 
CBF deficit was assessed by the Pearson correlation test. P values are 2 tailed, and 
values of P<0.05 were considered statistically significant. 
RESULTS 
Enhanced Susceptibility to Anoxic and Peri-Infarct Depolarizations. Anoxic 
depolarization is characterized by a sudden loss of membrane ionic gradients, 
uncontrolled glutamate release, and cell swelling, triggered by the failure of Na+/
K+ ATPase under ischemic conditions. We found significantly earlier onset of anoxic 
depolarization in FHM1 mutants after fMCAO by monitoring its vasoconstrictive effect 
on cerebral vasculature as previously described (Figure 1A and 1B).18,19 Importantly, the 
magnitude of CBF reduction in the ischemic core did not differ among groups in this 
fMCAO model, eliminating the possibility that faster anoxic depolarization rates were 
due to more severe ischemia (residual CBF, 10% to 17% of baseline in both S218L and 
R192Q; P=0.634 and 0.599, respectively; data not shown). 
PIDs are recurrent propagating depolarization waves akin to spreading depression 
that exacerbate the metabolic mismatch in penumbra and promote infarct growth 
during hyperacute stroke.18-21 We reasoned that FHM1 mutations that enhance 
spreading depression susceptibility13 might also facilitate the occurrence of PIDs. 
Using intracortical microelectrode recordings during fMCAO, we indeed found a 
2-fold increase in the frequency of PIDs in mutants over WT (5.3±1.3 versus 2.6±0.3 PIDs 
per hour; P=0.028; Figure 1C–1F). In the mutants, PIDs sometimes occurred in clusters, 
possibly reflecting circling around the ischemic core (see below),22 but otherwise did 
not differ from WT in terms of durations and amplitudes (not shown). Together, these 
data suggest that genetically enhanced susceptibility to spreading depression11-14 
facilitates the occurrence of anoxic depolarization and PIDs during acute stroke as a 
novel mechanism to explain increased stroke vulnerability in migraineurs. 
Rapid Growth of Hyperacute Ischemic Core on MRI. To assess whether enhanced 
susceptibility to anoxic depolarization and PIDs accelerates the hyperacute stroke 
evolution in FHM1 mutants, we performed serial diffusion-weighted MRI during 
fMCAO. Reduced apparent diffusion coefficient values on diffusion-weighted MRI 
reflect anoxic depolarization, loss of transmembrane ionic gradients, and cell swelling 
(ie, ischemic core). We found that the apparent diffusion coefficient lesion volumes 
expanded more rapidly in FHM1 mutant strains compared with WT controls (Figure 2). 
Although larger apparent diffusion coefficient lesion volumes were due primarily 
to more severe cortical involvement, the hyperacute lesion also encompassed the 
hippocampus and thalamus in S218L mutants. 
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figure 1. faster anoxic depolarization (AD) rates and more frequent peri-infarct depolarizations 
(PIDs) in fHM1 mutant mice. (A) Representative laser Doppler tracings show cerebral blood flow 
(CBF) reduction on common carotid artery occlusion (CCAO) followed by filament occlusion of the 
middle cerebral artery (fMCAO). A further decline in CBF marks the onset of AD and is due to the 
vasoconstrictive effect of tissue depolarization on ischemic microvasculature.18 Scale bars: vertical, 10%; 
horizontal, 1 minute. (B) The latency to AD was shorter in S218L and R192Q mutants (P<0.001 and P=0.035, 
respectively), with a trend for an allele-dosage effect. *P<0.05 vs wild type (WT). (C) Representative 
electrophysiological tracings show more frequent PIDs in S218L homozygous (HOM) vs WT. Scale bars: 
vertical, 20 mV; horizontal, 4 minutes. (D) PIDs (round symbols shown as a function of time) occurred 
in S218L HOM mice more frequently and sometimes in clusters (rectangular boxes). Horizontal lines 
indicate the time of onset and end of electrophysiological recordings in each mouse (n=5 each). When 
the average PID frequency was calculated, these minor differences in recording duration were taken 
into account. (E) Pooled cumulative PID numbers as a function of time after fMCAO was more than 
doubled in S218L HOM mice (*P<0.001; n=5 each). (f) experimental setup showing 2 intracortical glass 
micropipettes (e1, e2) placed outside the ischemic territory to detect PIDs after fMCAO. Shaded area 
indicates typical distribution of CBF deficit after fMCAO. HeT indicates heterozygous.
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cerebral vasculature as previously described (Figure 1A and 1B).18,19 Importantly, the 
magnitude of CBF reduction in the ischemic core did not differ among groups in this 
fMCAO model, eliminating the possibility that faster anoxic depolarization rates were due 
to more severe ischemia (residual CBF, 10% to 17% of baseline in both S218L and R192Q; 
P=0.634 and 0.599, respectively; data not shown).  
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ischemic microvasculature.18 Scale bars: vertical, 10%; horizontal, 1 minute. (B) The latency 
to AD was shorter in S218L and R192Q mutants (P<0.001 and P=0.035, respectively), with a 
trend for an allele-dosage effect. *P<0.05 vs wild type (WT). (C) Representative 
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(*P<0.001; n=5 each). (F) Experimental setup showing 2 intracortical glass micropipettes (E1, 
E2) placed outside the ischemic territory to detect PIDs after fMCAO. Shaded area indicates 
typical distribution of CBF deficit after fMCAO. HET indicates heterozygous. 
Larger Perfusion Deficit During Hyperacute Stroke. Ischemic depolarizations 
compromise residual CBF within the territory supplied by the occluded artery via 
vasoconstrictive (ie, inverse) neurovascular coupling18,19 as a major determinant of 
outcome in cerebral ischemia. Using laser speckle flowmetry, we found larger cortical 
perfusion deficits after distal middle cerebral artery occlusion in FHM1 mutants 
(Figure 3A and 3B; only S218L shown), associated with an increased frequency of PIDs 
(0.9±0.3 versus 4.6±1.2 PIDs per hour in WT and S218L HOM, respectively; Figure 3C) 
that circled around the hypoperfused core in 38% of S218L mutants but not in the WT 
(movies I and II in the online-only Data Supplement).22 In fact, higher PID frequencies 
were associated with larger cortical CBF deficits (Figure 3D), bigger infarcts (Figure 3e 
and 3F), and worse neurological outcomes (deficit score, 1 [interquartile range, 1–1] 
versus 0 [interquartile range, 0–0.25] in S218L HOM and WT mice, respectively; 






Figure 2. FHM1 mutant mice show accelerated lesion growth on magnetic resonance 
imaging (MRI) during hyperacute stroke. (A) Apparent diffusion coefficient (ADC) lesion (ie, 
ischemic core with restricted water diffusion, purple) was larger on diffusion-weighted MRIs in 
S218L (left) and R192Q (right) mutants vs wild type (WT) during the hyperacute phase after 
filament occlusion of the middle cerebral artery (fMCAO). (B) ADC lesion volumes shown as 
a function of time after fMCAO were 40% to 50% larger in S218L and R192Q homozygous 
(HOM) vs WT as early as 30 minutes after fMCAO, suggesting faster growth of the ischemic 
core (P=0.019 and P=0.018, respectively). The difference remained significant at 60 minutes. 
Vertical and horizontal error bars reflect the SEs for total ADC lesion volume and timing of MRI 
scans, respectively. (C) Thirty minutes after stroke onset, enlarged ADC lesion volumes in 
S218L HOM and R192Q HOM were due primarily to more severe cortical involvement 
(P=0.015 and P=0.023, respectively), although S218L HOM mutants also showed hyperacute 
ADC changes in the hippocampus and thalamus (P=0.018 and P=0.117, respectively). Of 
note, the average regional ADC values in the center of ischemic core did not significantly differ 
between FHM1 mutants and their WT controls, suggesting that cytotoxic cell swelling is 
complete in ischemic core in all groups (60±7% versus 56±6% in R192Q WT and HOM, and 
57±5% versus 57±6% of contralateral hemisphere in S218L WT and HOM, respectively, 60 
minutes after stroke onset). *P<0.05 vs WT. Ctx, cortex; Str, striatum; Thal, thalamus; Hipp, 
hippocampus. 
figure 2. fHM1 mutant mice show accelerated lesion growth on magnetic resonance imaging 
(MRI) during hyperacute stroke. (A) Apparent diffusion coefficient (ADC) lesion (ie, ischemic core 
with restricted water diffusion, purple) was larger on diffusion-weighted MRIs in S218L (left) and 
R192Q (right) mutants vs wild type (WT) during the hyperacute phase after filament occlusion of the 
middle cerebral artery (fMCAO). (B) ADC lesion volumes shown as a function of time after fMCAO 
were 40% to 50% larger in S218L and R192Q homozygous (HOM) vs WT as early as 30 minutes after 
fMCAO, suggesting faster growth of the ischemic core (P=0.019 and P=0.018, respectively). T e 
difference remained significant at 60 minutes. Vertical and horizontal error bars reflect the Ses 
for total ADC l sion volume and timing of MRI scans, respectively. (C) Thirty minutes after stroke 
onset, enlarged ADC lesi n v lum s in S218L HOM and R192Q HOM were due primarily to more 
severe corti l involvement (P=0.015 and P=0.023, respectively), although S218L HOM muta ts 
also showed hyperacute ADC changes in the hippocampus and thalamus (P=0.018 and P=0.117, 
respectively). Of note, the average regional ADC values in the center of ischemic c re did not 
significantly differ between FHM1 mutants and their WT controls, suggesting that cytotoxic cell 
swelling is complete in ischemic core in all groups (60±7% versus 56±6% in R192Q WT and HOM, and 
57±5% versus 57±6% of contralateral hemisphere in S218L WT and HOM, respectively, 60 minutes 
after stroke onset). *P<0.05 vs WT. Ctx, cortex; Str, striatum; Thal, thalamus; Hipp, hippocampus.
perfusion deficits and exacerbate the metabolic and O2 supply-demand mismatch in 
FHM1 mutants, in part via vasoconstrictive (ie, inverse) neurovascular coupling as an 
additional hemodynamic mechanism for infarct growth.18,19,23 
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Importantly, we found no difference in absolute resting CBF values between 
WT and R192Q HOM mice in the cortex, striatum, and cerebellum using the [14C]
iodoamphetamine method (Supplemental Table 2), indicating that differences in 
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anatomy did not contribute to worse perfusion deficits in the mutant mice (Supplemental 
Figure 1 and Supplemental Table 3).  
 
 
Figure 3. FHM1 mutant mice develop larger areas of cerebral blood flow (CBF) deficit 
during distal middle cerebral artery occlusion (dMCAO) because of increased 
susceptibility to ischemic depolarizations. (A) Representative laser speckle contrast 
images show the area of cortex with ≤30% residual CBF vs preischemic baseline (blue pixels) 
60 minutes after dMCAO in wild-type (WT) and S218L homozygous (HOM) mice. Similar data 
were obtained with the R192Q strain (n=6 mutant and 6 WT; data not shown). Imaging was 
performed over the right hemisphere (light gray–shaded rectangle in the inset) through intact 
skull. Arrowheads indicate clip occlusion. (B) The area of CBF deficit expanded rapidly in 
S218L HOM throughout the 60-minute dMCAO (*P=0.004). (C) Representative tracings show 
cortical blood flow reductions in penumbra (measured within the gray squares shown in A) 
after dMCAO. Anoxic depolarization triggers the first peri-infarct depolarization (PID; blue 
arrowheads), marking a second abrupt reduction in perfusion. Each subsequent PID (red 
arrowheads) causes a characteristic blood flow transient. (D) The frequency of PIDs was 
higher in S218L HOM and correlated with the area of hypoperfused cortex 60 minutes after 
dMCAO (#P<0.001). Each symbol represents the PID frequency in individual mice. (E) 
Representative 2,3,5-triphenyltetrazolium chloride–stained whole brains show enlarged 
infarcts in S218L HOM 48 hours after 60 minutes of dMCAO. (F) The area of infarcts in 1-mm-
thick coronal slices (0=anterior, 9=posterior) were larger in S218L HOM vs WT (*P=0.016, 
S218L HOM vs WT for infarct areas). Integrated total infarct volumes were also larger in the 
mutants (19±3 versus 11±2 mm3, respectively; P=0.008).  
figure 3. fHM1 mutant mice develop larger areas of cerebral blood flow (CBf) deficit during 
distal middle cerebral artery occlusion (dMCAO) because of increased susceptibility to 
ischemic depolarizations. (A) Representative laser speckle contrast images show the area of 
cortex with ≤30% residual CBF vs preischemic baseline (blue pixels) 60 minutes after dMCAO in 
wild-type (WT) and S218L homozygous (HOM) mice. Similar data were obtained with the R192Q 
strain (n=6 mutant and 6 WT; data not shown). Imaging was performed over the right hemisphere 
(light gray–shaded rectangle in the inset) through intact skull. Arrowheads indicate clip occlusion. 
(B) The area of CBF deficit expanded rapidly in S218L HOM throughout the 60-minute dMCAO 
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mice. (E) Representative 2,3,5-triphenyltetrazolium chloride–stained whole brains show enlarged 
infarcts in S218L HOM 48 hours after 60 minutes of dMCAO. (f) The area of infarcts in 1-mm-thick 
coronal slices (0=anterior, 9=posterior) were larger in S218L HOM vs WT (*P=0.016, S218L HOM vs 
WT for infarct areas). Integrated total infarct volumes were also larger in the mutants (19±3 versus 
11±2 mm3, respectively; P=0.008). 
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preischemic resting CBF did not influence our measurements. We also confirmed 
this in WT and S218L HOM mice under isoflurane anesthesia using the correlation 
time values obtained by laser speckle imaging, which allow direct comparison of 
resting CBF among groups of mice (data not shown).24,25 Moreover, the incidence 
of incomplete circle of Willis, the diameter of its major branches, and the number 
and location of pial arterial anastomoses did not differ between WT and S218L HOM 
mice, suggesting that developmental differences in cerebrovascular anatomy did not 
contribute to worse perfusion deficits in the mutant mice (Supplemental Figure 1 and 
Supplemental Table 3). 
Higher CBf Threshold for Tissue Survival. To determine the critical tissue perfusion 
level below which infarction ensued (ie, viability threshold), we calculated the regional 
CBF at the infarct margin by spatially coregistering the laser speckle perfusion map 
during distal middle cerebral artery occlusion with the infarct that developed 48 hours 
later (Figure 4). We found that cortical tissue in S218L HOM mutants required a higher 
CBF level for survival compared with WT mice (42±3% versus 35±2% of baseline CBF, 
respectively; P=0.048). These data underscore the importance of parenchymal 
mechanisms such as neuronal hyperexcitability and ischemic depolarizations as 
the main cause for increased vulnerability to ischemic stroke in FHM1 mutants 
independently of the severity of CBF deficit.
Worse Stroke Outcomes. enhanced susceptibility to anoxic depolarization and PID 
and accelerated hyperacute infarct growth with more severe CBF deficits translated 
into worse stroke outcomes in FHM1 mutants. Transient fMCAO for 1 hour produced 
larger infarcts in both S218L and R192Q mutant mice compared with their WT controls 
(Figure 5A). Larger infarcts reflected predominantly more severe cortical involvement 
in both mutants (>70% of total infarct volume); however, the incidence of hippocampal 
or thalamic infarction also tended to be higher in the S218L mutant (present in 33% of 
S218L HeT mice compared with 13% of WT; P=0.1; data not shown), consistent with a 
higher incidence of subcortical infarction observed on MRI in this strain (see above). 
Functional outcomes, assessed with a combined death and neurological disability 
score as a clinically relevant end point, were worse in mutants compared with WT 
(Table 1). Indeed, the mortality rate was significantly higher in the S218L mutants, 
reaching 100% in the HOM within 24 hours after stroke onset (Supplemental Figure 
2a). The timing of death after stroke was variable (12±3 hours after stroke onset) and 
was not associated with overt seizure activity. Immediate postmortem examination 
revealed 2-fold larger infarcts in S218L HOM compared with WT mice euthanized at 
the same time point of death of each mutant after 60 minutes of fMCAO (95±15 versus 
44±7 mm3, respectively; n=5 and 4; P=0.031), suggesting that selection bias resulting 
from high mortality in the mutants diminished the strain differences in outcome. 
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These data were excluded from the overall comparisons among genotypes (Figure 5) 
because of variable time of death. Ischemic brain swelling tended to be more severe in 
the mutants in proportion to the actual infarct volume and might have contributed to 
the high mortality in the S218L mutants. 
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Higher CBF Threshold for Tissue Survival. To determine the critical tissue perfusion 
level below which infarction ensued (ie, viability threshold), we calculated the regional CBF 
at the infarct margin by spatially coregistering the laser speckle perfusion map during distal 
middle cerebral artery occlusion with the infarct that developed 48 hours later (Figure 4). 
We found that cortical tissue in S218L HOM mutants required a higher CBF level for 
survival compared with WT mice (42±3% versus 35±2% of baseline CBF, respectively; 
P=0.048). These data underscore the importance of parenchymal mechanisms such as 
neuronal hyperexcitability and ischemic depolarizations as the main cause for increased 
vulnerability to ischemic stroke in FHM1 mutants independently of the severity of CBF 
deficit. 
  
figure 4. Elevated blood flow threshold for tissue survival in fHM1 mutant mice. (A) 
Representative laser speckle contrast images (LSCI) during distal middle cerebral artery occlusion 
(dMCAO; left) and 2,3,5-triphenyltetrazolium chloride (TTC)-stained brain showing the infarct 48 
hours after 60 minutes of dMCAO (right) are shown for wild-type (WT) and S218L homozygous 
(HOM) mice. Imaging field was positioned as shown in Figure 3A. Images were spatially coregistered 
through the use of surface landmarks. Line profiles (blue and green oblique lines, labeled in mm) 
were drawn between lambda and the clip occluding the middle cerebral artery branch (yellow 
arrowheads). (B) For each animal, cortical blood flow (CBF) was plotted along these line profiles as a 
function of distance from lambda using laser speckle images, and the blood flow level corresponding 
to the infarct edge was determined (red dotted lines). This value represented the CBF threshold for 
viability, below which the tissue infarcted in each mouse. (C) The average viability threshold was 
significantly higher in S218L HOM mutants vs WT controls (P=0.048), indicating that FHM1 mutant 
brains are more vulnerable to ischemia and require higher blood flow to survive. The numbers of 
mice are shown on each bar. *P<0.05 vs WT.
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To mimic transient ischemic attacks and to circumvent the high mortality rate in 
S218L HOM mice, we subjected this mutant strain to 30 minutes of fMCAO. With a 
shorter duration of ischemia, we did not detect overt infarcts in 27% of WT mice using 
TTC staining, whereas all S218L HeT and HOM mutant mice developed conspicuous 
territorial infarcts (P=0.077). Selective ischemic changes in scattered neurons were 
nevertheless present on histological examination of brains without an overt infarct 
(not shown). Infarct volumes were once again larger in the S218L mutants compared 
with WT mice (Figure 5B). The volume of subcortical infarction, limited to the striatum 
in this shorter ischemia model, was also larger in the S218L HeT compared with WT mice 
(17±4 and 5±1 mm3, respectively, in males, P=0.002; 16±3 and 4±2 mm3, respectively, in 
females, P=0.013). Despite the shorter ischemia duration, mortality was still high in 
the S218L HOM mutants (75%), but all HeT mutants survived for at least 24 hours and 
showed a trend for worse functional outcome compared with WT (P=0.086; Table 1). 
Because classic migraine, sporadic migraine, and FHM are more prevalent in women 
of reproductive age5,26-29 and because susceptibility to spreading depression is higher 
in female FHM1 mutant mice compared with males,13,30 we also studied female mice 
and found an even more striking increase in infarct volumes in S218L HeT compared 
with WT (Figure 5B). To assess long-term tissue and neurological outcome (2 weeks) in 
FHM1 mutants, we subjected female S218L HeT and WT mice to 30 minutes of fMCAO. 
However, we observed >60% mortality in the mutants predominantly between 24 
and 96 hours, which precluded outcome comparisons between the mutant and WT 





Our data provide a novel mechanism to explain the higher incidence of ischemic stroke in 
migraineurs. Two genetic mouse models expressing FHM1 mutations were at risk of 
developing large infarcts and worse n urological outcomes after transient focal cerebral 
ischemia. Consistent with the higher stroke risk in women compared with men with 
migr ine with aura, w  found more striking increases in infarct volume in female mutants 
compared with males. Faster anoxic depolarization rates, more frequent PIDs, and 
enhanced neuroprotective fficacy of the NMDA antagonist MK-801 in the mutants 
implicated glutamatergic neuronal hyperexcitability as 1 mechanism, and larger perfusion 
defects linked to ischemic depolarizations implicated vasoco strictive neurovascular 
coupling as another. Therefore, neuronal and vascular mechanisms together render 
migraineurs more vuln rable to cerebral infarction on ischemia.  
Table 1. Death and Neurological Disability After Transient Filament Occlusion of the 
Middle Cerebral Artery in S218L Mutant Mice. fMCAO indicates filament occlusion of the 
middle cerebral artery; WT, wild type; HET, heterozygous; and HOM, homozygous. Functional 
outcome scores are shown as median (interquartile range); 0 best, 5 worst (see Methods for 
the scoring system). *P<0.001 and P=0.008 for the effect of genotype on mortality and 
functional outcome score, respectively. †P=0.353 and P=0.757 for the effect of genotype on 
mortality and functional outcome score, respectively. ‡P=0.303 and P=0.315 for the effect of 
MK-801 on mortality and functional outcome score, respectively, in WT and P=0.022 and 
P=0.009, respectively, in the S218L HET compared with the untreated group. §P<0.001 and 
P=0.086 for the effect of genotype on mortality and functional outcome score in males, 
respectively, and P=0.02 for the effect of genotype on functional outcome score in females 
after 30 minutes of fMCAO. In the R192Q mutant strain, the mortality rate was 17%, 0%, and 
14% in WT, HET, and HOM, respectively; neurological disability was not studied in this mutant 
strain.  
Table 1. Death and Neurological Disability After Transient filament Occlusion of the Middle 
Cerebral Artery in S218L Mutant Mice. fMCAO indicates filament occlusion of the middle cerebral 
artery; WT, wild type; HeT, heterozygous; and HO , homozygous. Functional o tc me scores 
are shown as median (interquartile range); 0 best, 5 w rst (see Methods for the scoring system). 
*P<0.001 and P=0.008 f r the eff ct of genotype on mortality and functional outcome score, 
respectively. †P=0.353 and P=0.757 for the effect of genotype on mortality and functional outcome 
score, respectively. ‡P=0.303 and P=0.315 for the effect of MK-801 on mortality and functional outcome 
score, respectively, in WT and P=0.022 and P=0.009, respectively, in the S218L HeT compared with the 
untreated group. §P<0.001 and P=0.086 for the effect of genotype on mortality and functional outcome 
score in males, respectively, and P=0.02 for the effect of genotype on functional outcome score in 
females after 30 minutes of fMCAO. In the R192Q mutant strain, the mortality rate was 17%, 0%, and 





Because classic migraine, sporadic migraine, and FHM are more prevalent in women of 
reproductive age5,26-29 and because susceptibility to spreading depression is higher in 
Figure 5. FHM1 mutant mice develop larger infarcts after experimental stroke selectively 
attenuated by the N-methyl-D-aspartate receptor antagonist MK-801. Left, Representative 
infarcts (unstained white tissue) 24 hours after filament occlusion of the middle cerebral artery 
(fMCAO). Right, Infarct and ischemic swelling volumes (gray and white bars, respectively). (A) 
After 60 minutes of fMCAO, infarcts were larger in both R192Q and S218L mutants vs wild 
type (WT; P=0.007 and P=0.019, respectively). One of 9 WT, 8 of 23 S218L heterozygous 
(HET), and all 8 S218L homozygous (HOM; †) mice died within 24 hours (Table 1) and were 
excluded from infarct volume analysis. Because genetic backgrounds and infarct volumes 
differed significantly between WT controls of the 2 mutant strains, we did not directly compare 
S218L and R192Q mutants in this study. MK-801 (1 mg/kg IP 15 minutes before fMCAO) 
significantly reduced infarct volume in the S218L HET mutants (P<0.001 vs untreated S218L 
HET shown in A) but not in the WT (P=0.061 vs untreated WT shown in A). Therefore, MK-
801 was more efficacious in FHM1 mutants (P=0.026 for infarct reduction by MK-801 between 
WT and FHM1 mutants). As a result, after MK-801, infarct and swelling volumes were 
comparable between WT and S218L HET mice (P=0.367), as were neurological outcomes 
(Table 1). (B) Thirty minutes of fMCAO also resulted in larger infarcts in male and female 
S218L mutants vs WT (P=0.028). Despite shorter ischemia, 3 of 4 S218L HOM mutants died 
within 24 hours and were again excluded from infarct volume analysis; the data from the only 
surviving HOM mutant are shown. There was no mortality in the WT and HET groups after 30 
minutes of fMCAO. The numbers of mice are shown on each bar. SE bars and P values refer 
to total volume (ie, infarct plus swelling). *P<0.05 vs WT, #P<0.05 vs untreated S218L HET 
after 60 minutes of fMCAO.  
figure 5. fHM1 mutant mice develop larger infarcts after experimental stroke selectively 
attenuated by the N-methyl-D-aspartate receptor antagonist MK-801. Left, Representative 
infarcts (unstained white tissue) 24 hours after filament occlusion of the middle cerebral artery 
(fMCAO). Right, Infarct and ischemic swelling volumes (gray and white bars, respectively). (A) 
After 60 minutes of fMCAO, infarcts were larger in both R192Q and S218L mutants vs wild type 
(WT; P=0.007 and P=0.019, respectively). One of 9 WT, 8 of 23 S218L heterozygous (HeT), and all 
8 S218L homozygous (HOM; †) mice died within 24 hours (Table 1) and were excluded from infarct 
volume analysis. Because genetic backgrounds and infarct volumes differed significantly between 
WT controls of the 2 mutant strains, we did not directly compare S218L and R192Q mutants in this 
study. MK-801 (1 mg/kg IP 15 minutes before fMCAO) significantly reduced infarct volume in the 
S218L HeT mutants (P<0.001 vs untreated S218L HeT shown in A) but not in the WT (P=0.061 vs 
untreated WT shown in A). Therefore, MK-801 was more efficacious in FHM1 mutants (P=0.026 for 
infarct reduction by MK-801 between WT and FHM1 mutants). As a result, after MK-801, infarct and 
swelling volumes were comparable between WT and S218L HeT mice (P=0.367), as were neurological 
outcomes (Table 1). (B) Thirty minutes of fMCAO also resulted in larger infarcts in male and female 
S218L mutants vs WT (P=0.028). Despite shorter ischemia, 3 of 4 S218L HOM mutants died within 24 
hours and were again excluded from infarct volume analysis; the data from the only surviving HOM 
mutant are shown. here was no mortality in the WT and HeT groups after 30 minutes of fMCAO. 
The numbe  of mice are shown on each bar. Se bars and P values refer to total volume (ie, infarct 
plus swelling). *P<0.05 vs WT, #P<0.05 vs untreated S218L HeT af er 60 minutes of fMCAO. 
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that mice expressing FHM1 mutations are particularly susceptible to infarction when 
challenged by cerebral arterial occlusion. 
Enhanced Neuroprotective Efficacy of Glutamate Receptor Antagonist 
MK-801. FHM1 mutations enhance glutamate release,11 and glutamate plays a pivotal 
role in spreading depression and ischemic depolarizations, as well as in excitotoxic cell 
death, mainly via the N-methyl-D-aspartate (NMDA) subtype of receptors. Therefore, 
we tested whether enhanced glutamatergic activity in FHM1 mutants is responsible 
for their vulnerability to infarction. Preischemic treatment with the NMDA receptor 
inhibitor MK-801 abolished the differences in stroke phenotype between genotypes. 
MK-801 reduced infarct volume by 45% in S218L HeT compared with only 23% in WT 
(Figure 5A), and functional outcome was improved only in S218L mutants (Table 1). 
As an important control, we also examined the density of glutamate and 
GABA
A
 binding sites in the FHM1 mutant and WT mice using quantitative in vitro 
autoradiography and did not find overt differences (Supplemental Figure 3 and 
Supplemental Table 4). These data are consistent with recent proteomics analysis of 
cortical synapses in this mutant31 and suggest that enhanced susceptibility to ischemic 
depolarizations in FHM1 mutants is unlikely to reflect changes in neurotransmitter 
receptors and reuptake mechanisms. 
DISCUSSION 
Our data provide a novel mechanism to explain the higher incidence of ischemic 
stroke in migraineurs. Two genetic mouse models expressing FHM1 mutations were at 
risk of developing large infarcts and worse neurological outcomes after transient focal 
cerebral ischemia. Consistent with the higher stroke risk in women compared with men 
with migraine with aura, we found more striking increases in infarct volume in female 
mutants compared with males. Faster anoxic depolarization rates, more frequent 
PIDs, and enhanced neuroprotective efficacy of the NMDA antagonist MK-801 in the 
mutants implicated glutamatergic neuronal hyperexcitability as 1 mechanism, and 
larger perfusion defects linked to ischemic depolarizations implicated vasoconstrictive 
neurovascular coupling as another. Therefore, neuronal and vascular mechanisms 
together render migraineurs more vulnerable to cerebral infarction on ischemia. 
The data have clinical implications. In susceptible migraineurs, increased sensitivity 
to ischemia may predispose to strokes during mild ischemic events, which remain 
clinically silent or manifest only as transient ischemic attacks in nonmigraineurs. 
Moreover, elevated CBF threshold for viability,32 a sign of increased vulnerability to 
ischemia, may promote rapid infarct expansion into tissue with milder perfusion 
deficits, diminish salvageable tissue at risk (ie, ischemic penumbra), and shorten 
the therapeutic window of acute stroke interventions in migraineurs. Lastly, higher 
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mortality among the S218L mutants may have implications for malignant infarcts, 
large supratentorial strokes characterized by progressive loss of consciousness over 
48 hours with up to 80% mortality if untreated.33 To date, there has been no reliable 
predictor for malignant infarction, and history of migraine with aura (or its genetic 
determinants) may be 1 such marker increasing the risk of stroke progression and, in 
case of large territorial infarcts, the risk of death, as has recently been reported for 
hemorrhagic stroke in migraineurs.34 
Mechanisms of Ischemic Vulnerability in fHM1 Mice. Biological mechanisms 
underlying the association between migraine and stroke are unknown, although in 
both diseases dynamic interactions among the constituents of the neurovascular unit 
are important to the pathophysiology. At the onset of cerebral ischemia, the gradual 
failure of Na+/K+-ATPase causes a slow rise in extracellular K+ and loss of neuronal 
membrane potential until a critical threshold for initiation of anoxic depolarization 
is reached.35,36 FHM1 mutations shift the Ca
V
2.1 channel opening voltage to more 
negative membrane potentials so that channels open with smaller depolarizations, 
triggering glutamate release, which can explain faster anoxic depolarization onset in 
the mutants. Glutamate is also critical for PIDs, which are spreading depolarization 
waves triggered in ischemic penumbra. Therefore, enhanced release in ischemic 
penumbra can also explain higher PID frequencies in FHM1 mutants.11 Delayed Ca
V
2.1 
channel inactivation may exacerbate the excitotoxicity by prolonging the Ca2+ 
influx and glutamate release during PIDs in penumbra. Moreover, PIDs exacerbate 
the metabolic mismatch in penumbra by stimulating O
2
 and glucose consumption 
and by worsening tissue perfusion via vasoconstrictive (ie, inverse) neurovascular 
coupling,18,19,23 particularly when they occur with high frequency and in clusters, as 
observed in FHM1 mutants.19,37-39 With each PID, more of the penumbra is incorporated 
into the core, accounting for concentric infarct growth over time.22,40-42 PIDs occur 
frequently in human brain after ischemic or hemorrhagic stroke and head trauma 
and appear to worsen patient outcomes, similar to experimental stroke.38,43-45 Hence, 
migraine with aura may be a risk factor for increased occurrence of PIDs and worse 
outcomes in human stroke, as recently suggested in subarachnoid hemorrhage.46 
Association Between Migraine and Stroke. Our data in FHM1 mutant mice support 
shared genetic risk factors enhancing susceptibility to spreading depression as 
a mechanism to explain the migraine-stroke association. Shared genetic factors 
enhancing susceptibility to migraine and stroke such as NOTCH3 mutations in cerebral 
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
have been described.47-50 Indeed, NOTCH3 mutations, despite being exclusively 
expressed in vascular smooth muscle cells, augment susceptibility to spreading 
depression.51 Mutations associated with FHM2 and FHM3 are also predicted to 
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enhance neuronal excitability and spreading depression susceptibility possibly via 
glutamatergic mechanisms.52 Glutamatergic mechanisms and hyperexcitability also 
are implicated in common forms of migraine by recent studies linking AEG1, encoding 
a regulator of glial glutamate transporter eAAT2, and KCNK18, encoding the TReSK 
potassium channel, to migraine.15,16 Vascular mechanisms (eg, endothelial dysfunction) 
have also been implicated in increasing stroke risk in migraineurs.53,54 Indeed, 
functional Ca
v
2.1 channel expression has been reported in renovascular smooth muscle 
cells,55,56 but whether FHM1 mutations alter cerebrovascular physiology is not known. 
Together with parenchymal mechanisms that enhance vulnerability to perfusion 
deficits, vascular mechanisms might further augment stroke risk in migraineurs. For 
example, highly focal and mild ischemic vascular events such as microembolism57 
may trigger spreading depression more readily in migraineurs highly susceptible to 
ischemic depolarizations, providing a possible explanation for the origin of a subset 
of migraine auras. 
Conclusions. A monogenic determinant of migraine with aura increases stroke 
vulnerability via glutamatergic mechanisms that enhance susceptibility to ischemic 
depolarizations akin to spreading depression and accelerate stroke evolution. Hence, 
our data put FHM1 mutations among the shared genetic determinants of migraine with 
aura and stroke. More work is needed to extrapolate these data to other monogenic 
syndromes and to the more common and genetically more complex forms of migraine 
with aura and to determine whether targeting hyperexcitability and spreading 
depression such as migraine prophylaxis58 confers ischemic protection in susceptible 
mouse strains or in migraineurs. 
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Supplemental Table 1. Age, body weight and systemic physiological parameters. There 
was no statistically significant difference between WT and HOM physiology was measured via 
a femoral artery catheter in non-survival experiments only, to minimize morbidity in survival 
groups.  
Supplemental Table 2. Resting cerebral blood flow. Values are absolute blood flow in 
ml/100g/min determined by [14C]-iodoamphetamine radioactive tracer method. N=5 each 
genotype.  
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Supplemental Table 3. Cerebrovascular anatomy. Data were obtained using intracardiac 
carbon black infusion. Please also see Supplementary Figure 1 for representative images, 
abbreviations and the method of measurements.  
Supplemental Table 4. Quantitative receptor autoradiography. Values indicate relative 
optical densities (x10-3). Although ligand binding differed among regions, we did not detect a 
statistically significant effect of genotype on ligand binding within cortex (visual, 
somatosensory, and parietal cortex), hippocampus (CA1 region) and striatum (N=8 each). The 
ligands were: D-[2,3-3H]Aspartic acid (GE Life Sciences, Piscataway, NJ) for, excitatory amino 
acid transporters (EAAT); DL-[5-methyl-3H]-(AMPA) (Perkin-Elmer, Boston) for α-amino-3-
Hydroxy-5-methylisoxazole-4-propionic acid (AMPA) ionotropic glutamate receptors; 
[3H]Kainic Acid for ionotropic glutamate kainic acid receptors; [3H]MK-801 (American 
Radiolabeled Chemicals, St-Louis, MO) for the N-methyl-D-aspartate (NMDA) subtype of 
ionotropic glutamate receptors; [3H]muscimol (Perkin-Elmer, Boston) for ionotropic GABAA 
receptors.  
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Supplemental Figure 1. Normal cerebrovascular anatomy in FHM1 mutant mice. 
Representative ventral (A, C) and dorsal (B, D) views of representative WT and S218L HOM 
brains show the circle of Willis anatomy, and pial arterial anastomoses between middle and 
anterior cerebral arteries, respectively, after transcardiac ink perfusion (1.4 ml, 0.5 ml/sec) 
under deep isoflurane anesthesia. Circles on the ventral surface (A, C) indicate where arterial 
diameters were measured, whereas circles on the dorsal surface (B, D) indicate the pial 
anatomoses (inset) that have been analyzed for their number and distance to midline. None 
of these endpoints significantly differed between WT and S218L HOM mice (Supplemental 
Table 3). Pial anastomoses were defined as the narrowest part of the vessel or half way 
between the nearest branch points of the anterior and the middle cerebral artery, localized by 
tracing the peripheral branches of these major vessels. ACA, anterior cerebral artery; MCA, 
middle cerebral artery; ICA, internal carotid artery; PCA, posterior cerebral artery; PComA, 
posterior communicating artery; BA, basilar artery.  
Supplemental figure 1. Normal cerebrovascular anatomy in fHM1 mutant mice. Representative 
ventral (A, C) and dorsal (B, D) vi ws of representative WT and S218L HOM brai s show the circle 
of Willis anatomy, and pial arterial anastomoses between middle and ant rior c rebral arteries, 
respectively, after transcardiac ink perfusion (1.4 l, 0.5 ml/sec) under deep isoflurane an sthesia. 
Circles on the ventral surface (A, C) indicate where arterial diameters were measured, whereas 
circles on the dorsal surface (B, D) indicate the pial anatomoses (inset) that have been analyzed for 
their number and distance to midline. None of these endpoints significantly differed between WT 
and S218L HOM mice (Supplemental Table 3). Pial anastomoses were defined as the narrowest part 
of the vessel or half way between the nearest branch points of the anterior and the middle cerebral 
artery, localized by tracing the peripheral branches of these major vessels. ACA, anterior cerebral 
artery; MCA, middle cerebral artery; ICA, internal carotid artery; PCA, posterior cerebral artery; 








Supplemental Figure 2. Increased mortality after stroke in FHM1 mutant mice. Survival 
curves show the timing of mortality after filament middle cerebral artery occlusion (fMCAO). 
Mortality rate was (a) 100% and 0% within 24h after 60 min fMCAO in male S218L HOM and 
WT mice, respectively (n=5 and 4), and (b) 62% and 30% within 2 weeks after 30 min fMCAO 
in female S218L HET and WT mice, respectively (n=8 and 7).  
Supplemental Figure 3. Normal density of Glutamate and GABAA binding sites in FHM1 
mutant mice. Representative autoradiograms on sagittal brain sections from WT and R192Q 
HOM mice showing specific binding for five commonly used ligands for ionotropic glutamate 
(N-methyl-D-aspartate, NMDA; α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate, AMPA; 
kainic acid, KA) and GABAA receptors and glutamate reuptake (EAAT) sites. Darker areas 
represent brain regions with higher levels of bound radioligand. Nonspecific binding, also 
shown, was not significantly different from background levels. Quantitative data are shown in 
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(n=5 and 4), and (B) 62% and 30% within 2 weeks after 30 in fMCAO in female S218L H T and WT 
mice, respectively (n=8 nd 7). 
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1. Cerebral blood flow changes during distal MCAO in WT mice. This representative 
movie of CBF shows the spatiotemporal hemodynamic changes upon distal MCAO 
by a microvascular clip through a temporal burr hole. Imaging field was positioned 
as shown in Figures 3 and 4 and imaging was performed through intact skull. Color 
bar shows CBF as % of pre-ischemic baseline. Time after imaging onset is shown 
on the top. MCA is clipped between 1 and 2 min (clip artifact visible in the lower 
right of the imaging field). Approximately 1-2 min after clipping, a wave of further 
decrease in perfusion originates from ischemic core and spreads throughout the 
ipsilateral hemisphere; this wave has previously been shown to correspond to 
anoxic depolarization. During the 60 min dMCAO, 1 distinct wave of spreading 
hypoperfusion is spontaneously triggered in the WT; this hypoperfusion transient 
corresponds to a peri-infarct depolarization. Reperfusion is achieved by removing 
the clip approximately 60 min after the onset of ischemia. 
2. Cerebral blood flow changes during distal MCAO in S218L HOM mutant 
mice. This representative movie of CBF shows the spatiotemporal hemodynamic 
changes upon distal MCAO by a microvascular clip through a temporal burr hole, 
in S218L HOM mutant mice. Please see legend to Movie 1 for imaging details. 
During the 60  min dMCAO, 8 distinct waves of spreading hypoperfusion events 
are spontaneously triggered in the S218L HOM mutant; these hypoperfusion 
transients correspond to peri-infarct depolarizations and cause a lasting decrease 
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Background and Purpose: Migraine with aura is an established stroke risk factor, 
and excitatory mechanisms such as spreading depression (SD) are implicated in the 
pathogenesis of both migraine and stroke. Spontaneous SD waves originate within 
the peri-infarct tissue and exacerbate the metabolic mismatch during focal cerebral 
ischemia. Genetically enhanced SD susceptibility facilitates anoxic depolarizations and 
peri-infarct SDs and accelerates infarct growth, suggesting that susceptibility to SD is 
a critical determinant of vulnerability to ischemic injury. Because chronic treatment 
with migraine prophylactic drugs suppresses SD susceptibility, we tested whether 
migraine prophylaxis can also suppress ischemic depolarizations and improve stroke 
outcome.
Methods: We measured the cortical susceptibility to SD and ischemic depolarizations, 
and determined tissue and neurological outcomes after middle cerebral artery 
occlusion in wild-type and familial hemiplegic migraine type 1 knock-in mice treated 
with vehicle, topiramate or lamotrigine daily for 7 weeks or as a single dose shortly 
before testing. 
Results: Chronic treatment with topiramate or lamotrigine reduced the susceptibility 
to KCl-induced or electric stimulation-induced SDs as well as ischemic depolarizations 
in both wild-type and familial hemiplegic migraine type 1 mutant mice. Consequently, 
both tissue and neurological outcomes were improved. Notably, treatment with a 
single dose of either drug was ineffective.
Conclusions: These data underscore the importance of hyperexcitability as a 
mechanism for increased stroke risk in migraineurs, and suggest that migraine 
prophylaxis may not only prevent migraine attacks but also protect migraineurs 
against ischemic injury. 
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INTRODUCTION
Migraine is the most common neurological condition, affecting 10% to 20% of the 
population.1 Stroke is a major cause of death and disability worldwide. An intriguing 
association between migraine and stroke is well established. epidemiological studies 
identified migraine with aura as an independent factor increasing stroke risk by 
>2-fold.2 The relative risk is particularly high in otherwise healthy young adults without 
cardiovascular risk factors. The prevalence of migraine is on par with that of other 
known stroke risk factors. 
Spreading depression (SD), an intense depolarization that underlies migraine aura, 
also occurs in peri-infarct tissue as an overlapping mechanism between migraine and 
stroke. Although SD does not cause injury in the healthy brain, recurrent peri-infarct 
SDs and peri-infarct depolarizations (PIDs) worsen the metabolic mismatch in ischemic 
tissue and promote infarct growth during hyperacute stroke both in experimental 
animals3-5 and in humans.6,7 
Indirect evidence implicates enhanced cerebral excitability in common migraine,8,9 
as well as in familial hemiplegic migraine (FHM). FHM1 mutations enhance Ca
V
2.1 
channel open probability, presynaptic calcium influx and cortical glutamate release, 
and render the brain hyperexcitable.10 As a result, FHM1 mutations markedly 
enhance SD susceptibility.11,12 Underscoring the importance of SD in migraine and 
stroke, transgenic mice expressing FHM1 mutations exhibit faster onset of anoxic 
depolarization (AD) and rapid infarct growth linked to higher frequency of PIDs during 
experimentally induced focal cerebral ischemia.13 
Chronic treatment with widely prescribed migraine prophylactic drugs of various 
pharmacological classes dose-dependently suppresses SD susceptibility in rats as a 
possible mechanism of action.14 The majority of these drugs, however, are ineffective 
after a single dose, reminiscent of the delayed onset of action requiring chronic 
treatment in migraine prophylaxis. We, therefore, examined the efficacy of migraine 
prophylactic drugs on stroke outcome and its mechanisms in relation to ischemic 
depolarizations. We chose topiramate as a prophylactic drug because it is efficacious in 
migraine prophylaxis,15 and inhibits experimental SD on chronic treatment in rats.14 We 
tested lamotrigine because it also inhibits SD on chronic treatment in rats,16 although 
its efficacy in migraine is not proven.17 Both drugs have been studied previously in 
experimental focal ischemia models without consistent efficacy, albeit as a single dose 
or as short-term postischemic dosing.18-22 Therefore, neither drug has been tested as a 
prophylactic intervention in stroke. 
We, therefore, tested these drugs in commonly used experimental models of focal 
cerebral ischemia, and did this not only in wild-type (WT) but also in FHM1 mutant 
mice to test drug efficacy on a background of cerebral hyperexcitability modeling 
migraine. Here, we show that chronic daily treatment for 7 weeks with the migraine 
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prophylactic drugs topiramate or lamotrigine delays AD, inhibits PID occurrence and 
improves tissue and neurological outcomes after filament occlusion of the middle 
cerebral artery in both WT and FHM1 mutant mice. In contrast, single doses of each 
drug are ineffective, suggesting that the efficacy of migraine prophylactic drugs in 
stroke corresponds to their efficacy on SD, and that SD susceptibility is a critical but 
modifiable determinant of vulnerability to ischemic injury.
METHODS
Experimental Animals. All experimental procedures were carried out in accordance 
with the Guide for Care and Use of Laboratory Animals (National Health Institutes 
Publication No. 85-23, 1996) and were approved by the institutional review board 
(Massachusetts General Hospital Subcommittee on Research Animal Care [MGH 
SRAC]). In addition to C57BL/6J WT mice, transgenic knock-in Cacna1a migraine mouse 
models homozygous for the R192Q FHM1 mutation were used, generated by a gene 
targeting approach,11,23 and backcrossed on C57BL/6J background for >10 generations. 
We studied mice between 2 and 6 months of age (23-30 g) because stroke risk is 
highest in young adult migraineurs. We studied male mice in stroke experiments to 
avoid the confounding effects of female hormones on outcome,24,25 and female mice 
in SD experiments because of their higher SD susceptibility compared with males,12 
and because migraine is more prevalent in women.
Treatment Paradigm. In the chronic treatment group, we treated mice for 7 weeks 
with once a day orogastric gavage doses of migraine prophylactic drugs topiramate 
(80 mg kg−1 d−1) or lamotrigine (30 mg kg−1 d−1), and compared these with vehicle (Ora 
plus/Ora sweet); the last daily dose was administered 2 hours before the experiment. In 
a separate cohort, we tested the efficacy of a single dose of these drugs administered 
2 hours before the experiment. We selected the doses based on previously reported 
efficacy in other experimental models in mice.26,27 All experiments were performed with 
the investigators blinded, and confirmatory genotyping was done in mutant cohorts. 
Study Design. Study end points were defined a priori. experiments were performed in 
3 stages. First, efficacy of topiramate and lamotrigine was tested on SD susceptibility end 
points in WT and FHM1 mutant mice. Second, efficacy of both drugs on PID frequency 
and ischemic outcome was tested in 2 separate cohorts of WT mice. Finally, efficacy 
of both drugs on ischemic outcome was tested in FHM1 mutant mice. Animals were 
randomly assigned to the treatment groups for each cohort. A different experimenter 
blinded to the treatment performed each experimental stage. experiments were 
performed according to the intention-to-treat principle; therefore, data points 
were excluded only if technical failures prevented reliable data collection. Because 
focal cerebral ischemia experiments in WT and FHM1 mutant mouse cohorts were 
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separated in time, and performed by different operators using different equipment 
and experimental setups, we could not perform comparisons of ischemic tissue and 
neurological outcome end points between WT and FHM1 mutant strains in this study. 




, and blood pressure were 
measured via a femoral artery catheter under isoflurane anesthesia (2.5% induction, 
1.5% maintenance, in 70% N
2
O and 30% O
2
; Table) and maintained by endotracheal 
intubation and mechanical ventilation during electrophysiological recordings (ie, SD 
susceptibility, PID frequency). In 24-hour survival experiments, these interventions 
were not performed to minimize morbidity and improve survival rates. Rectal 
temperature was controlled at 37°C. 
SD Susceptibility. As described previously,12 3 burr holes were drilled under saline 
cooling at the following coordinates (mm from bregma): 3.5 posterior, 2 lateral 
(2  mm diameter for electric stimulation and KCl application onto occipital cortex); 
1.5 posterior, 2 lateral (1 mm diameter, recording site 1); 0.5 anterior, 2 lateral (1 mm 
diameter, recording site 2). The dura was kept intact to minimize trauma. Two glass 
capillary microelectrodes were placed to record extracellular steady (DC) potential 
and electrocorticogram. electric SD threshold was determined by escalating intensity 
cathodal square pulses (10-8000 μC) via a bipolar electrode placed on the occipital 
cortex, and then a 1-mm cotton ball soaked in 300 mmol/L KCl was topically applied 
for 1 hour to record the frequency of evoked SDs. The protocol was then repeated on 
the opposite hemisphere. Data were averaged between the 2 hemispheres to yield a 
Table. Physiological Parameters. Data are displayed as mean±SD. PID indicates peri-infarct 
depolarization; SD, spreading depression; and WT, wild-type.
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data point per animal. SD frequency and threshold were taken as primary end points. 
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single data point per animal. SD frequency and threshold were taken as primary end 
points. The amplitude, propagation speed (distance/latency between the 2 recording 
electrodes), and duration at half-amplitude of the first SD in each hemisphere were 
also measured as secondary end points. There was no technical failure leading to 
exclusion in this cohort.
Transient filament Occlusion of the Middle Cerebral Artery. A nylon monofilament 
was inserted into the internal via the external carotid artery followed by reperfusion 
after 60 minutes, under isoflurane anesthesia (2.5% induction, 1.5% maintenance, in 
70% N
2
O and 30% O
2
) and laser Doppler monitoring (Perimed, Järfälla, Sweden), as 
described previously.13 
PID Occurrence. To record PIDs after transient filament occlusion of the middle 
cerebral artery (fMCAO), mice were transferred to a stereotaxic frame and two 0.5-mm 
diameter burr holes were carefully drilled under saline irrigation at the following 
coordinates (mm from bregma): 1.5 anterior, 0.5 lateral; 3.5 posterior, 0.5  lateral. 
These coordinates were chosen to be reliably outside the focal ischemic cortex to 
allow detection of PIDs. Two intracortical glass micropipettes were inserted at a 
depth of 250 μm, and extracellular slow potential changes were recorded for ≈2 hours 
starting ≈20 minutes after the onset of fMCAO. PID frequency was taken as a primary 
end point. Technical failures occurred in WT cohorts only, and led to the exclusion of 
1 chronic and 1 single dose vehicle, 1 chronic and 1 single dose topiramate, and 3 single 
dose lamotrigine-treated mice for PID assessments. extensive surgery, intubation, 
mechanical ventilation, and arterial cannulation for PID monitoring precluded 24-hour 
survival. Therefore, infarct volumes were determined in a separate cohort. 
Assessment of Tissue and Neurological Outcome After fMCAO. After reperfusion, 
mice were transferred to a temperature-controlled incubator with access to food and 
water ad libitum. Neurological outcomes were scored as a primary end point 24 hours 
after reperfusion, using a 5-point scale: 0, normal; 1, forepaw monoparesis; 2, circling 
to left; 3, falling to left; 4, no spontaneous walking and depressed consciousness; and 
5, death. Premature death after ischemia was incorporated in the neurological outcome 
scale because of the intention-to-treat design; however, infarct volume data from these 
mice were not measured because of postmortem confounders. Infarct volume was 
calculated by integrating the infarct area in ten 1-mm-thick 2,3,5-triphenyltetrazolium 
chloride-stained coronal sections. Infarct volume was calculated as a primary end point by 
subtracting the volume of ipsilateral noninfarcted tissue from contralateral hemisphere. 
Ischemic swelling volume was also calculated as a secondary end point by subtracting the 
volume of contralateral hemisphere from the volume of ipsilateral hemisphere. Technical 
failures occurred in FHM1 cohorts only, and led to the exclusion of 2 chronic vehicle and 1 
chronic topiramate-treated mice for tissue and neurological outcome assessments.
127
Measurement of AD Latency. The latency between fMCAO and AD onset was 
measured as a secondary end point using the characteristic secondary hypoperfusion 
caused by AD on laser Doppler tracings, as described in detail previously.13 We 
measured this parameter in all WT mice undergoing fMCAO either for PID frequency 
determination or infarct and neurological outcome assessment. Absence of a 
detectable secondary hypoperfusion because of technical reasons was taken as an a 
priori exclusion criterion for this data set. Although this occurred more commonly, it 
resulted in the exclusion of only 16 of 112 animals in which this secondary end point was 
studied, distributed relatively evenly among experimental groups.
Statistical Analysis. Data were analyzed using SPSS (v11.0) and GraphPad Prism 6, and 
presented as whisker-box plot (whiskers, full range; box, 25% to 75% range; line, median; 
cross, mean) in the figures and mean±SD in the table. Statistical tests used to analyze 
each data set, group sizes (n) and details of statistical outcomes are provided in the 
figure legends. P values are 2-tailed, and P<0.05 was considered statistically significant.
RESULTS 
Suppression of KCl-Induced or Electrically Triggered Cortical SD. We have previously 
shown in rats that migraine prophylactic drugs suppress SD susceptibility.14 To first test 
whether migraine prophylactic drugs are also efficacious in mice, we treated WT and 
FHM1 knock-in mice with chronic daily doses of topiramate or lamotrigine for 7 weeks. 
Chronic treatment with topiramate or lamotrigine elevated the electrical threshold for 
SD induction and reduced the frequency of KCl-induced SDs (Figure 1A). Both drugs 
also reduced the SD propagation speed by ≈30%, albeit only in the FHM1 mutant. In 
addition, lamotrigine decreased SD duration, and tended to be more efficacious on all 
SD end points compared with topiramate. A single dose of either drug administered 
2 hours before SD, tested in WT mice only, did not affect any of the SD attributes 
although a trend for lamotrigine to elevate the electrical threshold and reduce KCl-
induced SD frequency was noted (Figure 1B).
Suppression of Cortical PIDs During Middle Cerebral Artery Occlusion. We next 
tested whether migraine prophylactic drugs also suppress PIDs, akin to SD. Intracortical 
microelectrode recordings during fMCAO showed that chronic treatment with 
topiramate or lamotrigine reduced PID occurrence by 50% and 80%, respectively 
(Figure 2A). A single dose of topiramate 2 hours before ischemia onset was ineffective, 
whereas lamotrigine showed a strong trend (Figure 2B). In a separate cohort of mice, we 
found that chronic treatment with valproate (200 mg/kg, IP for 6 weeks) also reduced 
the number of PIDs (3.1±0.6 PIDs/h) compared with vehicle (5.7±0.5 PIDs/h; P<0.001, n=5 
each), consistent with its inhibitory effect on KCl or electrically induced SDs previously 






Figure 1. Chronic topiramate and lamotrigine treatment suppresses spreading 
depression (SD) susceptibility. A, Representative electrophysiological tracings show SD 
triggered on stepwise escalating cortical cathodal stimulation at intensities indicated above 
each tracing to determine the SD threshold (left), and repetitive SDs triggered by continuous 
topical KCl application for 1 hour onto the cortex to determine SD frequency (right), in wild-
type (WT) or familial hemiplegic migraine type 1 (R192Q) mutant mice after 7 weeks of daily 
treatment with vehicle (VEH, blue), topiramate (TPM, red), or lamotrigine (LTG, green). 
Whisker-box plots summarize the effects of chronic treatment on SD threshold, frequency, 
speed, and duration; n=6, 7, and 6 WT mice in vehicle, topiramate and lamotrigine groups, 
respectively; n=7 R192Q mice in vehicle, topiramate, and lamotrigine groups each. Two-way 
ANOVA followed by Sidak and Tukey multiple comparisons. SD threshold: genotype effect 
F(1,34)=18.8, P=0.0001; treatment effect F(2,34)=8.4, P=0.0011; interaction F(2,34)=1.9, 
P=0.1674. SD frequency: genotype effect F(1,34)=83.8, P<0.0001; treatment effect 
F(2,34)=15.4, P<0.0001; interaction F(2,34)=1.8, P=0.1857. SD speed: genotype effect 
F(1,34)=42.8, P<0.0001; treatment effect F(2,34)=10.7, P=0.0002; interaction F(2,34)=4.8, 
P=0.0142. SD duration: genotype effect F(1,34)=0.3, P=0.5647; treatment effect F(2,34)=7.8, 
P=0.0016; interaction F(2,34)=3.8, P=0.0332. Post hoc comparisons: *P<0.05 vs vehicle; 
†P<0.05 vs WT. B, Whisker-box plots summarize the effect of a single dose of each drug on 
SD frequency, threshold, speed, and duration in WT mice. n=10, 6, and 9 mice in vehicle, 
topiramate, and lamotrigine groups, respectively. One-way ANOVA followed by Holm–Sidak 
multiple comparisons test. Treatment effects were not statistically significant. 
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Figure 2. Chronic topiramate and lamotrigine treatment suppresses peri-infarct 
depolarizations (PIDs). A, Upper panel shows representative electrophysiological tracings 
of repetitive PIDs that spontaneously arise around focal ischemic tissue during filament 
middle cerebral artery occlusion (fMCAO) after 7 weeks of daily treatment with vehicle (VEH, 
blue), topiramate (TPM, red), or lamotrigine (LTG, green) in WT mice. Lower left panel 
summarizes all experiments. Horizontal lines indicate the time of onset and end of 
electrophysiological recordings with respect to fMCAO onset in each mouse, and circles 
indicate PIDs. Line graph shows average cumulative PID occurrence per mouse as a 
function of time. When calculating the cumulative PID occurrence over time, differences in 
group sizes and recording durations were taken into account. Whisker-box plots show 
average overall PID frequency; n=6, 9, and 8 mice in vehicle, topiramate, and lamotrigine 
groups, respectively. One-way ANOVA followed by Holm–Sidak multiple comparisons test. 
Treatment effect F(2,23)=18.1, P<0.0001. Post hoc comparisons: *P<0.05 vs VEH; †P<0.05 
vs TPM. B, Left panel summarizes all experiments where horizontal lines indicate the time of 
onset and end of electrophysiological recordings with respect to fMCAO onset in each 
mouse, and circles indicate PIDs. Line graph shows average cumulative PID occurrence per 
mouse as a function of time. When calculating the cumulative PID occurrence over time, 
differences in group sizes and recording durations were taken into account and corrected for. 
Whisker-box plots show average overall PID frequency; n=7, 5, and 4 mice in vehicle, 
topiramate, and lamotrigine groups, respectively. One-way ANOVA followed by Holm–Sidak 
multiple comparisons test. Treatment effects were not statistically significant. 
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depolarizations (PIDs). (A) Upper panel shows representative electrophysiological tracings 
of repetitive PIDs that spontaneously arise around focal ischemic tissue during filament middle 
cerebral artery occlusion (fMCAO) after 7 weeks of daily treatment with vehicle (VeH, blue), 
topiramate (TPM, red), or lamotrigine (LTG, green) in WT mice. Lower left panel summarizes all 
experiments. Horizontal lines indicate the time of onset and end of electrophysiological recordings 
with respect to fMCAO onset in each mouse, and circles indicate PIDs. Line graph shows average 
cumulative PID occurrence per mouse as a function of time. When calculating the cumulative PID 
occurrence over time, differences in group sizes and recording durations were taken into account. 
Whisker-box plots show average overall PID frequency; n=6, 9, and 8 mice in vehicle, topiramate, and 
lamotrigine groups, respectively. One-way ANOVA followed by Holm–Sidak multiple comparisons 
test. Treatment effect F(2,23)=18.1, P<0.0001. Post hoc comparisons: *P<0.05 vs VeH; †P<0.05 vs TPM. 
(B) Left panel summarizes all experiments where horizontal lines indicate the time of onset and end 
of electrophysiological recordings with respect to fMCAO onset in each mouse, and circles indicate 
PIDs. Line graph shows average cumulative PID occurrence per mouse as a function of time. When 
calculating the cumulative PID occurrence over time, differences in group sizes and recording 
durations were taken into account and corrected for. Whisker-box plots show average overall PID 
frequency; n=7, 5, and 4 mice in vehicle, topiramate, and lamotrigine groups, respectively. On -way 




Improved Stroke Outcomes After Chronic Treatment. We next tested whether 
suppression of PIDs translated into improved stroke outcomes in WT mice. Chronic 
treatment with either drug reduced the infarct size after transient fMCAO by ≈30%, 
and improved neurological outcomes (Figure 3A). Smaller infarcts predominantly 
reflected less severe cortical involvement (71±10, 50±11, and 48±9 mm3 in vehicle, 
topiramate, and lamotrigine groups, respectively; P<0.05). Ischemic brain swelling, 
calculated by subtracting the contralateral from ipsilateral hemispheric volume, was 
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AD onset was because of milder ischemia. A single dose of either drug did not affect the 
latency to AD (Figure 4B). 
 
 
Figure 3. Chronic topiramate and lamotrigine treatment improves stroke outcomes. A, 
Representative 2,3,5-triphenyltetrazolium chloride-stained 1-mm-thick coronal sections show 
the infarct 24 hours after 1-hour transient filament middle cerebral artery occlusion. Whisker-
box plot summarizes the indirect infarct volumes after 7 weeks of daily treatment with vehicle 
(VEH, blue), topiramate (TPM, red) or lamotrigine (LTG, green) in wild-type mice. 
Neurological deficit scores are also shown in individual animals; n=10, 11 and 9 mice in 
vehicle, topiramate and lamotrigine groups, respectively. One-way ANOVA followed by 
Holm-Sidak multiple comparisons test for infarct volume, or Kruskal–Wallis followed by Dunn 
multiple comparisons test for neurological deficit score. Infarct volume: treatment effect 
F(2,27)=5.5, P=0.01. Neuroscore: treatment effect Kruskal–Wallis statistic 12.3, P=0.0021. 
Post hoc comparisons: *P<0.05 vs vehicle. B, Whisker-box plot summarizes the indirect 
infarct volumes after a single dose of vehicle, topiramate or lamotrigine; n=10, 11, and 9 
mice in vehicle, topiramate, and lamotrigine groups, respectively. One-way ANOVA followed 
by Holm-Sidak multiple comparisons test. Neuroscore: treatment effect Kruskal–Wallis 
statistic 9.4, P=0.009. Post hoc comparisons: †P<0.05 vs topiramate. 
figure 3. Chronic topiramate and lamotrigine treatment improves stroke outcomes. (A) 
Representative 2,3,5-triphenyltetrazolium chloride-stained 1-mm-thick coronal sections show the 
infarct 24 hours after 1-hour transient filament middle cerebral artery occlusion. Whisker-box plot 
summarizes he indi ect infarct volumes after 7 weeks of daily treatment with vehicle (VeH, blue), 
topiramate (TPM, red) or lamot igine (LTG, green) in wild-typ  mice. Neu ological deficit scores are 
also shown in individual animals; n=10, 11 and 9 mice in vehicle, topiramate and lamotrigine groups, 
respectively. One-way ANOVA followed by Holm-Sidak multiple comparisons test for infarct 
volume, or Kruskal–Wallis followed by Dunn multiple comparisons test for neurological deficit 
score. Infarct volume: treatment effect F(2,27)=5.5, P=0.01. Neuroscore: treatment effect Kruskal–
Wallis statistic 12.3, P=0.0021. P st hoc comparisons: *P<0.05 vs vehicle. (B) Whisker-box plot 
summarizes the indirect infarct volumes after a single dose of vehicle, topiramate or lamotrigine; 
n=10, 11, and 9 mice in vehicle, topiramate, and lamotrigine groups, respectively. One-way ANOVA 
followed by Holm-Sidak multiple comparisons test. Neuroscore: treatment effect Kruskal–Wallis 
statistic 9.4, P=0.009. Post hoc comparisons: †P<0.05 vs topiramate.
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also reduced by chronic topiramate or lamotrigine treatment compared with vehicle 
(8±2, 8±2, and 16±2 mm3, respectively; P<0.05), possibly linked to less frequent PIDs. 
Neurological outcomes assessed using a combined death and disability score as a 
clinically relevant end point13 were improved after chronic treatment with topiramate 
or lamotrigine compared with vehicle (Figure 3A). In contrast to chronic treatment, 
single doses of either drug did not affect any of the outcome end points compared 
with vehicle after transient fMCAO (Figure 3B).
Delayed AD Onset. AD represents loss of membrane ionic gradients on ischemic 
failure of Na+/K+-ATPase function. We have previously shown that migraine mutations 
hasten AD after focal ischemia and this correlated well with SD susceptibility and 
tissue outcome.13 Therefore, we assessed whether decreased SD susceptibility after 
administrating migraine prophylactic drugs was associated with delayed AD onset in 
WT mice, detected by its cerebral vasoconstrictive effect as previously described.4,13 
Chronic treatment with lamotrigine, but not topiramate, delayed the onset of AD by 
≈25% (Figure 4A). The magnitude of cerebral blood flow reduction in the ischemic 
core did not differ among groups (residual cerebral blood flow 12±5%, 13±5%, and 
12±3% of baseline for vehicle, topiramate, and lamotrigine, respectively), eliminating 
the possibility that slower AD onset was because of milder ischemia. A single dose of 
either drug did not affect the latency to AD (Figure 4B).
figure 4. Chronic topiramate and lamotrigine treatment shortens anoxic depolarization (AD) 
latency after ischemia onset. (A) Left panel shows representative laser Doppler cerebral blood 
flow (CBF) reductions induced by occlusion of the common carotid artery and the middle cerebral 
artery, and the subsequent drop in CBF that marks the onset of AD. AD latency is measured as shown 
by the horizontal line. This secondary end point was measured in all transient filament occlusion 
of the middle cerebral artery experiments performed for peri-infarct depolarizations frequency 
and tissue and neurological outcome assessments. Whisker-box plot summarizes AD latency after 
7 weeks of daily treatment with vehicle (VeH, blue), topiramate (TPM, red), or lamotrigine (LTG, 
green) in wild-type mice; n=17, 14, and 13 mice in vehicle, topiramate, and lamotrigine groups, 
respectively. One-way ANOVA followed by Holm-Sidak multiple comparisons test. Treatment effect 
F(2,41)=16.0, P<0.0001. Post hoc comparisons: *P<0.05 vs vehicle and topiramate. (B) Whisker-box 
plot summarizes AD latency after a single dose of vehicle, topiramate or lamotrigine; n=13, 16, and 
13 mice in vehicle, topiramate, and lamotrigine groups, respectively. Oneway ANOVA followed by 
Holm-Sidak multiple comparisons test. Treatment effects were not statistically significant.
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Improved Stroke Outcomes After Chronic Treatment in FHM1 Mice. After showing 
that migraine prophyl xis with topiramate and lamotrigine improves strok  outcomes in 
WT mice, we also tested whether efficacy is sustained in migraine-susceptible FHM1 
brains. Chronic treatm nt with eith r topiramate or lamotrigine reduced infarct s ze after 
transient fMCAO in FHM1 mutants by 30% to 35% (Figure 5); however, improved 
neurological function and the delay in the onset of AD reached statistical significance 
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outcome assessments. Whisker-box plot summarizes AD latency after 7 weeks of daily 
treatment with vehicle (VEH, blue), topiramate (TPM, red), or lamotrigine (LTG, green) in 
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Chapter 3B
Improved Stroke Outcomes After Chronic Treatment in fHM1 Mice. After showing 
that migraine prophylaxis with topiramate and lamotrigine improves stroke outcomes 
in WT mice, we also tested whether efficacy is sustained in migraine-susceptible FHM1 
brains. Chronic treatment with either topiramate or lamotrigine reduced infarct size 
after transient fMCAO in FHM1 mutants by 30% to 35% (Figure 5); however, improved 
neurological function and the delay in the onset of AD reached statistical significance 





Migraine is an established risk factor for ischemic stroke. We have recently shown that 
genetically enhanced SD susceptibility worsens the effect of cerebral ischemia on the 
brain by facilitating ischemic depolarization events,13 as a mechanism to explain the 
increased risk of stroke in migraineurs. Conversely, we here show that pharmacological 
suppression of SD susceptibility by migraine prophylactic drugs inhibits AD and PIDs 
and improves stroke evolution in both WT and FHM1 mutant mice. The magnitude of SD 
suppression by each drug corresponded well with the magnitude of AD and PID 
suppression, and stroke outcome. Consistent with this, genetically reduced susceptibility 
to SD as observed in rolling Nagoya and leaner mice, which have spontaneously arisen 
Figure 5. Chronic topiramate and lamotrigine treatment improves stroke outcomes in 
familial hemiplegic migraine type 1 mutant mice. A, Whisker-box plot summarizes the 
indirect infarct volumes after 7 weeks of daily treatment with vehicle (VEH, blue), topiramate 
(TPM, red), or lamotrigine (LTG, green) in R192Q mutant mice. Neurological deficit scores are 
also shown in individual animals; n=7, 10, and 10 mice in vehicle, topiramate, and 
lamotrigine groups, respectively. *P<0.05 vs vehicle. One-way ANOVA followed by Holm-
Sidak multiple comparisons test for infarct volume, and Kruskal–Wallis followed by Dunn 
multiple comparisons test for neurological deficit score. Infarct volume: treatment effect 
F(2,24)=6.0, P=0.0075. Neuroscore: treatment effect Kruskal–Wallis statistic 8.6, P=0.0136. 
Post hoc comparisons: *P<0.05 vs vehicle. B, Whisker-box plot summarizes anoxic 
depolarization latency after a single dose of vehicle, topiramate, or lamotrigine (LTG, green) 
in R192Q mutant mice; n=5, 11, and 10 mice in vehicle, topiramate, and lamotrigine groups, 
respectively. One-way ANOVA followed by Holm-Sidak multiple comparisons test. Treatment 
effect F(2,23)=6.8, P=0.0048. Post hoc comparisons: *P<0.05 vs vehicle and topiramate. 
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familial hemiplegic migraine type 1 mutant mice. (A) Whisker-box plot summarizes the indirect 
infarct volum s aft r 7 weeks of daily treatment with vehicle (VeH, lue), topiramate (TPM, red), 
or lamotrigi e (LTG, green) in R192Q mutant mic . Neurological deficit scores are also shown in 
individual animals; n=7, 10, and 10 mice in vehicle, topiramate, and lamotrigine groups, respectively. 
*P<0.05 vs vehicle. One-way ANOVA followed by Holm-Sidak multiple comparisons test for infarct 
volume, and Kruskal–Wallis followed by Dunn multiple comparisons test for neurological deficit 
score. Infarct volume: treatment effect F(2,24)=6.0, P=0.0075. Neuroscore: treatment effect 
Kruskal–Wallis statistic 8.6, P=0.0136. Post hoc comparisons: *P<0.05 vs vehicle. (B) Whisker-box plot 
summarizes anoxic depolarization latency after a single dose of vehicle, topira ate, or lamotrigine 
(LTG, green) in R192Q mutant mice; n=5, 11, and 10 mice in vehicle, topiramate, and lamotrigine 
groups, respectively. One-way ANOVA followed by Holm-Sidak multiple comparisons test. 
Treatment effect F(2,23)=6.8, P=0.0048. Post hoc comparisons: *P<0.05 vs vehicle and topiramate.
DISCUSSION 
Migraine is an established risk factor for ischemic stroke. We have recently shown 
that genetically enhanced SD susceptibility worsens the effect of cerebral ischemia 
on the brain by facilitating ischemic depolarization events,13 as a mechanism to 
explain the increased risk of stroke in migraineurs. Conversely, we here show that 
pharmacological suppression of SD susceptibility by migraine prophylactic drugs 
inhibits AD and PIDs and improves stroke evolution in both WT and FHM1 mutant mice. 
The magnitude of SD suppression by each drug corresponded well with the magnitude 
of AD and PID suppression, and stroke outcome. Consistent with this, genetically 
reduced susceptibility to SD as observed in rolling Nagoya and leaner mice, which 
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have spontaneously arisen mutations in the Cacna1a gene leading to loss of Ca
V
2.1 
function, was associated with smaller infarcts, compared with WT on experimental 
stroke.28 These data strongly support intrinsic SD susceptibility of brain tissue (ie, the 
tissue factor) as an important determinant of stroke outcome. 
Although in vitro studies of topiramate and lamotrigine have suggested a 
neuroprotective effect,29 in vivo studies were generally negative in various models of 
focal cerebral ischemia.18–22 All studies, however, have tested single doses or short-
term treatment administered before or after ischemia onset. Our data suggest that 
chronic treatment is required for efficacy, as has been the case for SD suppression in 
rats14,16 and for the prophylactic effect on migraine in patients. Both topiramate and 
lamotrigine have been shown to acutely inhibit various voltage-gated ion channels 
as well as glutamatergic neurotransmission.30,31 However, whether chronic treatment 
simply enhances these effects by achieving higher tissue levels, or induces structural 
or gene expression changes, remains to be determined. 
Although PIDs are generally thought to enlarge infarcts by worsening the supply demand 
mismatch, an alternative and possibly complementary mechanism is a further increase 
in cerebral excitability by SD shown in neocortical slices32,33; PID inhibition by migraine 
prophylaxis may prevent this delayed hyperexcitability and improve outcome. Of course, 
glial cells critically modulate SD susceptibility, and glial protective effects of topiramate and 
lamotrigine34–36 may also contribute to PID suppression and infarct reduction. 
It is well established that PIDs worsen stroke outcomes,6,37 and that drugs acutely 
inhibiting PIDs after a single dose (eg, NMDA receptor antagonists) are protective 
in focal cerebral ischemia both in experimental animals and in stroke patients.4,38–40 
However, clinical translation of this neuroprotective target has been difficult because 
of the cognitive and sedative side effects of such potent drugs.41–43 In this respect, 
migraine prophylaxis may provide a better-tolerated antiexcitatory treatment 
alternative targeting SD and PIDs in stroke prophylaxis. Consistent with this notion, 
chronic treatment with lamotrigine was reported to diminish stroke-like episodes 
in a migraineur with mitochondrial encephalopathy, lactic acidosis, and stroke-
like episodes,44 suggesting that the approach may be even more efficacious in 
hyperexcitable subsets of patients.
Summary and Conclusions. In summary, our data suggest that pharmacological 
suppression of SD susceptibility may protect against ischemic injury in patients at high 
risk for stroke, migraineurs, and nonmigraineurs alike. Whether migraine prophylaxis 
clinically improves stroke outcomes or reduces the stroke risk remains to be tested 
in large population-based studies. Although chronic treatment purely as a form of 
stroke prophylaxis may not be justified at this time because of potential side effects, 
migraine patients who are already on a migraine prophylactic regimen may indeed see 
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Objective: Migraine, particularly with aura, is a risk factor for ischemic stroke. Recent 
data in migraine mutant mice suggest that cerebral hyperexcitability associated with 
migraine accelerates recruitment of ischemic penumbra into the core, resulting in 
faster infarct growth compared with wild type. We hypothesized that individuals with 
a history of migraine are more likely to exhibit increased recruitment of ischemic 
tissue into the infarct in acute stroke.
Methods: In this retrospective case-control study, we identified participants with 
reliably documented migraine history, measured lesion volumes on diffusion-weighted 
and perfusion-weighted MRI obtained within 72 hours of symptom onset, calculated 
the proportion of ischemic tissue on perfusion-weighted imaging (PWI) hyperintense 
on diffusion-weighted imaging (DWI), and compared the proportion of patients with 
no-mismatch pattern defined as DWI lesion >83% of PWI lesion.
Results: Migraineurs (n = 45) were younger, more often female, less likely to have 
vascular risk factors, and more often had cervical artery dissection, but otherwise did 
not differ from controls (n = 27). A significantly larger proportion of migraineurs had 
no-mismatch pattern, indicating that the entire perfusion defect was recruited into 
the infarct by the time of MRI (22% vs 4% of migraineurs and controls, respectively; 
p = 0.044). The difference was even more prominent in migraineurs with aura (36% vs 
4%, p = 0.019). The association between migraine and no-mismatch pattern persisted 
after adjustment for time to MRI (p = 0.041). 
Conclusions: This case-control study supports the hypothesis that a history of 
migraine, particularly with aura, is associated with a no-mismatch pattern during acute 
ischemic stroke, consistent with data obtained in migraine mutant mice.
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INTRODUCTION
Recent experimental data suggest that genetic susceptibility to migraine aura may 
be a factor rendering the brain tissue more sensitive to ischemia.1 Transgenic mice 
expressing familial hemiplegic migraine type 1 (FHM1) mutations, frequently used as 
animal models for migraine, develop accelerated infarct growth because of faster 
anoxic depolarization and more frequent peri-infarct spreading depressions during 
acute focal cerebral ischemia.1 Mutant animals require higher blood flow to survive 
focal ischemia, and develop larger infarcts and worse neurologic outcomes compared 
with wild type. In addition, larger infarcts were observed in migraineurs with aura in a 
recent preliminary study.2 We, therefore, sought to determine whether patients with 
acute ischemic stroke and a history of migraine develop faster infarct growth as a 
reflection of increased tissue vulnerability to ischemia. 
METHODS
Study population. We retrospectively studied consecutive patients (age >18 years) 
with imaging-confirmed acute ischemic stroke admitted within 72 hours of symptom 
onset at a single tertiary care hospital (Massachusetts General Hospital) between 
2003 and 2014, with approval from the Institutional Review Board. A priori inclusion 
criteria were (1) diffusion- and perfusion-weighted MRI within 72 hours of symptom 
onset and (2) patients whose records included a physician note that explicitly stated a 
history of migraine (with or without aura, or unspecified) and controls whose records 
explicitly stated that the participant had no history of migraine. Cases could not be 
matched with controls for age and sex because of the need to have migraine status 
documented in the chart.
Image analysis. experienced neurologists blinded to case-control assignments 
manually outlined regions that were hyperintense on diffusion-weighted images (DWI) 
and hypointense on apparent diffusion coefficient (ADC) maps and hyperintense 
regions on mean transit time (MTT) maps using MRIcron software (University of 
Nottingham, UK). We determined the arterial territory involved using standard 
templates based on infarct distribution on DWI. We also recorded whether there was 
intracranial arterial occlusion on CT or magnetic resonance angiograms obtained at 
the same session with MRI. We considered an occlusion proximal when it was located 
within the first 3 segments of the intracranial arterial system.
Study endpoint. We hypothesized that migraineurs would show faster recruitment 
of hypoperfused but viable tissue (i.e., DWI-MTT mismatch) into the infarct (DWI 
lesion) during acute ischemic stroke.3,4 We reasoned that by the time MRI was done a 
larger proportion of migraineurs compared to controls would develop a no-mismatch 
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pattern. We defined nomismatch as DWI lesion volume >83% of perfusion-weighted 
imaging (PWI) lesion volume.5,6 We excluded participants if DWI and PWI volumes 
were both less than 10 mL because of the poor reliability of volumetric analyses in this 
subset.7 None of the patients had MRI before a reperfusion intervention. 
Statistical analysis. We used χ2 or Fisher exact tests for group-wise comparisons 
among categorical variables and Mann-Whitney U test for comparisons among 
numerical variables. To assess the association between migraine status and tissue 
vulnerability to ischemia, we used a logistic regression model in which no-mismatch 
was the dependent variable and stroke features with a univariate p < 0.150 were the 
covariates. A p value of <0.05 was considered statistically significant. All analyses 
were performed using SPSS 16.0.
RESULTS 
We identified 207 patients with reliable documentation of migraine status and an MRI 
within 72 hours of symptom onset confirming acute infarction (figure, A). Patients with 
a history of migraine (n = 142) were younger, predominantly female, more likely to 
have uncommon etiologies such as cervical artery dissection, and less likely to have 
multiple vascular risk factors as compared to those who did not have migraine (n = 65). 
All these associations were in the same direction in migraineurs with aura.
Of the 207 patients, 107 had both DWI and PWI. Thirty-five of these 107 patients 
had lesions <10 mL and were excluded from further analyses (figure, A). The remaining 
cohort of 45 migraineurs (11 with aura) and 27 control participants showed similar 
demographic, clinical, and radiologic findings noted in the excluded participants, 
except that the exclusion of small lesions eliminated lacunar infarcts from the etiologic 
subtypes (table 1). Median time from symptom onset to MRI was approximately 7 hours 
(figure, B).
The frequency histogram of DWI/PWI ratios displayed a bimodal distribution in 
migraineurs (figure, C). In contrast, the proportion of nonmigraineurs continuously 
decreased as DWI/PWI ratio increased. A receiver operating characteristic curve 
analysis revealed that the optimal operating point for DWI/PWI ratio to discriminate 
migraineurs from nonmigraineurs was 0.82. There was a significantly higher 
proportion of migraineurs with no-mismatch compared with controls (22% vs 4%, 
respectively; p = 0.044). The relationship was even stronger in migraine patients with 
aura (36% vs 4%, respectively; p = 0.019; figure, D), but did not reach significance for 
migraine without aura. Among all covariates (table 2), only time from symptom onset 
to MRI showed a borderline association with no-mismatch (p = 0.105). The association 
between DWI/PWI ratio and migraine status was significant when adjusted for time to 
MRI (p = 0.041; figure, D). There was a trend towards a similar relationship between 
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figure. Study flowchart, time to MRI, and DWI/PWI distribution for the analysis of no-mismatch 
pattern. (A) Study flowchart. MA = migraine with aura; MO = migraine without aura; MU = migraine 
of unknown type. (B) Histogram of time from symptom onset to MRI. (C) Frequency histogram 
for diffusion-weighted imaging (DWI)/perfusion-weighted imaging (PWI) ratio in controls and 
migraineurs showed a bimodal distribution in migraineurs. (D) Subgroup analyses for no-mismatch 
pattern adjusted for time to MRI. Horizontal bars represent odds ratio and 95% confidence interval. 





Figure. Study flowchart, time to MRI, and DWI/PWI distribution for the analysis of no-
mismatch pattern. (A) Study flowchart. MA = migraine with aura; MO = migraine without 
aura; MU = migraine of unknown type. (B) Histogram of time from symptom onset to MRI. 
(C) Frequency histogram for diffusion-weighted imaging (DWI)/perfusion-weighted imaging 
(PWI) ratio in controls and migraineurs showed a bimodal distribution in migraineurs. (D) 
Subgroup analyses for no-mismatch pattern adjusted for time to MRI. Horizontal bars 





We identified 207 patients with reliable documentation of migraine status and an MRI 
within 72 hours of symptom onset confirming acute infarction (figure, A). Patients with a 
history of migraine (n = 142) were younger, predominantly female, more likely to have 
uncommon etiologies such as cervical artery dissection, and less likely to have multiple 
vascular risk factors as compared to those who did not have migraine (n = 65). All these 
associations were in the same direction in migraineurs with aura. 
 
 
Table 1. Demographic, clinical, and radiologic characteristics of the study cohort (with 
PWI) stratified according to migraine history. Abbreviations: DWI = diffusion-weighted 
imaging; IQR = interquartile range; PWI = perfusion-weighted imaging. aSignificant. 
Table 1. Demographic, clinical, and radiologic characteristics of the study cohort (with PWI) 
stratified according to migraine history. Abbreviations: DWI = diffusion-weighted imaging; IQR = 






Our data suggest a novel link between migraine and human stroke by showing that a 
history of migraine, particularly with aura, may accelerate loss of viable tissue at risk for 
infarction during acute cerebral ischemia. Compared to controls, a significantly higher 
proportion of migraineurs displayed nomismatch early after stroke onset (median 7 
Table 2. Demographic, clinical, and radiologic characteristics of the study cohort (with 
PWI) stratified according to complete infarction status. Abbreviations: IQR = interquartile 
range; PWI = perfusion-weighted imaging. 
Table 2. Demographic, clinical, and radiologic characteristics of the study cohort (with PWI) 




migraine and tissue outcome in more homogeneous subgroups, such as in patients 
with MRI obtained within 24 hours of stroke onset, patients with persistent proximal 
occlusion, or patients who did not receive reperfusion therapies (figure, D). 
DISCUSSION
Our data suggest a novel link between migraine and human stroke by showing that a 
history of migraine, particularly with aura, may accelerate loss of viable tissue at risk for 
infarction during acute cerebral ischemia. Compared to controls, a significantly higher 
proportion of migraineurs displayed nomismatch early after stroke onset (median 
7 hours), a pattern suggestive of malignant progression in which penumbra is rapidly 
recruited into the ischemic core. The risk was particularly high in migraineurs with 
aura, which is in agreement with experimental findings in transgenic mouse models 
of enhanced genetic susceptibility to migraine aura.1 Importantly, the relationship 
observed between migraine and no-mismatch persisted when adjusted for time from 
symptom onset to imaging, a wellknown determinant of the conversion of penumbra 
into definite infarction. 
This study was subject to selection and documentation bias; a history of migraine is 
more likely to be inquired in young patients with no known risk factors. Migraine status 
is also more likely to be documented in medical records if it is present than absent. 
Nevertheless, the present migraine cohort was similar to previously reported larger 
stroke cohorts with migraine in age and sex, risk factor profile, presumed stroke etiology, 
and involved vascular territory, suggesting that retrospective design did not introduce 
an important bias towards selection of a particular risk population.8,9 It was not possible 
to retrieve data on migraine features (e.g., active vs remote history of migraine, attack 
frequency or severity, aura with each attack vs only occasional auras, aura without 
headache) that might influence the rate of progression to infarction. Small sample size 
and retrospective design also precluded reliable assessment of the effect of different 
modes of migraine prophylaxis. Future prospective studies will address these hypotheses. 
Brain regions abnormal on MTT maps indicate both critically and noncritically 
hypoperfused tissue. More frequent no-mismatch based on the MTT criterion 
suggests that even moderately oligemic tissue is at risk of infarction in migraineurs, 
further supporting the notion of increased tissue sensitivity to ischemia. Although 
statistically significant, the association between tissue outcome and migraine status 
was not absolute; 78% of the patients with migraine did not exhibit a no-mismatch, 
suggesting that increased risk of no-mismatch originated from a subset of highly 
susceptible patients, perhaps those with a genetic predisposition to develop anoxic 
and spreading depolarizations. Importantly, although our a priori time to MRI cutoff 
was <72 hours of symptom onset, the vast majority of patients in our final cohort had 
times to MRI <36 hours. Indeed, secondary analyses using 48 hours time to MRI cutoff 
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yielded the same conclusion (odds ratio 18.2 for no-mismatch in migraineurs with aura 
compared with controls; p = 0.025). Therefore, long inclusion times toMRI did not 
confound our conclusions in this hypothesis-generating study. 
This study raises several important hypotheses10 to be tested in subsequent 
studies. First, our findings support a shorter therapeutic window for reperfusion in 
migraineurs due to rapid loss of viable and salvageable tissue at risk. Second, higher 
sensitivity to ischemia may require more stringent monitoring and management of 
stroke risk factors and possibly antithrombotic prophylaxis in migraineurs. Third, 
migraine prophylaxis may reduce tissue vulnerability to ischemic injury by suppressing 
the susceptibility to spreading depolarizations.11
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Background: Migraine, particularly with aura, increases the risk for ischemic stroke, 
at least in a subset of patients. The underlying mechanisms are poorly understood and 
probably multifactorial. 
Methods: We carried out an extended literature review of experimental and clinical 
evidence supporting the association between migraine and ischemic stroke to identify 
potential mechanisms that can explain the association. 
Results: Observational, imaging and genetic evidence support a link between 
migraine and ischemic stroke. Based on clinical and experimental data, we propose 
mechanistic hypotheses to explain the link, such as microembolic triggers of migraine 
and enhanced sensitivity to ischemic injury in migraineurs. 
Discussion: We discuss the possible practical implications of clinical and experimental 
data, such as aggressive risk factor screening and management, stroke prophylaxis 
and specific acute stroke management in migraineurs. However, evidence from 




Migraine is the most common neurological disorder and a major cause of disability 
in the western world, with a prevalence of approximately 13% (9% among men, 
18% among women in the United States (US)).1 An aura is present in up to 30% of 
migraineurs, usually during the hour preceding the headache.2,3 Spreading depression 
(SD), an intense neuronal and glial depolarization wave that slowly propagates in brain 
tissue at a rate of around 3mm/min, is widely accepted as the electrophysiological 
substrate of migraine aura.4,5 
Migraine has traditionally been viewed as a benign, chronic episodic condition. 
However, accumulating evidence suggests that migraine, particularly with aura, 
can be associated with increased risk for stroke and white matter lesions.6-12 The 
association is even more striking considering the clinical contrasts between migraine 
and stroke. Unlike migraine, stroke is an acute and often catastrophic cerebrovascular 
event. In contrast to the perceived benign nature of migraine (i.e. no imminent risk 
of injury), stroke is the leading cause of acquired physical disability in adults in the 
US,13 and the second leading cause of mortality worldwide.14 The prevalence of both 
ischemic (85% of all strokes) and hemorrhagic stroke in the US is 2.9% in individuals 
18 years or older,13 much lower than the prevalence of migraine. And lastly, stroke is 
predominantly a disease of the elderly, while migraine prevalence peaks around age 
40. As per International Headache Society (IHS) criteria, migraine headache may be 
termed secondary when it is present as part of an underlying disease process such as 
patent foramen ovale (PFO) or antiphospholipid antibody syndrome; many of these 
disorders are also associated with increased risk of cardiovascular and cerebrovascular 
events, discussed in detail below. 
In this paper, we briefly summarize the evidence supporting a clinical association 
between migraine and stroke, propose mechanistic hypotheses that may explain the 
association, and review the experimental data supporting or refuting some of these 
hypotheses. Inevitably, in the absence of robust evidence the proposed mechanisms 
remain speculative. Our overarching aim is to stimulate translational investigations on 
the mechanisms linking migraine and stroke toward improved patient care. Of note, 
migraine also appears to increase the risk of hemorrhagic stroke.15 However, available 
data are less robust, and mechanistic insight is lacking particularly in the experimental 
setting; therefore, we will limit the discussion to ischemic stroke. 
CLINICAL EVIDENCE LINKING MIGRAINE AND STROKE 
Observational data. Although limited by the lack of biomarkers to identify migraine 
with certainty and quantitative data on intensity, duration and frequency of attacks, 
abundant observational data from retrospective or population- or hospital-based 
case-control studies as well as small and large population-based prospective studies 
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including tens of thousands of individuals have firmly established a link between 
migraine and ischemic stroke, which have been the subject of three meta-analyses.10,16,17 
The most recent meta-analysis10 of 13 case-control and eight cohort studies with a 
total of 622,381 participants also showed a link between migraine and ischemic stroke 
with an odds ratio (OR) of 2.04 (95% confidence interval (CI) 1.72-2.43). 
The association relied on migraine with aura (OR 2.51, 95% CI 1.52-4.14), and was 
not significant in migraine without aura (OR 1.29, 95% CI 0.81-2.06). Further subgroup 
analyses revealed a stronger association in women (OR 2.89, 95% CI 2.43-3.45),10 as well 
as in patients younger than 45 (OR 2.65, 95% CI 1.41-4.97), in smokers (OR 9.03, 95% 
CI 4.22-19.34) and in women using oral contraceptives (OR 7.02, 95% CI 1.51-32.68).17 
Moreover, in the Women’s Health Study (WHS), increased risk appeared to be mainly in 
those who experienced active migraine attacks within the year before completing the 
baseline questionnaire, and not in those with just a history of migraine without recent 
attacks (OR, 1.91 95% CI 1.17-3.10).18 The risk was also higher in those who experienced 
>12 attacks per year (OR, 1.7 95% CI 1.1-2.8) in the Stroke Prevention in young Women 
study.19 Interestingly, most ischemic events appeared to be transient, or strokes with 
good clinical outcomes (modified Rankin Scale 0 to 1) in the WHS.20 
Much less is known about the stroke subtype in association with migraine. A 
tendency for strokes of undetermined cause (OR 1.4, 95% CI 0.9-2.0) or lacunar strokes 
has been suggested (OR 1.5, 95% CI 0.7-3.3),19 and in the Italian Project on Stroke in 
young adults Study21 the frequency of right to left shunts was higher in stroke in 
migraineurs with aura (OR 2.41, 95% CI 1.47-3.95). Based on clinical presentation, a 
predilection for anterior or posterior circulation has not been demonstrated.19,21 
Lastly, there may be an association between migraine and systemic cardiovascular 
event risk (e.g. myocardial ischemia and infarction, cardiovascular mortality, peripheral 
vascular disease). Although an earlier meta-analysis of eight studies did not show an 
increased risk of myocardial infarction among migraineurs (OR 1.12, 95% CI 0.95-13.2),17 
a more recent large case-control study suggested a higher risk (OR 2.16, 95% CI 1.7-
2.76).22 Most recently, a population-based prospective study showed an increased risk 
of ischemic heart disease (hazard ratio (HR) 2.5, 95% CI 1.8-3.5) in participants between 
the ages of 18 and 45.23 Likewise, a large prospective cohort with a median follow-up 
of 26 years suggested increased cardiac mortality among migraineurs with aura;24 
however, the association was not significant in a meta-analysis.25 
Neuroimaging. A number of neuroimaging studies over the past decade revealed a 
higher prevalence of subclinical brain abnormalities in migraineurs, including infarcts 
and white matter hyperintensities, suggesting acute or chronic ischemic disease. 
Infarcts. Cerebral Abnormalities in Migraine and epidemiological Risk Analysis 
(CAMeRA) was a cross-sectional, population-based magnetic resonance imaging 
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(MRI) lesion prevalence study in patients between the ages of 30 and 60 (mean age 
48; 161 migraine with aura, 134 migraine without aura and 140 matched controls) 
randomly selected from the Genetic epidemiology of Migraine study. Results suggest 
increased risk of subclinical posterior circulation infarct-like lesions, mostly located 
in the cerebellum, in migraineurs compared to controls (OR 7.1, 95% CI 0.9-55).11,26 
The risk was substantially higher in migraineurs with aura (OR 13.7, 95% CI 1.7-112), 
especially with frequent migraine attacks (≥1 attack/month) (OR 15.8, 95% CI 1.8-140), 
and independent of triptan use or vascular risk factors, although the study was not 
powered to test the latter. There was no difference in the frequency of such lesions 
in the anterior circulation. In the nine-year follow-up of the same cohort, none of the 
lesions disappeared, and new posterior circulation infarct-like lesions were found in 
5% of migraineurs compared with none in control subjects.27 
The overall conclusions were later independently confirmed in the Age Gene/
environment Susceptibility Reykjavik study,28 albeit using similar criteria. In this 
population-based cohort study, 689 patients with a mean age of 60 years (i.e. mid-life) 
were interviewed for migraine status, and MRI was performed at a mean age of 76 
years. This study revealed that women (but not men) who reported active migraine 
with aura in mid-life had an increased risk of late-life infarct-like lesions compared to 
non-migraineurs (OR 1.9, 95% CI 1.4-2.6), independently from vascular risk factors. 
These lesions were also mostly in the cerebellum. 
The population-based epidemiology of Vascular Aging study (780 participants, 
mean age of 69) also found an increased risk of cerebral infarcts in migraineurs with 
aura only.29 Although the interpretation was limited by the relatively small number of 
patients with migraine with aura (17 out of 116 migraineurs), the definition of infarct 
was stricter, and therefore, data were more specific for ischemic mechanisms. The 
lesions were mostly located outside the cerebellum and the brain stem. 
There have been conflicting data as well, albeit from smaller datasets or from 
studies designed to test other associations. For example, the Helsinki young Stroke 
Registry of 669 patients with first-ever stroke between 15 and 49 years of age did not 
find any association between the presence of silent brain infarcts and migraine status, 
despite an overall high frequency of silent brain infarcts (13%).30 All patients with a 
lesion had at least two vascular risk factors. Similarly, a cohort of 100 consecutive 
women with chronic migraine with51 or without49 aura (mean age 44) revealed a much 
lower frequency of infarct-like lesions on MRI than expected by the high frequency of 
migraine attacks (6%, all with associated vascular risk factors); however, the absence 
of a control group precluded firm conclusions.31 
White matter hyperintensities. A meta-analysis of retrospective case-control studies 
(312 subjects, 317 controls) also suggested an increased risk for white matter MRI 
hyperintensities in migraineurs (OR 3.9, 95% CI 2.26-6.72), even in younger individuals 
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and when controlled for comorbid vascular risk factors.32 Most recent meta-analysis 
of this association suggested an increased risk in migraine with aura (OR 1.7, 95% CI 
1.1-2.7), but not in migraine without aura (OR 1.3, 95% CI 0.96-1.87).12 
Although the CAMeRA study did not show a difference for periventricular or deep 
white matter lesions between migraineurs and controls, subgroup analysis revealed 
higher risk for deep white matter lesions only in women with migraine (OR 2.1 95% 
CI 1.0-4.1); there was no effect of aura status and the risk increased with increasing 
attack frequency.11 A subsequent analysis also suggested an increased prevalence of 
infratentorial (mostly pontine) hyperintensities in migraineurs with and without aura.33 
The nine-year CAMeRA follow-up revealed a higher incidence of deep white matter 
lesions in women with migraine (OR 2.1 95% CI 1.0-4.1), highest in the migraine without 
aura group.27 There was no association between lesion progression and attack type, 
duration, frequency and cumulative number, or specific migraine treatments. 
In the epidemiology of Vascular Aging study, individuals with lifetime history of 
severe headaches (116 migraineurs and 47 non-migraine headache) were more likely 
to be in the highest tertile of total white matter hyperintensity volume (OR 2.0, 95% 
CI 1.3-3.1), preferentially located in deep white matter regions in migraineurs with 
aura.29 More recently, the prospective Atherosclerosis Risk in Communities cohort of 
1028 patients with a mean age of 60 showed an increased risk of moderate to severe 
white matter MRI hyperintensities (defined as a score 3 on a visual rating scale from 0 
with no white matter hyperintensity to 9 with confluent and extensive white matter 
hyperintensities) in migraineurs without aura compared to participants without 
headache (OR 1.87, 95% CI 1.04-3.37).34 However, follow-up between eight to 15 years 
did not reveal a difference in progression of white matter hyperintensities between 
migraineurs and controls. 
In summary, structural brain imaging strongly suggests an increased risk of infarcts 
and white matter hyperintensities in migraineurs, and perhaps all severe headaches. 
The conclusions, however, have not been unanimous. The vascular origin of infarcts 
and white matter hyperintensities has not been confirmed, in part because of imprecise 
definition of lesions on MRI and lack of neuropathological correlation.35 Furthermore, 
the association between the severity or duration of migraine and the severity of 
structural brain abnormalities is inconsistent. An association may be absent, or may be 
obscured by low power of individual studies and differences in the definition of lesion 
severity. It should be remembered, however, that migraineurs suffer countless attacks 
during their lifetime, but develop only a small number of neuropathological lesions. 
Therefore, it is unlikely that individual attacks directly cause injury. 
Monogenic and other rare diseases. Albeit rare, monogenic diseases may help 
understand the pathophysiology of more common polygenic or multifactorial 
conditions. An association between migraine and stroke is further supported by 
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frequent co-existence of the two in monogenic diseases. For example, migraine with 
aura is often the first symptom in cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL), present in 20%-40% of 
patients. CADASIL is the most common monogenic inherited cerebral small-vessel 
disease in middle-aged adults. It is caused by mutations in the NOTCH3 gene that 
are exclusively expressed in vascular smooth muscle cells in the adult brain. Besides 
migraine with aura, CADASIL patients progressively develop subcortical infarcts, 
mood disorders and cognitive impairment culminating in frank dementia.36 Most 
migraine attacks are typical, but 50% of patients also experience attacks with atypical 
aura including basilar or hemiplegic migraines, or prolonged migraine auras.37 
Hereditary infantile hemiparesis, retinal arteriolar tortuosity and 
leukoencephalopathy (HIHRATL) is another autosomal dominant cerebral small-
artery disease associated with migraine with or without aura. Mutations in the 
COL4A1 gene encoding type IV collagen α1 chain destabilize the triple helix domain 
of collagen IV found in the basement membranes. First described in mutant mice with 
porencephaly generated by random mutagenesis,38 COL4A1 mutations have now been 
detected in many human families, in whom newborns and adults may be affected.39,40 
The phenotype is variable, and besides migraine, may include infantile hemiparesis, 
porencephaly, seizures, white matter hyperintensities, hemorrhagic more than 
ischemic stroke, renal and ocular vessel tortuosity, and intracranial asymptomatic 
aneurysms.41 
Retinal vasculopathy with cerebral leukodystrophy is an autosomal dominant 
small-vessel disease of middle-age onset, previously known as cerebro-retinal 
vasculopathy, hereditary vascular retinopathy and hereditary endotheliopathy, 
retinopathy, nephropathy and stroke. All entities have been linked to mutations in the 
TREX1 gene,42 which encodes a DNA-specific exonuclease implicated in DNA repair 
under conditions of oxidative stress. The clinical presentation includes progressive 
loss of visual acuity related to retinal vasculopathy, small cerebral infarcts and white 
matter hyperintensities that can coalesce to form pseudotumors. Although migraine 
or ‘‘migraine-like’’ headache has been described in all phenotypes, migraine, equally 
with or without aura, seems to be more frequent in hereditary vascular retinopathy,43 
where it is found in 70% of patients and often associated with Raynaud phenomenon. 
Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes 
(MeLAS) is caused by mutations in the mitochondrial genome with a maternal pattern 
of inheritance. It mostly affects children and young adults, with 90% of patients having 
symptoms before 30 years of age. Attacks of migraine are present in 70% of cases 
and may be isolated, or more frequently accompany seizures and/or focal or global 
neurological deficits related to post-ictal symptoms or ischemic stroke. Remarkably, 
strokes occur early in life, do not match a particular vascular territory, often progress 
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slowly (over days or weeks) and can often be partially reversible, which justifies the term 
‘‘stroke-like episodes.’’ However, residual deficits often accumulate leading to motor, 
visual or cognitive disability. Systemic features include short stature, sensorineural 
hearing loss, diabetes mellitus, cardiac disease, myopathy, and gastrointestinal and 
renal involvement.44-46 
Hereditary hemorrhagic telangiectasia is an autosomal dominant disorder 
characterized by mucocutaneous telangiectasia and arteriovenous malformations of 
the brain, lung, gastrointestinal tract and liver due to mutations of endoglin or activin 
receptor-like kinase 1.47 Migraine is present in up to 40% of patients, in addition to 
the classical epistaxis and other sites of hemorrhage that start almost always before 
40 years of age. Although migraine and stroke, mostly hemorrhagic, may be related 
to intracerebral arteriovenous malformations,48 migraine, mostly with aura, occurs 
typically independent of cerebral vascular malformations and is associated with 
an increased probability of pulmonary arteriovenous malformation, which is also 
associated with an increased risk of cerebral ischemic events.49-51 Interestingly, in 
hereditary hemorrhagic telangiectasia patients without a pulmonary arteriovenous 
malformation, prevalence of migraine without aura was also higher in one study.52 
Outside of hereditary hemorrhagic telangiectasia, an association between migraine 
and occipital arteriovenous malformations has been noted,53 and migraine is a 
recognized accompaniment of Sturge-Weber syndrome,54 and has been noted 
in association with moyamoya disease,55 underscoring the link between vascular 
structural abnormalities and migraine. 
Potential caveats in interpretation of clinical evidence. Heterogeneity of 
migraine and inconsistent use of diagnostic criteria, referral bias, difficulty 
differentiating between a migraine attack and a transient ischemic attack (TIA) in 
the absence of biomarkers, presence of comorbidities and concurrent medications, 
and overrepresentation of younger patients can all complicate and confound the 
interpretation of clinical data. It is highly unlikely that increased stroke risk in migraine 
with aura can be explained entirely by secondary migraine in the setting of other 
diseases such as CADASIL or hereditary hemorrhagic telangiectasia. These potential 
caveats notwithstanding, the evidence firmly supports an association, and in many 
cases provides clues to the pathogenesis. 
MECHANISMS Of ASSOCIATION 
Observational, genetic and neuroimaging data suggest that migraineurs with aura 
have an increased risk of ischemic stroke. The nature and mechanisms of elevated 
risk and whether the risk is modifiable are unclear, and the risk likely applies only to 
a subset of migraineurs. For obvious reasons, we cannot perform experiments to 
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dissect the mechanisms linking migraine and stroke in human subjects, and one has to 
employ experimental animal models to test hypotheses. 
Based on available clinical and experimental data, one can postulate mechanisms 
to explain the association between migraine and ischemic stroke. The conceptual 
framework (Figure 1) is undeniably an oversimplification, but nevertheless allows 
one to generate hypotheses. These mechanisms are not mutually exclusive; they 
may be operational in different patients, or overlap in the same patient and interact 
to synergize. Some of the potential mechanisms are supported by clinical and 
experimental data, which we will discuss individually and elaborate on in specific 
subcontexts. 
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Figure 1.  A conceptual framework for possible mechanisms linking migraine and stroke 
based on available direct or indirect clinical and experimental evidence. (a) Upstream vascular 
and metabolic risk factors for cerebral ischemia (e.g. endothelial dysfunction, cervical artery 
dissection, hypercoagulable states, paradoxical embolism, adverse lifestyle) can trigger 
migraine with aura when mild, and cause ischemic stroke when severe. (b) Upstream genetic 
risk factors that enhance susceptibility to spreading depression (SD) as a migraine trigger may 
sensitize the tissue to ischemia, so that infarction ensues with a milder degree of ischemia or 
ischemic injury progresses more rapidly. (c) Migraine with aura may increase vascular and 
metabolic risk of ischemia (e.g. migrainous infarction, vasoconstrictive complications of 
migraine medications, adverse lifestyle, endothelial dysfunction or platelet aggregability 
caused by migraine with aura). 
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Migrainous infarction. A first report of migrainous infarction goes back to the 19th 
century.56 As defined by IHS, migrainous infarct is an ischemic infarct demonstrated by 
neuroimaging that develops during a typical migraine with aura attack with abnormally 
prolonged aura symptoms (>60 min), in a patient with a history of migraine with aura, 
in the absence of an alternative cause for the infarct.2 Implicit in this definition is the 
fact that migrainous infarct is caused by the migraine attack. Therefore, migrainous 
infarction is by definition a diagnosis of exclusion, and depends on the depth of 
work-up for an alternative etiology. 
The rarity (~0.5% of all ischemic strokes) of true migrainous infarction is further 
underscored in clinical series. A retrospective multicenter study spanning more than 
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20 years identified only 33 patients who fit the IHS criteria for migrainous infarct, almost 
half of the patients had no other vascular work-up than Doppler ultrasonography, and 
more than a third did not have transoesophageal echocardiography.57 Moreover, 40% 
of patients indeed had a PFO. In a prospective study spanning 11 years, migrainous 
infarcts made up only 0.2% of all etiologic diagnoses; a third of migrainous infarcts 
was a first-ever aura attack (i.e. did not fulfill the IHS criteria), two-thirds had a PFO, 
and almost all had other vascular risk factors.58 Moreover, detailed investigations 
revealed rare causes of stroke in almost a quarter of those originally diagnosed as 
migrainous infarction. 
The diagnosis has become even more problematic after clinical and experimental 
evidence clearly showed that ischemic events can trigger symptomatic migraine 
attacks, as well as a SD as the aura surrogate.59-62 Hence, a primary ischemic event 
can cause prolonged neurological signs and symptoms that may be perceived as aura; 
therefore, migrainous infarct should not be diagnosed without an extensive work-up 
to exclude other causes. The condition is even more likely to be over-diagnosed in 
young patients, as 40% of ischemic strokes in the young remain cryptogenic. 
Nevertheless, there may be a mechanistic basis for migraine aura culminating 
in infarction. SD (i.e. aura) has profound metabolic and hemodynamic effects on 
the brain tissue. While adenosine triphosphate (ATP), O
2
 and glucose consumption 
increase dramatically during and after SD, substrate delivery via blood flow may not 
be sufficient, thereby creating supply-demand mismatch.63-65 Although SD by itself 
is not injurious in otherwise healthy brain tissue,66 under certain conditions, SD may 
be associated with abnormal neurovascular coupling, causing marked and prolonged 
vasoconstriction (i.e. inverse coupling) and severely limiting tissue O
2
 delivery.67,68 For 
example, reduced nitric oxide levels when combined with mildly elevated extracellular 
K+ or low glucose leads to constriction and laminar cortical necrosis during SD.69,70 In 
theory, such ionic disturbances may even be precipitated by endothelial ion channel 
or pump dysfunction.71 However, whether genetic, hormonal or environmental factors 
can modulate the hemodynamic and metabolic response and create severe supply-
demand mismatch during SD to precipitate infarction in otherwise healthy brain 
remains to be proven. At least in MeLAS, such a mechanism is possible (see below). 
Migraine drugs predisposing to ischemic events. Another potential mechanism 
one can postulate to explain increased stroke risk in migraineurs is exposure to 
high-risk external factors linked to migraine. For example, drugs frequently used 
in the management of migraine may increase stroke risk. Indeed, triptans and 
ergotamine have vasoconstrictive properties, and are not recommended in patients 
with complicated migraine with aura due to the associated oligemia. Moreover, 
these drugs, as well as serotonin reuptake inhibitor antidepressants, can precipitate 
reversible cerebral vasoconstriction syndrome (RCVS), a clinical and radiological 
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syndrome characterized by severe unusual headache and transient multifocal cerebral 
vasoconstriction that can lead to stroke, subarachnoid hemorrhage and/or brain 
edema.72 Interestingly, migraine is more common in RCVS patients even in the absence 
of an offending drug treatment,72 suggesting that other factors also play a role. 
However, large studies have not substantiated a link between triptan use and the 
risk of stroke in migraineurs (e.g. General Practice Research database, HR 1.13, 95% CI 
0.78-1.65; United Healthcare database, OR 0.90, 95% CI 0.64-1.26).73,74 A large, nested 
case-control study of cardiovascular events in triptan overuse also did not show a 
significant increase in the risk of hospitalization for ischemic events (OR 1.43, 95% CI 
0.82-2.49).75 And lastly, MR angiography has recently failed to show vasoconstriction 
in intracranial arteries upon triptan administration, despite vasoconstriction 
of extracranial vessels.76 ergotamine did increase the risk of hospitalization for 
cardiovascular and cerebral ischemic events (OR 2.55, 95% CI 1.22-5.36); however, this 
occurred only in patients with other cardiovascular comorbidities who overused the 
drug,75 and was not confirmed in other studies (OR 1.49, 95% CI 0.93-2.41).74 Moreover, 
ergotamine has not been a commonly used drug clinically. It should also be noted that 
the association between migraine and stroke is mainly driven by migraine with aura, 
while migraine drugs are used by all migraineurs regardless of aura status. For these 
reasons, migraine drug use is unlikely to explain the increased stroke risk in migraine, 
unless there is a specific interaction with aura. 
Migraine predisposing to ischemic events indirectly through lifestyle changes. 
Migraine can have profound effects on a patient’s mood and lifestyle, and may 
indirectly augment behavior patterns posing a vascular risk. For example, obesity has 
been associated both with episodic and chronic migraine, mostly in patients with high 
attack frequency,77-79 although the direction of causality is not clear. Migraine could 
predispose to obesity, as women with a history of childhood migraine have a higher 
risk of weight gain later in life.80 In theory, obesity may be a side effect of migraine 
treatments, or due to reduced physical activity to avoid triggering or exacerbating 
migraine attacks, although regular exercise could also reduce migraine attacks.81 
Indeed, migraineurs also exercise less, as yet another factor that can increase 
cardiovascular risk.82 Conversely, obesity may predispose to migraine through 
hormones released from the adipose tissue, such as adiponectin.83 Finally, migraine 
and obesity may also be linked by a shared underlying disorder, such as abnormalities 
in hypothalamic function or serotonergic transmission.84 Regardless of the causal 
relationship, obesity and associated metabolic syndrome are well-known stroke risk 
factors, and may also link migraine with coronary and peripheral artery disease.17,22,85 
Indeed, the Genetic epidemiology in Migraine study, a population-based, cross-
sectional study including 620 migraineurs and 5135 non-migraineurs, showed that 
patients with migraine, in particular with aura, are more likely to smoke and have 
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unfavorable cholesterol profiles and higher Framingham risk scores than non-
migraineurs.86 This was corroborated by the American Migraine Prevalence and 
Prevention study, a case-control study including 6102 patients and 5243 controls, 
which showed that migraineurs were more likely to have vascular risk factors and 
higher Framingham scores.22 The lower consumption of alcohol by migraineurs,82,87 
probably avoidance due to its ability to induce attacks, could also increase stroke risk 
in migraineurs by the loss of its vascular protective effect when consumed in moderate 
amounts. Moreover, migraineurs are more likely to smoke,82,86 or use hormone 
therapy after menopause,29 as additional risk factors. Lastly, migraine and depression 
are linked, and although bidirectional causality has been suggested,88 recent data 
from the WHS suggest that migraine (as well as non-migraine headache) increases the 
risk of incident depression in middle-aged women (relative risk 1.48, 95% CI 1.37-1.60), 
particularly in individuals with high attack frequency.89 Depression is a risk factor for 
stroke,90 and may contribute to increased stroke risk in migraineurs. Based on these 
data, one might speculate that often-modifiable lifestyle factors may add to increased 
stroke risk in migraineurs. 
However, large-scale epidemiological studies have also shown that stroke risk 
in migraineurs is independent of vascular risk factors.10,16,17 For example, the WHS 
revealed that the association between active migraine with aura and ischemic stroke 
was apparent only among women in the lowest Framingham risk score group.87 
Likewise, the Italian Project on Stroke in young adults Study showed lower vascular risk 
factor profile in migraineurs with stroke, and the Stroke Prevention in young Woman 
study showed that women without a history of hypertension, diabetes or myocardial 
infarct were at greatest risk of migraine-associated stroke.19,21 Moreover, large-artery 
atherosclerosis as a stroke mechanism did not differ between migraineurs and controls. 
Lastly, no correlation was found between migraine status and atherosclerosis markers 
(e.g. intima-media thickness, pulse wave velocity and ankle-brachial index) in a large 
case-control study including 617 controls and 360 migraineurs,91 further arguing against 
a role for atherosclerosis as the link between migraine and stroke. Unfortunately, 
there are no experimental data to support or refute these potential mechanisms. 
Migraine and cervical artery dissection. Cervical artery dissection is a well-known 
cause of stroke, particularly in the young population. A meta-analysis of case-control 
studies has shown that migraineurs have an increased risk of cervical artery dissection 
with an OR of 2.06 (95% CI 1.33-3.19),92 later confirmed in a larger international 
multicenter study consisting of 968 stroke patients with dissection and 653 stroke 
patients without dissection (Cervical Artery Dissection and Ischemic Stroke Patients 
study; OR of 1.51, 95% CI 1.15-1.99).93 In a recent series, 60% of patients who presented 
with concurrent cervical artery dissection and reversible cerebral vasoconstriction 
syndrome were migraineurs.94 The mechanisms responsible for cervical artery 
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dissection are poorly understood,95 as is the causal relationship with migraine. Of 
course, ischemia due to embolism or hemodynamic insufficiency precipitated by a 
dissection can directly trigger a migraine attack,59 as well as stroke. In this context, 
migraine attacks can be considered TIAs. It may be speculated that endothelial injury 
and microdissections are not infrequent in everyday life and most go unnoticed. A 
small hemodynamically insignificant dissection invisible by routine imaging tools 
can still activate platelet aggregation and serotonin release, which may increase 
the likelihood of a migraine attack without causing stroke.96 However, absence of a 
predilection for migraine with aura is not fully congruous with an ischemic trigger for 
migraine in this setting. Conversely, migraine may increase the risk for cervical artery 
dissection, for example, by inducing matrix metalloproteinase (MMP) expression,97 
the levels of which are elevated in migraineurs both ictally and interictally,98 and in 
patients with cervical artery dissection.99 Indeed, a significant association has been 
demonstrated between migraine, especially with aura, and interictal serum elastase 
activity.100 Therefore, chronic (i.e. ictal and interictal) elevation of MMP and elastase 
levels in migraineurs may perhaps cumulatively weaken the arterial wall to predispose 
to dissections upon mild traumatic insults. Although unrelated to dissections, a curious 
relationship has been reported between anatomical variations in the posterior circle 
of Willis (i.e. fetal posterior cerebral artery origin or basilar hypoplasia) and migraine 
with or without aura.101 Although this is an interesting concept, the data have been 
inconsistent among studies and remain to be replicated.102,103 
Hypercoagulability and endothelial dysfunction. endothelial dysfunction has 
also been suggested as a possible link between migraine and stroke.104 Studies of 
vascular reactivity as a surrogate for endothelial function in migraineurs have revealed 
conflicting results. In peripheral arteries vascular reactivity was reported decreased105-107 
or unchanged108-111 in different studies. Similarly, cerebrovascular reactivity was either 
increased112-114 or decreased.115-117 Further complicating the issue, cerebral and peripheral 
vascular reactivity do not always correlate,109 anterior and posterior circulation often 
differ in reactivity readouts,118 and subject selection (e.g. aura status, exclusion of 
vascular comorbidities) and the method used to assess reactivity are highly variable 
among studies. Biomarker studies also suggest endothelial dysfunction. Migraineurs 
have higher interictal levels of circulating t-PA, high-sensitivity C-reactive protein, von 
Willebrand factor, vascular endothelial growth factor and nitric oxide metabolites, 
some only in migraineurs with aura.110,119 Likewise, the number of circulating endothelial 
progenitors cells, believed to repair injured endothelium, is lower in migraineurs.110,120 
It is not known whether migraine and stroke are both facilitated by the underlying 
endothelial dysfunction, or whether migraine can facilitate endothelial dysfunction 
as a stroke risk factor. Overall, the clinical relevance of endothelial dysfunction and its 
role linking migraine and ischemic stroke, if any, remain to be tested. The association 
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between migraine and livedo reticularis (e.g. Sneddon’s syndrome) is interesting to 
note in the context of vascular endothelial dysfunction.121 
Data on acquired or inheritable hypercoagulable states in migraineurs have also been 
conflicting and not always replicated. In a small early study consisting of 35 migraineurs 
and 24 controls, elevated prothrombin fragment 1.2 levels in migraineurs with aura 
suggested activation of clotting cascade.122 Some studies suggested a hypercoagulable 
state in migraineurs,123,124 while others failed to show a difference from controls.125-129 
Low sample size, varying from 20 to 276 participants, has been a major limitation. 
Studies on specific markers of acquired or inherited hypercoaguble states have been 
more conclusive. A recent study in 1456 women (mean age 34) with a personal or 
familial history of venous thrombosis has shown an increased risk of migraine with aura 
in carriers of factor V Leiden or factor II G20210A mutations (OR 1.76, 95% CI 1.02-3.06), 
strongly supporting an association between thrombophilia and migraine.130 Moreover, 
a higher prevalence of hypercoaguble state was found in stroke patients with migraine 
when compared to non-migraineurs, providing further support to the association.21,131 
Other causes of hypercoagulable states, such as antiphospholipid syndrome, systemic 
lupus erythematosus and polycythemia, have also been linked to migraine with aura in 
case-control studies, small case series and anecdotal reports; however, in the absence 
of robust datasets, some of these associations may be spurious.132-134 Lastly, data from 
two studies consistently showed that methylenetetrahydrofolate reductase (MTHFR) 
677 TT genotype combined with migraine aura confers an increased risk of ischemic 
stroke (OR 1.81, 95% CI 1.02-3.22, and HR 4.19, 95% CI 1.38-12.74).135,136 The MTHFR TT 
genotype appears to increase the risk of migraine with aura, whereas angiotensin-
converting enzyme II genotype decreases the risk of any migraine,137 as other potential 
shared genetic modulators of stroke risk. 
Paradoxical embolism predisposing to migraine and ischemic events. PFO is an 
incomplete closure of the fetal communication between right and left atrium that 
can serve as a conduit for circulating particulate and chemical substances to bypass 
pulmonary circulation, and reach the brain unfiltered. Classical epidemiological 
data have linked migraine and PFO. A meta-analysis of case-control studies have 
demonstrated an increased risk for migraine in patients with PFO (OR 5.13, 95% CI 
4.67-5.59) and an increased risk for PFO in migraineurs (2.54, 95% CI 2.01-3.08); the 
association is even stronger in migraine with aura.138 Furthermore, a study in 20 families 
with PFO and migraine with aura has suggested an autosomal pattern of inheritance 
of atrial shunts that in some families could be linked to inheritance of migraine with 
aura.139 Highly promising anecdotal data from retrospective open-label studies on 
the efficacy of PFO closure in reducing migraine attack frequency, such as headache 
resolution in up to 80% of patients,138 particularly in patients who experience a 
migraine attack during PFO closure,140 paved the way for the Migraine Intervention 
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with STARFlex Technology trial (MIST). MIST randomized 147 migraineurs with aura 
and a PFO with moderate to large right-to-left interatrial shunt, to PFO closure or 
sham procedure in a double-blind fashion. The primary and most secondary outcome 
measures did not differ between treatment and sham arms, effectively MISTifying the 
field, and hampering forward progress. However, the MIST trial included only patients 
with highly frequent attacks (~5 attacks and five to 23 headache days/month) who had 
previously failed at least two prophylactic treatments.141 Hence, most patients had 
intractable migraines unresponsive to multiple therapeutic trials; therefore, inclusion 
criteria were chosen not as an indication but a justification for an invasive procedure. 
Although this was probably not the best cohort in which to test the efficacy of an 
experimental intervention, the results of a recent meta-analysis of well-designed, 
unbiased studies also questioned the existence and strength of an association 
between migraine and PFO.142 
Nevertheless, PFO is clearly linked to cryptogenic stroke,143 and may act as a source 
of arterial micro-emboli or chemical offenders. For example, injection of sclerosing 
agents to treat varicose veins triggered a migraine with aura attack in a subset of 
individuals, almost all of whom harbor a PFO.144,145 Moreover, intravenous injection 
of agitated saline with air microbubbles has been reported as a migraine trigger in 
patients with a PFO and large right-to-left shunt.146,147 Besides triggering an attack, 
microbubbles can also alter cerebral electrical activity in migraineurs with aura and 
a PFO, but not in migraineurs with aura without a PFO or in patients with a PFO but 
no migraine history,148 perhaps suggesting that microvascular hypoxia/ischemia may 
induce cortical SD in a susceptible set of patients. 
Indeed, the principle that microemboli can trigger SD as an aura surrogate 
without causing ischemic injury has been tested and proven in the experimental 
setting. Intracarotid infusion of particulate material of various size and compositions 
(e.g. cholesterol particles of <70 μm, polystyrene microspheres of 5-20 μm), as well 
as air microbubbles (10 μl), reliably evoked cortical SD in mice.60 The mechanism 
involved transient cerebral hypoperfusion as shown by real-time, fullfield blood flow 
imaging using laser speckle flowmetry. The probability of SD induction related to the 
duration and severity of hypoperfusion, which in turn was determined by the size and 
composition of the emboli. When microembolic hypoperfusion reached a threshold 
severity and duration, an SD occurred. In more than half the animals that developed an 
SD, no ischemic injury was detected by a meticulous examination of serial histological 
sections throughout the brain, as well as by MRI. This study suggests that in a subset of 
migraineurs, transient cerebral ischemia induced by microemboli may be responsible 
for triggering a migraine attack, and when ischemia is severe enough, triggering an 
ischemic stroke. In humans, PFO, as well as pulmonary arteriovenous malformation 
such as in hereditary hemorrhagic telangiectasia, and atrial myxoma,149 may serve as a 
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source of microembolism. Of course, microembolism is unlikely to be the trigger for 
every attack in all migraineurs with aura and a right-to-left shunt. 
Right-to-left intracardiac shunts may also allow neuroactive and/or vasoactive 
chemicals to access the brain. One such chemical is endothelin, plasma levels 
of which are elevated during a migraine attack.150-153 Interestingly, endothelin A 
receptor polymorphisms have been shown to modulate migraine risk.154 Although air 
microembolism has been hypothesized as a mechanism for attacks of migraine often 
with aura after foam sclerotherapy of varicosities,144,145 attacks were also triggered 
after liquid sclerotherapy, which does not predispose to air embolism. An alternative 
hypothesis is endothelin release from the irritated endothelium during sclerotherapy 
into the venous circulation gaining access to the brain through a right to left shunt.155 
This is supported by elevated plasma endothelin concentrations after sclerotherapy in 
rats, regardless of whether liquid or foam sclerosing agent was used.155,156 Similar plasma 
endothelin elevations have also been shown in humans after foam sclerotherapy.156 
endothelin 1 indeed potently triggers SD in rats through endothelin A receptors,157,158 
and the mechanism involves severe vasoconstriction and hypoperfusion, leading to 
infarction, providing a direct link between migraine and ischemic stroke.159 Altogether, 
these data suggest that right-to-left shunts are associated with migraine and can 
explain a subset of ischemic strokes in migraineurs. 
Increased sensitivity to ischemic injury. An alternative hypothesis to explain a 
migraine-stroke association is that cerebral hyperexcitability phenotype associated 
with migraine sensitizes the tissue to ischemia. Recent experimental data in mice 
expressing familial hemiplegic migraine (FHM) type 1 mutations provided direct 
support for such a mechanism. FHM is an autosomal-dominant subtype of migraine 
with often severe and prolonged auras associated with motor deficits, sometimes 
accompanied by sensory, aphasic, visual and basilar symptoms. A third of patients 
can experience a decrease in level of consciousness and even coma, which may be 
prolonged.160 FHM has been used as a model for more common forms of migraine with 
aura because of shared clinical features and trigger factors, female preponderance, 
and because two-thirds of FHM patients and their first-degree relatives also suffer 
from attacks of common migraine with and without aura. 
FHM type 1 is caused by mutations in the pore-forming α
1A
 subunit of Ca
v
2.1 voltage-
gated Ca2+ channels, which are critical for presynaptic glutamate release. Mutant 
channels open on smaller membrane depolarizations and stay open longer. The net 
result is increased presynaptic Ca2+ entry and glutamate release, resulting in enhanced 
cerebral excitability,161 a mechanism likely shared with more common forms of 
migraine.162 Indeed, FHM1 mutants are highly susceptible to SD and frequently develop 
subcortical and re-entrant SDs with prolonged neurological deficits mimicking those 
observed in FHM patients.163,164 
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Availability of transgenic mouse models expressing FHM1 mutations has recently 
allowed testing of the hypothesis that the cerebral hyperexcitability phenotype 
associated with migraine sensitizes the brain tissue to ischemia. In support of the 
hypothesis, two FHM1 mutant mouse strains developed larger infarcts compared with 
wild type after transient focal cerebral ischemia.165 The phenotype correlated well 
with the strength of gain-of-function of each mutation (S218L mutant more severe 
than R192Q), and showed an allele-dosage effect whereby homozygous mutants fared 
worse than the heterozygotes. The mechanism was indeed linked to hyperexcitability, 
because anoxic depolarization developed faster and diffusion-weighted MRI lesions 
grew rapidly after stroke onset in the mutants. Perhaps more important, mutants 
developed many more peri-infarct depolarizations (PIDs) during acute stroke. PIDs 
are SD waves spontaneously triggered within the ischemic penumbra, and expand the 
infarct by worsening the supply-demand mismatch, thereby explaining the accelerated 
infarct growth in migraine mutants, as well as in humans.61,166 The data also showed that 
migraine mutants had an elevated minimum cerebral blood flow threshold required 
for tissue survival, directly supporting the hypothesis that brain tissue in migraineurs 
is more susceptible to ischemic injury. The study also showed that female mutants, 
which are even more hyperexcitable and susceptible to SD than males, developed 
larger infarcts and worse outcomes after ischemic stroke than wild-type controls, 
consistent with the clinical observations in women with migraine. Lastly, ischemic 
brain swelling appeared to be more severe in mutants and could explain the higher 
mortality in the S218L mutant strain.165 
Altogether, these data suggested that familial migraine mutations (e.g. FHM1) 
that are known to augment cerebral excitability also facilitate infarction if and when 
the tissue becomes ischemic, by predisposing to frequent ischemic depolarizations. 
Of course, whether the mechanism is valid in other monogenic migraine disorders 
or in sporadic migraine remains to be tested. The hyperexcitability phenotype in 
migraine appears to also enhance susceptibility to SD, which is likely the final common 
mechanism for tissue sensitization to ischemia. In this context, it is notable that 
CADASIL mutant mice (Notch3R90C) as well as Notch3 null mutants show markedly 
enhanced SD susceptibility.167 Indeed, both Notch3 null mice and transgenic mice 
expressing CADASIL mutations develop larger infarcts, and at least in the null mutants, 
this is associated with an increased frequency of PIDs.168,169 Although it is not clear how 
the mutations in the NOTCH3 gene, which is exclusively expressed in vascular smooth 
muscle cells in the adult brain, lead to cerebral hyperexcitability, the data strongly 
support the notion that enhanced SD susceptibility translates into susceptibility to 
ischemic infarction, which is consistent with the stronger epidemiologic association 
observed between stroke and migraine with aura compared with without aura. It is 
important to note that aside from the hyperexcitability, CADASIL mutations clearly 
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lead to cerebral small-vessel disease and vascular dysfunction,36 and increase the risk 
of occurrence of ischemic events and chronic cerebral hypoperfusion (e.g.,  lacunar 
infarcts, white matter disease), in addition to the risk of developing infarction during 
those events. In other words, mechanisms leading to lacunar infarcts and white 
matter disease may be different from those leading to hyperexcitability. This is 
further supported by the observation that the onset of migraine with aura attacks 
often precedes the emergence of clinical and radiological evidence of ischemic 
vascular disease in CADASIL, and in fact, attacks usually diminish in frequency and 
disappear as the ischemic lesion load increases. It remains to be tested whether 
other mutations clinically associated with small-vessel disease and migraine, such 
as TREX1 and COL4A1, also augment SD susceptibility and sensitize the brain tissue 
to ischemic injury. Transgenic mice expressing mutations in these genes have been 
developed, and at least in case of COL4A1, mutants develop ultrastructural changes 
in cerebral vasculature, endothelial and smooth muscle cell dysfunction, and blood 
pressure regulation.170 
And lastly, MeLAS is another disease in which migraine and stroke-like episodes 
coexist on a spectrum. Impaired mitochondrial oxidative phosphorylation in MeLAS 
creates a chronic state of energy shortage and inability to match increased demand, 
proposed as a potential mechanism linking hyperexcitability and sensitivity to 
ischemic injury.171,172 Other mechanisms may also be involved, such as accumulation of 
dysfunctional mitochondria in endothelium and smooth muscle cells of small cerebral 
vessels leading to endothelial dysfunction and increased capillary permeability.173,174 In 
the absence of representative animal models, whether the hyperexcitability is in any 
way related to SD remains to be tested. One can perhaps speculate that inadequate 
mitochondrial response to increased energy demand during SD impairs SD recovery, 
and markedly prolongs the depolarization predisposing to tissue injury. 
CLINICAL IMPLICATIONS 
Migraine as a symptom of TIA: Angina cephalis? As noted above, clinical and 
experimental evidence suggests that migraine attacks can be triggered by transient 
cerebral ischemic events (i.e. symptomatic migraine), and as such, they may carry a 
similarly elevated risk of impending stroke and should perhaps be treated as a TIA. 
Is antithrombotic stroke prophylaxis indicated in migraineurs? If migraine with aura 
is a TIA, antithrombotic use may not only diminish the stroke risk but also reduce the 
frequency of migraine attacks. A similar argument can be made for PFO closure, or for 
inhibitors of potential vasoactive or neuroactive mediators presumed to pass through 
a PFO into arterial circulation unfiltered by the pulmonary circulation and predispose 
to migraine attacks (e.g. endothelin). Although, failure to meet the primary efficacy 
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endpoints in the MIST trial rendered PFO closure in migraine highly controversial, for 
reasons discussed above (i.e. not the best cohort in which to test an investigational 
intervention, primary endpoints difficult to meet), we believe the evidence is not 
sufficient to support or refute the hypothesis at this time. The critical challenge will be 
to identify the best closure candidates in whom the PFO is symptomatic. 
Is aggressive avoidance of exacerbating factors (e.g. oral contraceptive use, smoking, 
risk of traumatic dissection) indicated in migraineurs? Along the same lines of 
reasoning as above, one might argue that given the geometrically increased risk of 
stroke by the presence of aggravating factors in highly susceptible migraineurs, such 
factors should be a part of aggressive risk management. For example, the World Health 
Organization recommends women with migraine with aura avoid combination oral 
contraceptives. Perhaps the warning against chiropractic cervical manipulations175,176 
should be particularly strong in migraineurs. Once again, reduced risk for ischemic 
events as a migraine trigger may also decrease the frequency of migraine attacks. 
Is complete screening for vascular risk factors (e.g. hypercoaguble state, PFO, genetic 
mutations) indicated in migraineurs in the absence of a stroke? Migraine with aura 
as a potential TIA, particularly when the diagnosis of migraine does not fulfill IHS 
criteria (e.g. first attack, atypical aura, abnormal neurological exam), when the aura 
is always on the same side, and in late-onset migraines or when the attack frequency 
or characteristics changes, might also justify searching for common stroke etiologies 
as part of the clinical work-up. The approach may also affect migraine classification. 
Migraine as a hyperexcitable state that sensitizes the brain to ischemic injury: The 
tissue factor. The clinical and experimental evidence reviewed above suggests that 
migraine with aura reflects a hyperexcitable state that enhances susceptibility to SD as 
a final common mechanism. experimental evidence also suggests that susceptibility to 
develop SD is related to the susceptibility to develop injury if and when the brain tissue 
becomes ischemic. Because aura (perceived or not) is the relevant risk biomarker, the 
frequency of attacks with aura, rather than the total frequency of attacks only rarely 
accompanied by aura, appears to be the critical determinant. It should be noted, 
however, that data supporting a direct link between SD susceptibility and injury 
susceptibility come exclusively from transgenic animal models of monogenic, familial 
forms of human migraine, and whether the principle applies to non-familial forms of 
migraine is not known. 
Is therapeutic time window for revascularization in ischemic stroke shorter in 
migraineurs? In FHM1 mutant mice, the diffusion-weighted MRI lesion (i.e. ischemic 
core) expanded rapidly because of enhanced susceptibility to anoxic depolarization 
and PIDs.165 If hyperexcitable brain tissue in migraineurs readily develops ischemic 
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depolarizations, then the core expands into the perfusion defect leading to rapid loss 
of viable tissue at risk (i.e. penumbra). This would effectively shorten the therapeutic 
time window of efficacy for stroke therapies in migraineurs. 
Does migraine prophylaxis diminish the stroke or white matter lesion risk or severity in 
migraineurs? Migraine prophylaxis suppresses SD susceptibility,177 and therefore, may 
also diminish susceptibility to ischemic injury by rendering the tissue more resistant to 
ischemic depolarizations. This approach to reduce tissue sensitivity to ischemia could 
also be efficacious in non-migraineurs as well. 
Is there a clinicopathological disconnect during acute stroke in migraineurs? PIDs are 
indistinguishable from SD waves when they propagate into the non-ischemic brain 
tissue, but they nevertheless cause transient electrophysiological silence in the tissue 
they invade, and can cause neurological deficits much like the aura symptoms during 
migraine attacks. If migraineurs develop more frequent PIDs, they may exhibit more 
severe and perhaps fluctuating neurological deficits than what would be expected 
based on the size and location of the ischemic lesion as seen on MRI. The concept 
may be true in other brain injury states as well, such as subarachnoid or intracerebral 
hemorrhage, and trauma, in which injury depolarizations akin to SD are known to 
occur in the human brain. 
Is malignant brain edema more frequent in migraineurs? It has been shown that 
SD disrupts the blood-brain barrier.97 Hence, frequent PIDs may be associated with 
more severe blood-brain barrier breakdown and ischemic edema formation after 
stroke, which can even become life threatening in case of large middle cerebral artery 
or cerebellar infarcts. If so, early decompressive craniectomy may be indicated in 
migraineurs with aura. 
CONCLUDING REMARKS 
Migraine is a stroke risk factor with an effect size and prevalence comparable to 
other risk factors. Its recognition as an important and perhaps modifiable vascular 
risk factor, sought and documented as part of the patient’s medical history, will 
certainly be facilitated by better definition of the mechanisms of this association and 
the causal relationships. Unfortunately, current diagnostic criteria do not distinguish 
patients with occasional vs. frequent auras,2 a distinction that is relevant for stroke 
risk and should be documented. With increased awareness, management of migraine 
will become more than management of a headache disorder, and more holistic as 
with other vascular risk factors. Of course, enough evidence to change practice can 
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Altogether, the data presented in this thesis suggest that familial hemiplegic migraine 
mutations (e.g., FHM1) augment cerebral excitability and cortical and subcortical SD 
susceptibility, modulated by gonadal hormones. By this way genetic susceptibility to 
migraine facilitates cerebral infarction by predisposing to ischemic depolarizations, 
if and when the tissue becomes ischemic. Moreover, pharmacological suppression 
of SD susceptibility has the opposite effect. Therefore, the hyperexcitability and 
enhanced SD susceptibility phenotype may be the final common determinant of tissue 
sensitization to ischemia in migraineurs. Retrospective clinical data suggest that the 
mechanism is not exclusive to FHM1, and that migraineurs in general population are 
also more sensitive to ischemic injury.
GENETIC CONTROL Of SD SUSCEPTIBILIT Y
In vivo and in vitro studies strongly suggest that cerebral hyperexcitability in FHM1 
stems from augmented release of excitatory neurotransmitters causing an imbalance 
between the excitatory and inhibitory synaptic transmission.1 In the context of 
migraine with aura, cerebral hyperexcitability also includes enhanced SD susceptibility. 
Other monogenic conditions associated with a migraine with aura phenotype also 
enhance SD susceptibility. For example, FHM2 mutations in the ATP1A2 gene encoding 
the α2 subunit of the Na,K-ATPase have been shown to lower the electrical threshold 
for cortical SD induction, and increase the SD propagation speed.2 It is known that 
the α2 subunit is exclusively expressed in astrocytes,3   at least in adults, and that 
enhanced SD susceptibility is probably a result of impaired K+ and/or glutamate uptake 
by astrocytes.2 Interestingly, however, the duration of SD was not prolonged in FHM2 
mutant mice, a shared phenotype with the FHM1 mutants,4-9 suggesting that K+ uptake 
is not impaired in the mutants, and that enhanced synaptic glutamate concentrations 
may be the final common mechanism for both FHM models, due to increased 
release in FHM1 and impaired clearance in FHM2.2 Glutamatergic mechanisms and 
hyperexcitability also are implicated in common forms of migraine by recent studies 
linking AEG1, encoding a regulator of glial glutamate transporter eAAT2, and KCNK18, 
encoding the TReSK potassium channel, to migraine.10-12
Increased SD susceptibility has been demonstrated in two other diseases 
characterized by migraine with aura. Cerebral autosomal dominant arteriopathy, 
subcortical infarcts and leukoencephalopathy (CADASIL) is the most common cause 
of monogenic inherited small vessel disease, and although the clinical features are 
dominated by lacunar infarcts, white matter degeneration and progressive subcortical 
dementia, migraine with often severe atypical aura (reminiscent of FHM) is the earliest 
symptom in the disease for which patients seek medical attention in their late teens 
and twenties.13,14 CADASIL is caused by mutations in the NOTCH3 gene, exclusively 
expressed in vascular smooth muscle cells in the adult brain.15,16 Despite this, CADASIL 
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mutations, when introduced in a transgenic overexpressor mouse model, also enhance 
SD susceptibility; electrical threshold is lowered and the frequency of KCl-induced SDs 
as well as the propagation speed are increased.17,18 Interestingly, SD susceptibility did 
not differ between male and female CADASIL mutants, suggesting that mutation-sex 
interaction is gene-specific. Therefore, CADASIL as a vascular disease provides an 
interesting overlap between migraine and stroke as proof-of-concept for SD being 
the final common determinant of sensitivity to ischemic injury in migraineurs. 
More recently, another monogenic condition, familial advanced sleep phase 
syndrome (FASP), was shown to enhance SD susceptibility. Patients with FASP show 
severe disruption of the sleep-wake-cycle and other circadian rhythms. The disease 
is caused by missense mutations in CSNK1D, encoding casein kinase Iδ (CK1δ) which 
is involved in the phosphorylation of the circadian clock protein Per2.19 A pathogenic 
CSNK1D mutation co-segregated in nine of 11 carriers with FASP and migraine with 
aura. In a transgenic overexpressor mouse model expressing a FASP mutation, the 
threshold volume of topically applied concentrated KCl to trigger an SD was lower, 
and the frequency of KCl-induced SDs was higher compared with the wild-type.20 
Altogether these data complement ours by showing that genetic modulation of SD 
susceptibility is a key determinant for a migraine with aura phenotype. 
INCREASED SENSITIVIT Y TO ISCHEMIC INjURY AffORDED BY 
MIGRAINE MUTATIONS
To explain the migraine-stroke association, we hypothesized that cerebral 
hyperexcitability (i.e., enhanced SD susceptibility) in migraineurs sensitizes the 
tissue to ischemia. In support of the hypothesis, two FHM1 mutant mouse strains 
developed larger infarcts compared with wild-type after transient focal cerebral 
ischemia21 (Chapter 3A). The phenotype correlated well with the strength of gain-
of-function of each mutation (S218L mutant being more severe than R192Q), and 
showed an allele-dosage effect where homozygous mutants fared worse than the 
heterozygotes. The mechanism was indeed linked to hyperexcitability, because 
anoxic depolarization developed faster and diffusion-weighted MRI lesions grew 
rapidly after stroke onset in the mutants, compared with the wild-type. Perhaps more 
importantly, mutants developed many more PIDs during acute stroke. As described 
in the General Introduction of this thesis, PIDs are SD waves spontaneously triggered 
within the ischemic penumbra, and expand the infarct by worsening the supply-
demand mismatch,22-24 thereby explaining the accelerated infarct growth25 in migraine 
mutants, as well as in humans.26 As a result of the SD susceptibility phenotype, 
migraine mutants required a higher level of minimum cerebral blood flow for tissue 
survival (i.e., the viability threshold),27 directly supporting the hypothesis that brain 
tissue in migraineurs is more susceptible to ischemic injury (Chapter 3A). The data 
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also showed that female mutants, which are even more hyperexcitable and susceptible 
to SD than males (Chapter 3A), developed even larger infarcts and worse outcomes 
after ischemic stroke compared with wild-type females, consistent with the clinical 
observations of higher stroke risk in women with migraine.28 
MIGRAINE AS A HYPERExCITABLE STATE THAT SENSITIZES 
THE BRAIN TO ISCHEMIC INjURY: “ THE TISSUE fACTOR” 
Clinical and experimental evidence suggests that migraine with aura reflects a 
hyperexcitable brain state that enhances susceptibility to SD as a final common 
mechanism. experimental evidence presented in this thesis indicates that susceptibility 
to develop SD is related to the susceptibility to develop injury if and when the 
brain tissue becomes ischemic. Because aura (perceived or not) is the relevant risk 
biomarker, the frequency of attacks with aura, rather than the total frequency of 
attacks only rarely accompanied by aura, is likely to be the critical determinant. In the 
field of stroke, we often focus on the severity and duration of perfusion defect as the 
final determinant of tissue outcome. In other words, we assume that given identical 
perfusion defects the outcome of ischemia will be the same between two brains; 
therefore, we ignore the intrinsic sensitivity of the brain to ischemia. Data presented 
in this thesis directly challenges the concept and underscores tissue sensitivity to 
ischemic injury as a genetic and modifiable stroke risk factor.
CAN WE ExTRAPOL ATE THESE fINDINGS TO OTHER 
MONOGENIC CONDITIONS? 
The data supporting a direct link between SD susceptibility and injury susceptibility in 
this thesis are exclusively obtained from a transgenic mouse model of a monogenic, 
familial form of human migraine (FHM1). Therefore, whether the principle applies to 
other monogenic conditions is not known. CADASIL (Cerebral Autosomal Dominant 
Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is another 
monogenic disease (mutations in the NOTCH3 gene) associated with migraine with 
often severe and prolonged auras. It is notable that transgenic overexpressor CADASIL 
mutant mice (Notch3R90C) as well as Notch3 null mutants show markedly enhanced 
SD susceptibility,17 and both Notch3 null mice and the transgenic overexpressor 
mice develop larger infarcts, and at least in the null mutants, this is associated with 
an increased frequency of PIDs,29,30 strongly supporting the notion that enhanced 
SD susceptibility translates into enhanced susceptibility to ischemic infarction. 
Although it is not clear how the mutations in the NOTCH3 gene, which is exclusively 
expressed in vascular smooth muscle cells and pericytes in adult brain, lead to cerebral 
hyperexcitability, the data are consistent with the stronger epidemiologic association 
observed between stroke and migraine with aura compared to without aura. It is 
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important to keep in mind that CADASIL mutations lead to cerebral small vessel disease 
and vascular dysfunction,13 and increase the risk of occurrence of ischemic events and 
chronic cerebral hypoperfusion (e.g., lacunar infarcts, white matter disease), and that 
mechanisms leading to lacunar infarcts and white matter disease may be different than 
those leading to hyperexcitability. This is further supported by the observation that 
the onset of migraine with aura attacks often precedes the emergence of clinical and 
radiological evidence of ischemic vascular disease in CADASIL, and in fact, migraine 
with aura attacks usually diminish in frequency and disappear as the ischemic lesion load 
increases. The latter may be explained by progressive neurodegeneration and gliosis 
in CADASIL,13 since both of these factors are expected to decrease SD susceptibility.
Last but not the least, future studies using mutant mouse models of a number of 
monogenic diseases in which migraine and stroke frequently co-exist may shed light 
into other aspects of the migraine-stroke association:
I. HIHRATL (Hereditary Infantile Hemiparesis, Retinal Arteriolar Tortuosity and 
Leukoencephalopathy) caused by mutations in the COL4A1 gene encoding type 
IV collagen α1 chain destabilize the triple helix domain of collagen IV found in the 
basement membranes.31,32
II. RVCL (Retinal Vasculopathy with Cerebral Leukodystrophy) linked to mutations in 
TREX1 gene,33 which encodes a DNA-specific exonuclease implicated in DNA repair 
under conditions of oxidative stress.34
III. MeLAS (Mitochondrial encephalomyopathy, Lactic Acidosis and Stroke-like 
episodes) is caused by mutations in mitochondrial genome with maternal pattern 
of inheritance.35-37
IV. HHT (Hereditary Hemorrhagic Telangiectasia) caused by mutations of endoglin or 
activin receptor-like kinase 1.38 
CAN WE ExTRAPOL ATE THE fINDINGS TO NON-MONOGENIC 
MIGRAINE? 
It is also not known to what extent the results obtained in this thesis apply to 
common (i.e., polygenic) migraine. However, the fact that clinical association 
between migraine with aura and stroke is demonstrated in the general 
population28,39-46 without the contribution of monogenic conditions suggests 
that the mechanism is active in non-monogenic migraine as well. Indeed, data 
obtained in our retrospective clinical study of acute infarct growth in migraineurs 
(Chapter 3C) directly support this notion, and underscore the clinical relevance 
of our findings.47 Unfortunately, because of the retrospective nature of our 
clinical study and relatively small sample sizes, we were unable to test the effect 
of modifiers such as active versus a remote history of migraine, and current use of 
migraine prophylactic drugs or antithrombotic prophylaxis in our cohort; this will 
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be the subject of future studies. However, because the average age in migraineurs 
and controls was ~60 years in our cohort, it is unlikely that active migraine was 
a significant determinant of ischemic injury progression, suggesting that the 
genetic propensity for migraine rather than whether the patient is suffering from 
active migraines was more important. Regardless, if brain tissue is more sensitive 
to ischemic injury in migraineurs with aura due to enhanced susceptibility to 
SD-like ischemic depolarization events, then the mechanism is operational in a 
very large population segment and may ultimately modify the clinical practice as 
discussed below.
IS  THERAPEUTIC TIME WINDOW fOR REVASCUL ARIZ ATION 
IN ISCHEMIC STROKE SHORTER IN MIGRAINEURS? 
In FHM1 mutant mice, diffusion-weighted MRI lesion (i.e., ischemic core) expanded 
rapidly because of enhanced susceptibility to anoxic depolarization and PIDs 
(Chapter  3A). This was indeed confirmed in our retrospective clinical study 
(Chapter 3C). If hyperexcitable brain tissue in migraineurs readily develops ischemic 
depolarizations, the core expands into the perfusion defect leading to rapid loss of 
viable tissue at risk (i.e., penumbra). This is a significant finding that would effectively 
shorten the therapeutic time window of efficacy for stroke therapies in migraineurs.
IS  AGGRESSIVE STROKE PROPHYL A xIS INDICATED IN 
MIGRAINEURS? 
Our data of Chapters 3A, 3B and 3C suggest that migraineurs are more susceptible 
to developing ischemic injury if and when they suffer from cerebral ischemic events. 
Although this does not mean they are at higher risk to develop cerebral ischemic 
events, their propensity to developing ischemic injury means that antithrombotic 
prophylaxis (e.g., acetyl salicylic acid)48-51 and aggressive avoidance of risk factors 
(e.g. oral contraceptive use, smoking, risk of traumatic dissection)48-51 may decrease 
the overall lesion burden by preventing the ischemic event in the first place. This 
can be tested clinically in different ways. For example, the relative risk of ischemic 
infarcts can be compared between patients on stroke prophylaxis and patients who 
are not in a migraine cohort. Alternatively, the efficacy of stroke prophylaxis can be 
tested in a prospective clinical trial comparing migraineurs with non-migraineurs. 
However, because the effect size is relatively small, in both cases very large cohorts 
will likely be needed to reach statistical power to demonstrate a differential effect in 
migraineurs. Instead, demonstration of faster acute infarct progression in migraineurs 
in a prospective study may provide sufficient justification to alter the practice and 
recommend antithrombotic prophylaxis in migraineurs. Along the same lines, a 
complete screening for vascular risk factors (e.g., hypercoaguble state, PFO, genetic 
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mutations)48-51 may be indicated in migraineurs in the absence of a prior cerebral 
ischemic event, so that aggressive stroke prophylaxis can be instituted preemptively. 
DOES MIGRAINE PROPHYL A xIS DIMINISH THE STROKE OR 
WHITE MAT TER LESION RISK OR SEVERIT Y IN MIGRAINEURS? 
Migraine prophylaxis suppresses SD susceptibility.52 If susceptibility to SD (i.e., aura) 
is a critical biomarker of susceptibility to ischemic injury, then migraine prophylaxis 
can reduce susceptibility to ischemic injury by rendering the tissue more resistant 
to ischemic depolarizations. This was indeed the case in our experimental model 
(Chapter 3B). If so, migraine prophylaxis may be beneficial in reducing ischemic lesion 
burden in migraineurs, and be indicated even if the frequency and severity of migraine 
attacks are not severe enough to justify chronic prophylaxis. In other words, clinicians’ 
threshold to start migraine prophylaxis may be lowered. This approach to reduce 
tissue sensitivity to ischemia could also be efficacious in non-migraineurs as well, as 
was the case in wild type mice in our study (Chapter 3B). 
IS  THERE A CLINICOPATHOLOGICAL DISCONNECT DURING 
ACUTE STROKE IN MIGRAINEURS? 
PIDs are indistinguishable from SD waves when they propagate into the non-ischemic 
brain tissue53-55, and as such, they cause transient electrophysiological silence in the 
tissue they invade. Consequently, PIDs cause neurological deficits much like the aura 
symptoms during migraine attacks, and worsen both the neurological examination 
and the clinical outcome.56,57 Therefore, more frequent PIDs in migraineurs can lead 
to more severe and perhaps fluctuating neurological deficits than would be expected 
based on lesion size and location on MRI. We know from the work by COSBID 
collaboration using the standard subdural electrode strips placed around the lesion 
that numerous PIDs occur both in the acute stroke stage as well as many days after 
stroke onset.58 
IS  MALIGNANT BRAIN EDEMA MORE fREQUENT IN 
MIGRAINEURS? 
In our experiments, ischemic brain swelling appeared to be more severe in mutants 
and could explain the higher mortality in the S218L mutant strain (Chapter 3A).21 It 
has been shown that SD disrupts blood brain barrier59. Hence, frequent PIDs may be 
associated with more severe blood brain barrier breakdown and ischemic edema 
formation after stroke,60 which can even become life threatening in case of large middle 
cerebral artery or cerebellar infarcts.60,61 If so, early decompressive craniectomy may 
be indicated in migraineurs with aura with large hemispheric stroke.62,63
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IMPLICATIONS fOR OTHER BRAIN INjURY STATES WHERE SDS 
OCCUR 
Indeed, SD-like injury depolarizations are not limited to ischemic stroke,55 but occur 
in other human brain injury states as well, such as subarachnoid or intracerebral 
hemorrhage,56,64-67 and head trauma,68-72 expanding the clinical relevance of transient 
or long-lasting neurological deficits caused by injury depolarizations (Figure 1). In this 
context it will be critical to test whether migraineurs with these brain injury states 
develop more frequent injury depolarizations, using subdural electrode strips. Of 
note, worse clinical outcomes have been reported in migraineurs after subarachnoid 
hemorrhage,73 although this has not yet been linked to frequent injury depolarizations 
via direct electrophysiological monitoring.
figure 1. Spreading depression, and closely related injury depolarizations constitute a 
pathophysiological overlap between migraine, stroke, subarachnoid and intracerebral 
hemorrhage, and traumatic brain injury. 
fUTURE RESEARCH 
The data presented in this thesis provide proof-of-concept and pave the way for future 
work to be built upon them. Among many important aspects to be explored in the 
future are: 1) test whether the principle of genetically-enhanced SD susceptibility as a 
critical determinant of stroke outcome holds true in other genetic conditions as well; 
2) test whether enhanced sensitivity to focal ischemic insults in FHM1 holds true for 
pure excitotoxic, hypoxic or global ischemic insults; 3) test whether repetitive SDs can 
lead to neuronal injury in the absence of energy shortage in genetically susceptible 
brains; and 4) clinical translation in prospective studies of acute stroke and stroke 
prophylaxis.
1) Is genetically-enhanced SD susceptibility a critical determinant of stroke outcome 
in other monogenic conditions? As noted above, there are several transgenic mouse 
models of monogenic conditions characterized by migraine with or without aura. 
These include FHM1,21 CADASIL,18 FHM22 and FASPS mutants.20 Among these, larger 
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infarct volumes and worse neurological outcomes after stroke have already been 
shown in some CADASIL mutant mouse models (Notch3 C455R and R1031C), albeit 
not in the same mutant (Notch3 R90C) in which enhanced SD susceptibility was 
demonstrated.17,18,29,30,74 Therefore, it will be important to study stroke outcomes in the 
Notch3 R90C mutant, and test whether PID frequency and AD latency are increased, 
as is the case with FHM1 mutants. In the Notch3 R169C mutant one could characterize 
both the SD and the PID phenotypes in this novel animal model.
2) Do FHM1 mutations sensitize against excitotoxicity, hypoxia or global forebrain 
ischemia? The data presented in this thesis clearly indicate that migrainous brain is 
more susceptible to focal ischemic injury. However, the pathophysiology of focal 
ischemic injury (i.e., ischemic stroke) differs from other forms insults such as direct 
excitotoxicity (e.g., glutamate, neurodegenerative conditions), hypoxia (e.g., drowning, 
suffocation) and global cerebral ischemia (e.g., cardiac arrest), in that the former 
involves PIDs. Therefore, we should test whether FHM1 mutations sensitize primary 
cortical neuronal cultures obtained from the mutants to glutamate excitotoxicity, high 
[K+] exposure or oxygen-glucose deprivation (OGD), in vitro.75 It will be interesting to 
test whether FHM1 mutants develop more severe neurological signs and neuronal 
death after moderate to severe hypoxic challenge (e.g., 7% O
2
 for 6 hours in a hypoxic 
chamber). And lastly, we should test whether bilateral common carotid occlusion for 
20 minutes causes more severe neurological deficits and hippocampal cell death in 
FHM1 mutants. As with focal cerebral ischemia, we will also seek an effect of genotype 
(R192Q vs. S218L), allele-dosage (heterozygotes vs. homozygotes), gonadal hormones 
(male vs. female, and the effect of gonadectomy), as well as the age.
3) Does exposure to repetitive SDs cause cortical injury in FHM1 mutants? It is well 
known that SD, regardless of its numbers, is not injurious unless it occurs in the 
presence of energy shortage (i.e., hypoxia, hypoglycemia, ischemia).76 However, FHM1 
mutations are predicted to augment pre and postsynaptic Ca2+ influx and glutamate 
release,77 and may therefore exert a stronger ionic and metabolic stress on neurons. 
Therefore, we should directly study intra-neuronal Ca2+ dynamics in FHM1 neurons 
using in vivo two-photon microscopy coupled with an intracellular Ca2+ indicator. The 
same set of studies will also allow morphological changes during SD to test whether 
dendritic beading or cell swelling differ between FHM1 mutants and wild-type 
controls. Furthermore, we should test whether chronic repetitive SDs cause injury in 
FHM1 brains, which has important clinical implications for FHM1 patients and possibly 
in classical migraine with aura as well. 
4) Does acute stroke injury progress faster in migraineurs? The clinical data presented 
in this thesis (Chapter 3C) strongly suggest faster infract growth in migraineurs. 
However, retrospective design has severe limitations, particularly in documentation 
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of migraine status and medication use, and timing of the MRI scans after stroke onset. 
These weaknesses can only be addressed through a prospective design. Therefore, 
we should undertake a prospective study in acute stroke, where migraine status, 
type and features, migraine prophylactic medication use, family history of migraine, 
and many other relevant clinical data will be collected, and infarct growth will be 
studied using MRI scans performed within fixed time intervals. We can then confirm 
the data from the retrospective study (Chapter 3C), and get additional insight, for 
example, on whether migraine prophylaxis normalizes the accelerated infarct growth 
in migraineurs. 
5) Do migraine prophylaxis and antithrombotic prophylaxis reduce the stroke 
occurrence in migraineurs and diminish the life-long cumulative lesion burden? 
This is the ultimate clinical study that will answer burning questions in the field: Do 
migraineurs need antithrombotic prophylaxis? Does migraine prophylaxis reduce 
the elevated stroke risk in migraineurs? However, such a study is also difficult to 
conclude, as large number of migraineurs will have to be randomized into control 
and prophylaxis arms, and followed for many years, possibly decades. Nevertheless, a 
collective multicenter effort can be effective.
CONCLUDING REMARKS
Migraine is a stroke risk factor with an effect size and prevalence comparable to 
other risk factors. Its recognition as an important and perhaps modifiable stroke risk 
factor, sought and documented as part of patient’s medical history, will certainly be 
facilitated by better definition of the mechanisms of this association and the causal 
relationships. With increased awareness, management of migraine will become more 
than management of a headache disorder, and more holistic as with other vascular risk 
factors. Of course, enough evidence to change practice can only be achieved in large 
prospective clinical studies targeting mechanisms and in therapeutic trials.
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The research in this thesis was aimed at investigating the central hypothesis that 
susceptibility to SD determines both the susceptibility to migraine with aura and the 
susceptibility to hypoxic/ischemic injury in the same direction. We envisage that 
factors that enhance the susceptibility to SD increase the likelihood of migraine with 
aura as well as ischemic stroke. To this end we assess to what extent genetic, hormonal 
and pharmacological modulators of SD susceptibility will influence the susceptible to 
ischemic injury. Thus we will unravel underlying mechanisms of SD susceptibility and 
susceptibility to ischemic injury. Central to this research is the use of two transgenic 
mouse models of migraine that carry migraine-relevant FHM1 gene mutations in 
voltage-gated Ca
V
2.1 Ca2+ channels.   
Chapter 1 provides an overview of the pathophysiology of migraine and aura, 
acute stroke and its progression, and the clinical association between migraine and 
stroke. The concepts of spreading depression, spreading depolarization, peri-infarct 
and injury depolarizations are introduced to put the data presented in Chapters 2-4 
in proper context. 
In Chapter 2A, we show that two FHM1 missense mutations in the Cacna1a gene 
(R192Q and S218L) enhance CSD susceptibility, and that the S218L mutation, which is 
associated with a more severe clinical phenotype than the R192Q mutation, enhances 
CSD susceptibility more than the R192Q mutation. We also show an allele-dosage effect 
where heterozygous mutants have an intermediate phenotype between homozygous 
mutants and wild-type controls. We demonstrate that the neurological signs 
(hemiparesis and circling behavior) precipitated by CSD induced within the cortex 
in R192Q and S218L knock-in mice closely mimic the clinical signs in FHM patients 
expressing the respective mutations. Furthermore, we dissect the modulatory role 
of female gonadal hormones by showing that female FHM1 mutants have higher CSD 
susceptibility than males, that ovariectomy diminishes and estrogen replacement 
restores the sex difference in CSD phenotype. These data are congruent with higher 
migraine susceptibility in women of reproductive age, and suggest an interaction 
between estrogen and the genetic determinants of migraine susceptibility. 
An alternative explanation for the female susceptibility to migraine is a protective 
effect by androgens. Therefore, in Chapter 2B, we investigate male gonadal hormone 
modulation of SD susceptibility. Using well-controlled electrophysiological methods, 
in vivo, we show that orchiectomy enhances and chronic testosterone replacement, 
but not a single dose, restores SD susceptibility, in an androgen receptor-dependent 
manner in FHM1 mutants. These data suggest that male and female gonadal hormones 
have opposite effects on SD susceptibility. As with the female mice, male gonadal 
hormones did not modulate SD susceptibility in wild-type animals, once again 
suggesting an interaction between hormonal status and genetic susceptibility factors. 
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In Chapter 2C we turn our attention to the severe and prolonged neurological 
deficits (e.g., coma and hemiparesis) that FHM1 mutant mice develop after a cortical 
SD (shown in Chapter 2A). Because cortical somatosensory evoked potentials 
recovered at about the same rate in wild-type and FHM1 mutant mice, delayed 
functional recovery of cortex did not appear to be the culprit in creating the severe 
and prolonged neurological deficits. Therefore, in Chapter 2C we investigate the 
alternative hypothesis that subcortical rather than cortical dysfunction is responsible 
for the severe and prolonged neurological deficits in FHM1. We employ multifocal 
intracerebral electrophysiological recordings in FHM1 mutants to show that SD 
susceptibility is significantly enhanced in striatum, thalamus and hippocampus, and 
that SD triggered in cortex is capable of propagating into all of these structures via 
direct gray matter connections, with the same genetic and sex-related modulation 
patterns described in Chapters 2A and 2B. Moreover, a subcortical SD can propagate 
back into the cortex, creating re-entrant and reverberating cortico-subcortical SDs in 
the highly susceptible FHM1 mutants, to explain the neurological deficits mimicking 
those observed in FHM patients.
In Chapter 3A, we test the central hypothesis that genetic and hormonal 
determinants of SD susceptibility sensitize the brain to ischemia, using in vivo 
electrophysiology, MRI, optical imaging of cerebral blood flow, combined with 
standard models of focal cerebral ischemia, all of which demonstrate that FHM1 
mutations worsen the tissue and neurological outcome after focal cerebral ischemia. 
We show sex differences in ischemic outcome (female mice fare worse than males), 
which are consistent with the gonadal hormone influences on SD susceptibility 
(shown in Chapters 2A and B), but in the opposite direction compared with wild-type 
animals. We also demonstrate an allele-dosage effect where the homozygous FHM1 
mutants fare worse than heterozygotes. Moreover, we identify enhanced AD and PIDs 
as the mechanism accelerating infarct growth in FHM1 mutants, akin to enhanced 
SD susceptibility explaining migraine aura. Therefore, we show data supporting the 
hypothesis that enhanced SD susceptibility worsens ischemic outcome, and form a 
direct mechanistic link between migraine with aura and ischemic stroke. 
It is known that migraine prophylactic drugs suppress SD susceptibility as one 
mechanism of action in migraine. Therefore, migraine prophylaxis presents an 
opportunity to modulate SD susceptibility in the opposite direct compared with 
migraine mutations. We, therefore, show in Chapter 3B that, conversely, suppression 
of SD susceptibility by chronic (>4 weeks) treatment with migraine prophylactic 
drugs topiramate and lamotrigine renders the brain resistant to ischemic injury. We 
show that the effect is present not only in wild-type mice but also in FHM1 mutants. 
In this chapter, we also confirm the efficacy of migraine prophylactic drugs on SD in 
mice, which has only been shown in rats in previous studies. Moreover, we show that 
197
treatment with a single dose of these drugs shortly before testing is ineffective, once 
again demonstrating the need for chronic treatment with these drugs. Lastly, we 
show that smaller ischemic infarcts are also associated with more favorable functional 
neurological outcomes, thus underscoring the clinical implications of our findings.
Chapter 4 discusses current knowledge on shared mechanisms of migraine and 
stroke.
Finally in Chapter 5, we put all our experimental findings, and others from the 
literature, together with the clinical observations on the association between 
migraine and stroke, in a comprehensive review focusing on potential mechanisms 
to explain the association, including the ones investigated in this thesis. We hope 
that the manuscript will spur thought and discussion and lead to new investigations 
on the association between migraine and cerebrovascular disease, discovery of new 





Het onderzoek in dit proefschrift had als doel om de centrale hypothese te testen 
of de gevoeligheid voor ‘spreading depolarization’ (SD) op gelijksoortige wijze de 
gevoeligheid beïnvloedt op migraine met aura en hypoxie/ischemie. Uitgangspunt 
hierbij is dat factoren die de gevoeligheid voor SD vergroten mogelijk ook de kans 
op het ontwikkelen van migraine en een ischemische beroerte vergroten. Om die 
reden werd onderzocht in hoe verre genetische, hormonale en farmacologische 
modulatoren de gevoeligheid voor ischemische schade beïnvloeden. Dit geeft inzicht 
in onderliggende mechanismen van de gevoeligheid van zowel SD als ischemische 
schade. Centraal in het onderzoek staat het gebruik van twee transgene migraine 
muismodellen met migraine-relevante FHM1 genmutaties in voltage-afhankelijke 
Ca
V
2.1 Ca2+ kanalen. 
Hoofdstuk 1 geeft een overzicht van de pathofysiologie van migraine met 
aura, acute beroerte en diens beloop, en de klinische associatie tussen migraine en 
beroerte. De concepten ‘spreading depression’, ‘spreading depolarization’, ‘peri-
infarct depolarizations’ en ‘injury depolarizations’ worden geïntroduceerd om data 
die gepresenteerd worden in de Hoofdstukken 2-4 in de juiste context te kunnen 
plaatsen. 
In Hoofdstuk 2A wordt aangetoond dat twee FHM1 missense mutaties in het 
Cacna1a gen (R192Q en S218L) de gevoeligheid voor CSD vergroten, en dat de S218L 
mutatie, die geassocieerd is met een ernstiger klinisch fenotype dan de R192Q mutatie, 
de gevoeligheid voor CSD in meer vergroot dan de R192Q mutatie. er werd ook een 
allel-dosis effect gevonden, waarbij heterozygote mutante dieren een intermediair 
fenotype hebben, dat ligt tussen dat van homozygote mutante en wild-type controle 
dieren. Neurologische uitingen (zoals hemiparese en het draaien van rondjes om de as) 
als gevolg van CSD, die geïnduceerd is in de hersenschors van R192Q en S218L knock-in 
muizen, blijken een grote gelijkenis te vertonen met de klinische verschijnselen die 
FHM patiënten met de respectievelijke mutaties laten zien. Daarnaast hebben we de 
modulatoire rol van vrouwelijke geslachtshormonen vast kunnen stellen door te laten 
zien, dat i) vrouwtjes FHM mutante dieren een grotere gevoeligheid voor CSD hebben 
dan mannetjes, ii) ovariectomie die gevoeligheid vermindert, en iii) toediening van 
estrogeen het geslachtsverschil in het CSD fenotype herstelt. Deze data passen goed 
bij de hogere gevoeligheid van vrouwen van reproductieve leeftijd om migraine te 
krijgen en geeft aan dat er een interactie bestaat tussen estrogeen en genetische 
factoren die gevoeligheid voor het hebben van migraine bepalen. 
een alternatieve verklaring voor de verhoogde gevoeligheid van vrouwen om 
migraine te krijgen zou een mogelijk beschermend effect van androgenen kunnen 
zijn. Om die reden hebben we in Hoofdstuk 2B de modulatoire rol van mannelijke 
geslachtshormonen bestudeerd. Met goed gecontroleerde elektrofysiologische 
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methoden werd aangetoond dat, in vivo, castratie (orchiectomie) de CSD 
gevoeligheid verhoogt en dat chronische toediening, maar niet een enkele dosis, 
van testosteron die gevoeligheid herstelt via een androgen-receptor afhankelijk 
mechanisme in FHM1 mutante dieren. Deze data suggereren dat mannelijke en 
vrouwelijke geslachtshormonen tegengestelde effecten hebben op de gevoeligheid 
voor CSD. Net als in vrouwelijke muizen, werd geen effect van mannelijke hormonen 
op de gevoeligheid van SD in wild-type dieren gevonden, wat opnieuw duidt op 
een interactie van de hormonale status en genetische factoren die de migraine 
gevoeligheid bepalen.    
In Hoofdstuk 2C gaat de aandacht naar het vaststellen van ernstige en langdurige 
neurologische gebreken (zoals coma en hemiparese) die FHM1 mutante dieren 
ontwikkelen na een corticale SD (als beschreven in Hoofdstuk 2A). Gezien het feit 
dat potentialen opgewekt in de corticale somatosensore hersenschors op ongeveer 
dezelfde wijze herstellen in wild-type en FHM1 mutante dieren, lijkt een vertraagd 
functioneel herstel van de hersenschors niet de boosdoener van de ernstige 
langdurige neurologische gebreken. Om die reden bestudeerden we in Hoofdstuk 2C 
de alternatieve hypothese namelijk dat een ontregeling in hersengebieden die 
zich bevinden onder de hersenschors (“subcortical”) verantwoordelijk zijn voor de 
ernstige langdurige neurologische gebreken in FHM. We maakten daarvoor gebruik 
van multifocale intracerebrale elektrofysiologische metingen in FHM mutante dieren 
en toonden aan dat de gevoeligheid voor SD significant is verhoogd in striatum, 
thalamus en hippocampus en dat SD golven, die opgewekt werden in de hersenschors, 
deze hersengebieden konden bereiken via grijze stofverbindingen met dezelfde 
genetische en geslachts-gerelateerde patronen van modulatie als beschreven in de 
Hoofdstukken 2A en 2B. Het is zelfs zo dat een ‘subcortical’ SD de hersenschors weer 
kan bereiken met herintredende terugkaatsende cortico-subcorticale SD golven in 
extra gevoelige FHM1 mutante dieren tot gevolg, die een verklaring kunnen zijn voor 
de neurologische gebreken die grote gelijking vertonen met die in FHM patiënten. 
In Hoofdstuk 3A testten we de centrale hypothese dat genetische en hormonale 
determinanten van de gevoeligheid voor CSD de hersenen gevoeliger maken voor 
ischemie, door in vivo elektrofysiologie, MRI, optische beeldvorming van de cerebrale 
doorbloeding te combineren met standaard modellen voor de bestudering van focale 
cerebrale ischemie. Wij toonden aan dat FHM1 mutaties nadelige gevolgen hebben voor 
het klinische beeld en het hersenweefsel na een focale cerebrale ischemie. er werden 
geslachtsverschillen gevonden voor de gevolgen van ischemie (vrouwtjes muizen 
doen het slechter dan mannetjes muizen), wat goed past bij de gevonden effecten van 
geslachtshormonen op de gevoeligheid van SD (als beschreven in Hoofdstukken 2A 
en 2B), maar met tegenovergesteld effect als waargenomen in wild-type dieren. We 
hebben ook een allel-dosis effect gevonden, waarbij homozygote FHM1 mutante dieren 
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het slechter deden dan heterozygote dieren. ‘Anoxic depolarisation’ en ‘peri-infarct 
depolarization’ werden als mechanisme geïdentificeerd voor de versnelde groei van 
de infarctgrootte in FHM1 mutante muizen, net als de verhoogde gevoeligheid voor 
SD die de migraine aura verschijnselen kan verklaren. Kortom, de data ondersteunen 
de hypothese dat een verhoogde gevoeligheid voor SD leidt tot een verslechtering 
van de gevolgen van ischemie, die hiermee een directe mechanistische link geeft 
tussen migraine met aura en ischemische beroerte.   
Het is bekend dat profylactische migraine drugs als werkingsmechanisme het 
onderdrukken van de gevoeligheid voor SD kunnen hebben. Migraine profylaxe 
geeft de mogelijkheid om de gevoeligheid voor SD te moduleren in de exact 
tegenovergestelde richting als gebeurt met migraine mutaties. In Hoofdstuk 3B 
laten we, paradoxaal, zien dat de onderdrukking van de gevoeligheid van SD met een 
chronische (>4 weken durende) behandeling met de migraine profylactische drugs 
topiramaat en lamotrigine de hersenen resistent maakt tegen ischemische schade. We 
lieten zien dat het effect aanwezig is zowel in wild-type muizen als FHM mutante dieren. 
In dat hoofdstuk bevestigen we ook de effectiviteit van profylactische migraine drugs 
op SD gevoeligheid, die tot dan toe alleen in ratten was aangetoond. Bovendien werd 
gevonden dat een behandeling met een enkele dosis van deze drugs vlak voor de test 
ineffectief is, waarmee nogmaals wordt aangetoond dat een chronische behandeling 
met de drugs noodzakelijk is. Tenslotte geven we bewijs dat kleinere ischemische 
infarcten leiden tot meer gewenste functionele neurologische uitkomstmaten, 
waarmee de klinische implicaties van onze bevindingen goed is geïllustreerd. 
In Hoofdstuk 4 wordt bestaande kennis van gedeelde mechanismen van migraine 
en beroerte bediscussieerd. 
Tenslotte, worden in Hoofdstuk 5 alle experimentele bevindingen en bevindingen 
uit de literatuur besproken in relatie tot klinische observaties over de associatie tussen 
migraine en beroerte, waarbij we ons richten op potentiële mechanismen voor die 
associatie, en andere die we hebben bestudeerd in dit proefschrift. We hopen dat dit 
proefschrift de weg zal vrijmaken voor nieuwe gedachtevorming en discussie omtrent 
additioneel onderzoek naar de associatie tussen migraine en cerebrovasculaire 
ziekten, de ontdekking van nieuwe ziektemechanismen, of de bevestiging van reeds 
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